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Aim of the study  
 
Globally, two important threats for public health are hypertension and obesity. It is well 
known that overweight or obese individuals are at more risk for the development of 
elevated blood pressure and cardiovascular diseases compared to normal individuals. As 
such, in the field of nutraceuticals and functional foods, focus is now given to the search 
for natural components that are able to reduce blood pressure and food intake targeting 
hypertension and obesity. Studies focusing on the potential role of phenolic compounds 
on these health issues increased over the last decades. Results from human and animal 
studies suggested the potential role of phenolic compounds in the battle against obesity 
and hypertension. However, mechanisms that are involved in the control and regulation 
of blood pressure, body weight and food intake, are many and complex. ACE 
(angiotensin-I-converting enzyme) plays a key role in the regulation of blood pressure. A 
few studies indicated that some flavonoids showed an ACE-inhibitory effect. For the 
regulation of body weight and food intake, it is known that cholecystokinin (CCK), a gut 
peptide hormone, plays an important regulating role in inducing satiety signals mediated 
by the activation of CCK receptors. Yet, the effects of phenolic compounds on the CCK 
signaling pathway and on the mechanistic insights related to satiety and body weight 
regulation are not available. Although a lot of studies demonstrated the effects of 
phenolic compounds in the regulation and inhibition of obesity and hypertension, more 
information is needed from mechanistic studies focusing on exact mechanisms that could 
be involved in the reported health claims. In addition, the reported claims in the reduction 
of risk disease by phenolic compounds are still needed to be discussed in more details in 
terms of structure-activity relationships. More information about these topics could lead 
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to a better insight and use of phenolic compounds.  
Specifically, the objectives of this work were:  
 To collect information from previous studies, in particular animal and human studies, 
on phenolic compounds with regard to their potential role in hypertensive and obesity 
management. A special attention was given to discuss possible physiological 
mechanisms responsible for these effects.  
 To evaluate the potential of different pure phenolic compounds belonging to different 
(sub)-classes for their ACE-inhibitory activity in a cell-free system and to build a 
structure-activity relationship;  
 To screen pure phenolic compounds for their effect on CCK and CCK-receptor 
signaling pathway using previously established Chinese Hamster Ovary (CHO) cells 
functionally expressing the rat CCK type-1 receptor (CCK1R) in a cell-based 
bioassay;  
 To screen pure phenolic compounds for their effect on stimulation of CCK secretion. 
For this purpose, the intestinal secretin tumor cell line (STC-1) which possesses many 
features of native intestinal enteroendocrine STC-1 cells and are routinely used in 
screening platforms to identify compounds that modulate secretion of gut hormones 
and particularly CCK in vitro.  
 
Outline of the thesis  
The figure below shows a schematic overview of the outline of the study. Chapter 1 
focuses on phenolic compounds and food rich in phenolic compounds in relation to 
hypertension and obesity. Literature screening was done with the aim of collecting all 
information from human and animal studies on the potential role of phenolic compounds 
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and food rich in phenolic compounds on hypertension and obesity. In chapter 2, we 
studied the effect of phenolic compounds on ACE activity. A specific attention was given 
to investigate the key structural elements and differences that contribute to ACE 
inhibition and thereby blood pressure-reducing potency. Chapter 3 was performed to 
examine the effect of phenolic compounds on the CCK1R signaling pathway as an 
important pathway in food intake and satiety management. Further in chapter 4, we 
investigated pure flavonoids for their potential to stimulate CCK secretion from STC-1 
cells. Finally, the general discussion and future perspectives from this work are presented 
in chapter 5. 
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Chapter 1 Literature review on phenolic compounds and their 
reported anti-hypertensive and anti-obesity effects 
 
1.1 Phenolic compounds 
 
1.1.1 Definition and classification 
 
Phenolic compounds are a large group of phytochemicals characterized by having an 
aromatic ring, bearing one or more hydroxyl groups. They range from simple phenolic 
molecules to highly polymerized compounds (1). Structurally, phenolic compounds can 
be categorized into several classes: phenolic acids, flavonoids, tannins, and stilbenes (2). 
In the plant kingdom, they are commonly found conjugated to organic acids and sugars. 
Phenolic acids  
 
They are found in many plant species and consist of two subclasses, i.e. the 
hydroxybenzoic and hydroxycinnamic acids. Both subclasses share a backbone of an 
aromatic ring and differ in the substitution patterns of hydroxylation and methoxylation 
on the aromatic ring. The most common hydroxybenzoic acids are gallic, p-
hydroxybenzoic, protocatechuic, vanillic and syringic acid. The most common 
hydroxycinnamic acids are caffeic, ferulic, p-coumaric and sinapic acid which share a 
three-carbon side chain. Phenolic acids are found in plants as conjugates and are quite 
seldom in the free form. Where the phenolic oxygen may be glycosylated with sugar, the 
carboxyl group can be esterified with sugar, tartaric acid, quinic acid or other organic 
acids (3, 4) 
Flavonoids 
 
Flavonoids are a group of phenolic compounds that form an important class of natural 
products present in fruits, vegetables, and beverages such as tea, coffee and red wine (5) 
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(5). They share the basic C6–C3–C6 configuration and consist of 2 aromatic C6 rings: 
ring A and ring B connected by the heterocyclic C ring. The basic ﬂavonoid skeleton can 
have different substituents such as hydroxyl groups, methyl groups, etc with majority of 
ﬂavonoids naturally exist as glycosides. Flavonoids are classified into six sub-groups 
namely ﬂavonols, ﬂavones, flavanols, anthocyanidins, ﬂavanones and isoﬂavonoids. 
Table 1.1 represents the sixth sub-classes of flavonoids with their basic structures, the 
main dietary sources and the most common flavonoids within each sub-class.  
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Table 1.1: The sixth subgroups of flavonoids and their food sources 
Sub-Classes           Food sources      The most                                                            Structure 
                                                            Common 
                                                            flavonoids                
 
Flavonols 
 
Onions, Leek 
Broccoli, Kale, 
apple 
 R1 R2 R3  
 
Quercetin 
 
 
OH 
 
OH 
 
OH 
 
Kaempferol 
 
OH H OH 
 
Rutin 
 
Glycoside OH OH 
 
Flavones 
 
Peppers, Celery, 
Parsely 
     
Apigenin 
 
 
H 
 
H 
 
OH 
 
 
 
 
 
luteolin 
 
H 
 
OH 
 
OH 
Baicalein OH H H 
 
Flavanols 
 
Cocoa, tea, 
Beans, 
chocolate 
 
 
Epicatechin 
 
 
 
 
  
 
OH 
 
 
OH 
 
 
 
 
 
Anthocyanidins 
Black, red, blue 
and purple 
berries, 
Aupergine 
Cyanidin    
 
 
Flavanones 
 
Orange, 
Grapefruit, 
Lemon 
Hesperidin 
 
 
Glycoside 
 
OCH3 
 
 
 
Naringenin 
 
 
OH 
 
OH 
 
 
Isoﬂavonoids 
Soyflour, 
Soybeans, 
Soymilk 
 
Genistein 
 
 
OH 
  
 
 
Daidzein 
 
 
H 
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Flavonols are the most widespread of the ﬂavonoids present in a wide variety of 
fruits, and vegetables. They are characterized by the presence of the double bond between 
C2 and C3 and the hydroxyl group at position 3. The most studies ﬂavonols are 
kaempferol, quercetin and myricetin for which the presence in the aglycone form is 
limited (6). Flavonols are mainly found as O-glycosides preferentially at the 3-position of 
the C-ring but substitutions can also occur at the 7- and 4'-carbons, although rarely occurs 
in plant foods (7). Onions (8), broccoli (9), and lettuce (10) are good sources for 
quercetin, where kale is a significant source for both quercetin and kaempferol (11). 
Rutin was found in large amount in asparagus shoots (12). In addition to vegetables, 
beverages such as tea and red wine are considered good sources of flavonols (13). 
Flavones are not widely distributed and less common than flavonols in fruits and 
vegetables. Apigenin, luteolin and baicalein are the most abundant flavones in plants. 
Celery and parsley are the main edible sources of flavones identified to date (14-16). 
Flavones have a wide range of substitutions including hydroxylation, methylation and O- 
and C-glycosylation. C-glycosides of flavones are reported to be present in cereals such 
as millet and wheat (17, 18). 
Flavan-3-ols are the most structurally complex subclass of flavonoids. They range 
from simple monomers (catechins) to complex structures in which the monomer forms a 
structural unit in the oligomeric and polymeric proanthocyanidins. Catechins are found in 
fruits and red wines but tea and chocolate are the richest sources (6, 19, 20). The most 
common flavan-3-ols and generally found in the free form are catechin and its isomer 
epicatechin, the main flavanols in fruit, and gallocatechin and epigallocatechin, mainly 
found in tea (6, 20). Contrary to other classes of flavonoids, flavanols are not 
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glycosylated in foods. However, the presence of the glycosylated or esterified forms has 
been reported in some studies (21). 
Anthocyanidins are widely spread throughout the plant kingdom. They present 
predominantly in the outer cell layers of different fruits such as cranberry, red grape, 
raspberry, strawberry, blueberry, and blackberry. Anthocyanidins are found as sugar 
conjugates in plant tissues and known as anthocyanins, which is responsible for their 
variable colors. Glycosylation occurs almost at the hydroxyl group on C3. The sugar 
residues can be D-glucose, D-galactose, L-rhamnose, L-arabinose, and D-xylose (22). 
The most widely spread anthocyanins are cyanidins which are found in the human diet 
from different sources such fruits, vegetables, and red wine (23).  
Flavanones are characterized by the presence of a chiral center at C-2 and the 
absence of the double bond between C2 and C3 in the C ring which is attached to the B-
ring at C2 in the α-configuration. Flavanones occur as glycosides in the plant kingdom 
(6) and are present only at high concentrations in citrus fruits such as lemon and orange 
(24, 25). The main aglycones are naringenin present in grapefruit and hesperetin in 
oranges (26). O-rutinoside, named hesperidin is the most common flavanone glycoside. 
Isoflavonoids such as daidzein and genistein have the B-ring attached at C3. They are 
classified as phytoestrogens because of the structural similarity with estradiol and their 
estrogenic activity in certain animal models (27). They occur mainly in leguminous 
plants, with the highest concentrations found in soybean. Non-fermented soya products 
contain the β-glycosides forms, while fermented products are rich in the aglycones as a 
result of hydrolysis of glycosides (28). 
Tannins 
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Tannins are polyphenols widely distributed in fruits, vegetables, red wine, cocoa, and 
certain food grains, such as sorghum, finger millets, and legume. They are classified into 
two groups according to the polyphenol groups in their molecules: hydrolysable and 
condensed tannins. Hydrolysable tannins are esters of gallic acid (gallo- and ellagi-
tannins). Condensed tannins are polymers structurally more complex than hydrolysable 
tannins and built up from ﬂavanoid precursors (29). 
Stilbenes  
 
Stilbenes have a C6–C2–C6 structure and are present in low quantities in the human diet 
(30). Resveratrol is the main stilbene which is present in red wine and peanuts (31, 32) 
and in lower amounts found in berries, red cabbage, spinach and certain herbs. 
Resveratrol occurs as cis and trans isomers, and conjugated derivatives, including trans-
resveratrol-3-O-glucoside (33).  
1.1.2 Phenolic compounds content in food and dietary intake  
 
The structural diversity causes difficulty in the evaluation of phenolic compounds content 
in food. Together with lack of standardized analytical methods and variation of content in 
a particular foodstuff, caused the lack of available estimations on dietary intake of in the 
literature. Total phenolic compounds intake is calculated from the polyphenol contents in 
food and food consumption tables. Scalbert and Williamson (34) reported that the dietary 
intake of phenolic compounds to be a round 1g/day with approximately one third from 
phenolic acids. In the United States, a quite old study (35) reported that the daily intake 
of dietary flavonoids was determined to be between 1 and 1.1 g/day. In the Spanish diet, 
the daily intake of phneolic compounds was estimated to be between 2.55 g and 3.01 g 
(36). Flavonoids account for two thirds of the total dietary intake of phenolic compounds, 
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while phenolic acids make about one third.  
Most foods contain a mixture of phenolic compounds but the distribution of these 
compounds at the tissue, cellular and sub cellular levels is not uniform (37). The outer 
layers of plants contain higher levels of phenolic compounds than inner parts (38). Also, 
some phenolic compounds like quercetin are found in all plant products; fruit, vegetables, 
cereals, fruit juices, tea, and wine, whereas flavanones and isoflavones are specific to 
particular foods. A lot of factors affect phenolic compounds content of plants like degree 
of ripeness at the time of harvest, environmental factors, processing and storage (39). 
Generally, it has been observed that ripening reduces the phenolic acids content. In 
contrast, anthocyanin concentrations increased during ripening. As a response to stress 
and infection, the concentrations of some phenolic compounds and especially phenolic 
acids may increase as they are directly involved in the healing process (40). Cooking also 
affects directly the concentration of phenolic compounds. For examples, onions and 
tomatoes lose between 75% and 80% of their initial quercetin content after boiling for 15 
min, 65% after cooking in a microwave oven, and 30% after frying (14). Additionally, 
food processing could influence the content of some phenolic compounds. Phenolic 
compounds in wheat grain are mainly present in the outer layers and so the refined flour 
loses its content from phenolic compounds. Similarly, quercetin is found in the peel in 
apple (1 mg/g fresh weight) and thus it is lost during peeling. Storage has a major effect 
on the phenolic compounds content in food due to oxidation (39). Oxidation reactions 
result in the formation of more or less polymerized substances, which lead to changes in 
the quality of foods. Storage of wheat flour for six months results in a significant loss in 
the concentration of phenolic acids compared with fresh (38). In US diet, it was claimed 
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that vegetables (dry legumes included) provide 218 mg of total phenolic compounds/d 
based on Folin assay (41). In general, fruits are considered to have higher content of 
phenolic compounds than vegetables. The total phenolic content approximately is 1–2 
g/100 g fresh weight for some fruits, such as plum and persimmon. Fruits such as apple, 
plum, and grape contain high amounts of proanthocyanidins. Cherries and other red fruits 
are rich in anthocyanins with contents vary from 0.15 to 4.5 mg/g in fresh fruits (42). 
Citrus fruits are the main food source of flavanones with hesperidin (from orange) being 
the most consumed flavanone. Oranges juice contains 125–250 mg/L (43). Chocolate is 
also very rich source in phenolic compounds and particularly contribute to catechin (44) 
and proanthocyanidin intake. Soy is the main source of isoflavones, which contains 1 mg 
of genistein and daidzein/g dry bean (45). Quercetin, which represents the main flavonol 
in the western diet, is present in many fruits and vegetables as well as in beverages. 
Mainly, it is abundant in onions (0.3 mg/g fresh weight) and tea (10–25 mg/L) (15). 
Dietary habits and preferences affect to a large extent the dietary intake of 
phenolic compounds. For example, coffee is richer in phenolic acids than flavonoids and 
thereby heavy coffee drinkers probably consume more phenolic acids. Also, the 
proportion of particular classes or individual compounds depends on the consumed food 
stuffs. For instance, consumption of beverages like tea, red wine or beer will provide 
more flavanols and proanthocyanidins than other flavonoids (42). Catechins contents in 
green tea is 1 g/L (46). Red wine contains 270mg/L catechins and 26 mg/L anthocyanins 
(47). In western diets, the intake of flavonols, flavones and isoflavones is lower than that 
of phenolic acids and other flavonoids, such as proanthocyanidins, anthocyanins (48). 
The proportion of compounds such as quercetin and genistein does not exceed 2–4% of 
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the total phenolic compounds consumed in Western diets (34)  . 
1.1.3 Bioavailability and absorption of phenoplic compounds 
 
Several definitions of the term “bioavailability” have been suggested. However, the most 
appropriate one could be as that fraction of an ingested nutrient or compound that reaches 
the systemic circulation and then distributes to the target tissues where it exerts its 
biological action various sites (49). Bioavailability of phenolic compounds is rather low 
and differs from one compound to another (50). After the consumption of 10–100 mg, the 
maximum concentration of a single phenolic compound in plasma rarely exceeds 1 µM. 
However, the total plasma concentration from phenolic compounds is probably higher 
due to the presence of metabolites formed in the body’s tissues or by the colonic 
microbiota (34). Singleton et al. (51) reported that the concentration of total polyphenols 
in plasma after the ingestion of 500 mg of polyphenols to be 50 μM. Another study 
showed an increase in the plasma polyphenol concentration of 15 μM after the 
consumption of one third of this quantity of red wine (100 ml) (52). 
Several factors might influence the bioavailability of phenolic compounds directly 
or indirectly by affecting their content in food (53). As examples of factors affect the 
bioavailability are external factors such as the environmental factors (sun exposure and 
rainfall) and degree of ripeness. These may affect the content of phenolic compounds in 
plants and thereby the bioavailability in humans. Other factors that influence the 
bioavailability of phenolic compounds indirectly are food processing-related factors such 
as thermal treatment, cooking, culinary preparations, homogenization and storage that 
influence the content of phenolic compounds in food. Other factors affecting the 
bioavailability are food-related factors. Food components such as proteins, carbohydrates, 
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fiber and fat can interact directly with phenolic compounds and subsequently influence 
their bioavailability. Next, interaction with other compounds in the human body 
represents an important factor that affect the bioavailability of phenolic compounds. It 
was reported that quercetin metabolites and epigallocatechin-3-O-gallate possess a high 
affinity to blood proteins like albumin, which may influence the delivery of these 
compounds to cells and tissues. The chemical structure of the compound which depends 
on the degree of glycosylation, acylation, conjugation with other phenolics, molecular 
size, degree of polymerization, and solubility, is considered one of the main factors 
affecting its absorption (54). In food and apart from anthocyanins, most of phenolic 
compounds are present as polymers or in glycosylated forms and so they need to be 
hydrolysed by intestinal enzymes or by the colonic microflora to be absorbed. Moreover, 
the basic structure (i.e., benzene or flavone derivatives) of the compound as well as the 
type of sugar attached is the determinant of the rate and the extent of intestinal 
absorption. 
Host-related factors like the intestinal factors are very important factors that can 
play a crucial role in the bioavailability of phenolic compounds. When dietary 
polyphenols are ingested, the absorption of some of these compounds happens in the 
small intestine. At the intestinal level, two possible mechanisms can be responsible for 
phenolic glycosides hydrolysis. The first one includes lactase phloridizin hydrolase 
(LPH), which is a cellular membrane-bound protein enzyme present on the luminal side 
of the brush-border of the small intestine epithelial cells. LPH deglycosylates phenolic 
compounds without transport of the glycosides into cells and then the produced aglycone 
with higher lipophilicity compared to its parent glycosides can enter the epithelial cell by 
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passive diffusion (55). A large number of flavonoid β-glucosides has been proved as 
substrates of LPH, such as daidzein-7-O-β-glucoside, genistein-7-O-β-glucoside, 
apigenin-7-O-β-glucoside, luteolin-7-O-β-glucoside, kaempferol-3-O-β-glucoside, 
quercetin-3-O-β-glucoside and quercetin-4’-O-β-glucoside. Therefore, the exclusive LPH 
expression in the small intestine suggests the important role of the intestinal mucosa in 
the deglycosylation of flavonoid glycosides and thereby a possible rapid intestinal 
absorption of flavonoids (56). The second mechanism that might attribute to phenolic 
glycosides hydrolysis, involves the transport of the polar glucosides into enterocytes 
through the active sodium-dependent glucose transporter SGLT1 where they undergo 
cleavage of the sugar moiety by cytosolic -glucosidase (CBG) which is present within 
the epithelial cells (57). 
Once they reach the colon, the non-absorbed phenolic compounds, and the 
fraction re-excreted in the bile undergo extensively structural modification by the 
microflora. The microbial conversion plays an important role in the biological activity of 
many phenolic compounds and in particular for those which are not absorbed in the small 
intestine and need this transformation to be absorbed (58, 59). For example rutin, a 
flavonoid glycoside, is not absorbed in the upper part of the intestinal tract, while the 
aglycone released by the action of colon microflora is reabsorbed (60). Most green tea 
catechins are mainly not absorbed in the small intestine and need the bacterial conversion 
in the colon which results in simpler compounds that could be absorbed (61).  
Colonic microflora can hydrolyze glycosides into aglycone and further degrade 
them to more simple compounds like phenolic acids which might be well absorbed 
through the colonic barrier. Gut microflora can also hydrolyse flavonoid glucuronides 
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excreted in the bile and the produced aglycone can be reabsorbed and as a result entering 
into an enterohepatic cycle (7, 58). 
Gut bacteria can not only hydrolyze glycosides, glucuronides, sulphates, amides, 
and esters (62) but also they carry out ring-cleavage, reduction, decarboxylation, 
demethylation, and dehydroxylation reactions (63).  Lactobacillus. plantarum is an 
example of the gut bacteria that can breakdown some hydroxybenzoic acids 
(protocatechuic acid and gallic and) and some hydroxycinnamic acids (caffeic, ferulic, p-
coumaric, and m-coumaric acid) via decarboxylation and reduction of the phenolic acid 
(64). It is worthy to mention that there is a big inter-individual variability in producing 
these active metabolites which could be linked with the genetic characteristics of the 
subjects (65). For instance, the isoflavone daidzin is converted to daidzein in the intestine 
by β-glucosidase. Further, daidzein undergoes more transforming by dihydrodaidzein to 
produce O-desmethylangolensin by the intestinal bacteria to result in equol. However, it 
is estimated that only one-third of human individuals to have intestinal microorganisms 
have the capacity to convert daidzein into equol (59). 
1.1.4 Metabolism of phenolic compounds  
 
Phenolic compounds are metabolized in both tissues such as the small intestine, liver, and 
kidneys and by the colonic microflora. They undergo hydrolysis and conjugation by 
enzymes located in the small intestine and colon and in the liver. First, they are 
hydrolyzed to their free aglycones, and then are conjugated to form O-glucuronides, 
sulphate esters and O-methyl ether. Conjugation first occurs in the gut barrier (66) and 
then the conjugates reach the liver where they undergo further metabolization (67). When 
quercetin was perfused in the gut of living rats, quercetin glucuronides were formed in 
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the gut mucosa and secreted back either to the gut lumen or to the serosal side (68). 
Catechin is extensively metabolized in the liver. This has been shown when it was 
perfused in the gut of rats as 99% of the catechin excreted in the bile was O-methylated, 
while before reaching the liver only half of the catechin circulating in the mesenteric 
plasma was in the O-methylated form (67). Apart from green tea catechins, the free 
aglycones in the plasma are absent or present with low concentrations (69). However, 
some studies with pharmacological doses showed the presence of aglycones which might 
suggest possible saturation for the conjugation pathways (70).  
The conjugation process occurs mainly in the liver. A methyl group from 
adenosyl-methionine transfer to phenolic compounds that contain a diphenolic moiety, 
such as quercetin, catechin, caffeic acid, and cyaniding. This is catalyzed by catechol-O-
methyltransferase (COMT) enzyme which is highly active in tissue liver (53). Uridine-5’-
diphosphate glucuronosyltransferases (UGTs) catalyzes the transfer of a glucuronic acid 
from UDP-glucuronic acid to polyphenols. UGTs are membrane-bound enzymes that are 
located in the endoplasmic reticulum in many tissues. Glucuronidation of polyphenols 
starts first in the enterocytes and then further continues in the liver (53). Regarding the 
sulfation, sulfotransferases (SULT) enzyme mediates the transfer of a sulfate moiety from 
phosphoadenosine-phosphosulfate to a hydroxyl group on various substrates such 
phenolic compounds (53). 
In humans, the conjugation process is considered to be very efficient and this is 
evidenced by the predominant presence of the flavonoids in the conjugated forms in 
plasma and also in urine. Liquid chromatography analyses with and without hydrolysis of 
the samples with β-glucuronidases and sulfatases showed the appearance of flavonoid 
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conjugates in humans including O-methylated conjugates (69, 71, 72). The conjugation 
efficiency depends on the type of catechins as the catechin aglycone can be found in the 
plasma and it ranges from 10% to 80% (69). Also, the type of phenolic acids influences 
the conjugation percentage which is reported to range between 13% and 100% (72). With 
excluding anthocyanin glycosides (71, 73), the deglycosylation of flavonoids glycosides 
is also reported to be very efficient as evidenced by the absence of glycosides in the 
plasma of subjects supplemented with quercetin glucosides (74). 
1.2 Hypertension  
 
1.2.1 Definition and status 
 
Hypertension or high blood pressure is one of the most important risk factors that 
contribute to the development of cardiovascular disease (CVD). Hypertension is 
responsible for 9.4 million deaths worldwide every year and it affects one-quarter of the 
world’s adult population, resulting in a public health burden in both developed and 
developing countries (75). Blood pressure (BP) involves two measurements, systolic 
blood pressure (SBP) and diastolic blood pressure (DBP). Criteria to define high blood 
pressure or hypertension criteria have undergone changes although most guidelines 
recommend SBP/DBP ≥140/90 mm Hg as a cutoff point. In 2013, the American Society 
of Hypertension (ASH) and the International Society of Hypertension (ISH) guideline 
recommended SBP/DBP ≥150/90 as a criteria of high BP in 80 year old individuals or 
older. In 2014, the eighth Joint National Committee (JNC 8) guideline defined 
hypertension in 60 year old patients and older when BP ≥ 150/90 mm Hg and ≥ 140/90 in 
younger adults (76). The pharmacological therapies for high BP include the use of drugs 
from 6 different classes: Angiotensin converting enzyme (ACE)-inhibitors, calcium-
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channel antagonists, diuretics, β-blockers, angiotensin II receptor blockers and direct 
vasodilators (77). Besides, non-pharmacological management or life style changes such 
as cessation of smoking, increased physical activity, reduced sodium intake, moderate 
alcohol intake and following a healthy diet are considered an important tool in the 
management and reduction of the risk of hypertension (78).  
1.2.2 Blood pressure regulation 
 
The regulation of blood pressure is a very complex process which involves different 
mechanisms. The diuretic or sodium system, the sympatho-adrenal system, and ACE 
regulated systems are the most important systems involved in the regulation of blood 
pressure. The diuretic system regulates indirectly the blood pressure by the release of 
atrial natriuretic peptide and vasopressin (79, 80). Vasopressin is a peptide hormone that 
plays a key role in homeostasis and the regulation of glucose, water, and salts in the 
blood. It affects the tissue's permeability, and thus controls the reabsorption of molecules 
in the tubules of the kidneys. Vasopressin increases peripheral vascular resistance, as 
well. This can result in an increase in arterial blood pressure (81). Two catecholamine 
transmitters are released in the sympatho-adrenal system, namely adrenaline and 
noradrenaline. The former is released from adrenal medulla and the latter is released from 
both nerve terminals and adrenal medulla. Catecholamine transmitters can induce an 
increase in the cardiac rate and contractile force and accelerate relaxation via β-
adrenoreceptors. In addition, they can cause blood vessel contraction by interaction with 
the α-receptors (80). 
ACE-regulated systems which are the renin-angiotensin-aldosterone system 
(RAAS) and the kallikrein-kinin system (KKS) have a major impact on cardiovascular 
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resistance and maintenance of blood pressure (figure 1.1). Renin-angiotensin-aldosterone 
system is a complex regulating system in which the decapeptide angiotensin I (Ang I) is 
released from angiotensinogen by the action of rennin. (ACE) metabolizes Ang I into the 
active octapeptide angiotensin II (AngII) which is known as a vasoconstrictor (82, 83). 
Ang II plays a crucial role in both acute and chronic blood pressure regulation. It 
functions as vasoconstrictive in blood vessels. In addition, AngII promotes the kidney to 
secrete aldosterone which causes sodium and water retention and potassium excretion. 
This altogether results in an increased BP. Ang II also has an important role in the growth 
and development of different cell types and thereby it can cause hypertrophy of the heart 
and blood vessels (77) . 
With regard to the kallikrein-kinin system (KKS), bradykinin and kallidin are bio-
active kinins released from kininogen by kallikrein (82). Bradykinin and kallidin play a 
role in physiological functions as blood pressure regulation and heart function. They both 
and mainly bradykinin have vasodilatory functions. However, ACE inactivates both 
bradykinin and kallidin by hydrolysis into inactive fractions (84). 
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Figure 1.1: Role of angiotensin converting enzyme in blood pressure regulation (85). 
 
 
1.2.3 Angiotensin converting enzyme (ACE) and its role in blood 
pressure  
 
ACE is a metallopeptidase in which the presence of a zinc atom in the active site is 
essential for the catalytic activity of the enzyme. Two different isoforms of ACE are 
present in the human body, somatic ACE (sACE) of approximately 170 kDa (kilodalton), 
and testicular ACE of approximately 100 kDa (86, 87) (Figure 1.2). Somatic ACE is 
found in most cells in the body and it controls blood pressure and kidney function (88), 
whereas testicular ACE exists only in the testes and plays an important role in fertility. 
Renin-angiotensin system Kallikrein-kinin system 
Angiotensin I Bradykinin 
Angiotensin II Inactive fragments 
  ACE 
Increased peripheral 
vascular resistance 
Increased Na+ and 
water retension  
Decreased peripheral 
vascular resistance 
Increased blood pressure Decreased blood pressure 
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Somatic ACE consists of two domains, called the N- and C-domains. Each domain has an 
active site with a typical zinc binding motif. On the other hand, the structure of testicular 
ACE is identical to the C-domain of somatic ACE (89). Somatic ACE has the 
predominant physiological role in blood pressure regulation. It acts as a dipeptidyl 
carboxypeptidase which releases a dipeptide from the C-terminus and thus converts Ang I 
to Ang II.  
 
Figure 1.2: Structure of ACE derived from plasma, somatic cell and the testis. It shows the 
active catalytic sites and zinc dependency. Also, it shows the amino (long area)- and carboxyl 
(short)-terminus ends which are anchored to the plasma membrane through a single 
transmembrane domain (90). 
 
1.2.4 ACE-inhibitors 
 
The use of ACE inhibitors is one of the important approaches used in the medication of 
high BP. Synthetic ACE-inhibitors inhibit ACE in a competitive manner by binding its 
zinc atom in the active site. Three classes of synthetic ACE-inhibitors were recognized 
based on the group that binds the zinc atom, namely sulfhydryl-, carboxyl- and 
phosphinyl-containing inhibitors (77). Captopril and lisinopril are the most used synthetic 
ACE-inhibitors in the battle against hypertension. The use of synthetic ACE-inhibitors 
might be accompanied with side-effects such as skin rashes, dry cough, hypotension, 
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angioedema etc (91). Therefore, the need for alternative inhibitors from natural sources is 
of great interest. 
So far, extensive research has been carried out to look for ACE inhibitors from 
natural products as the latter might have better drug profiles and less side-effect. Based 
on this research, some natural substances such as peptides (92, 93) and triterpenes (94) in 
the aim of ACE inhibition have been well described in literature. Moreover, recent 
studies also suggested the potential role of some phenolic compounds to inhibit ACE 
activity (95-98).  
 
1.3 Obesity  
 
1.3.1 Definition and status 
 
Obesity is a complex disease considered as one of the major public health concerns in 
developed and developing countries. Each year, about 3.4 million adults die as a result of 
overweight or being obese (99). Obesity and overweight predispose individuals to serious 
chronic conditions as it is reported that 44% of diabetes, 23% of ischaemic heart disease 
and between 7% and 41% of certain cancer burdens are attributable to overweight and 
obesity (100-102). 
Body mass index (BMI) is a simple tool used mostly to measure overweight and 
obesity in epidemiological studies. BMI is defined as the weight in kilograms divided by 
the square of the height in meters (kg/m
2
). A person with a BMI of more than 25 and 30 
is considered to be overweight and obese, respectively. Measurements of skin fold 
thickness and waist circumference, waist to hip circumference are other methods used for 
evaluating body fat (99). 
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1.3.2 Causes, health consequences and treatment of obesity 
 
The main cause of obesity is the impaired balance between energy uptake and physical 
activity which can be explained by increased consumption of energy-dense foods that are 
high in fat and sugar content and the sedentary nature of life nowadays according to 
WHO. Also, genetic predisposition, differences in hormone balances involving hunger 
and satiety and cultural/environmental situations could contribute in developing obesity 
(103). Additionally, the correlations between the composition and metabolic activity of 
the intestinal microbiota and obesity indicate the possible involvement of the intestinal 
microbiota in obesity (104).  
Obesity is recognized as a chronic disease and the second leading cause of 
preventable death. Obesity is a major risk factor for hypertension, cardiovascular disease, 
type 2 diabetes mellitus, and some cancers. In addition, obesity could be involved in 
other pathological conditions including sleep apnea, osteoarthritis, idiopathic intracranial 
hypertension, gastroesophageal reflux, and urinary stress incontinence (105). 
 
Medications used for the treatment of obesity and approved by FDA cause weight 
loss based on different mechanisms: 1) via reduction in calorie intake such as 
phentermine; 2) preventing the absorption of dietary fat through the inhibition of 
pancreatic lipase such as orlistat; 3) suppression of hunger and satiety induction such as 
lorcaserin (106-108). However, many of these drugs showed relative lack of efficacy. 
Besides, they are often responsible for cardiovascular and/or neurological side effects 
over a medication period of one-year or more. This limits their use to short term therapy 
with an exception of only orlistat to be approved for long term use (109, 110). 
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1.3.3 Cholecystokinin and its role in food intake regulation  
 
Cholecystokinin (CCK) is a hormone peptide that is released from the entire endocrine 
cells (I cell) in the proximal small intestine in a response to the ingestion of nutrients 
mainly dietary fat and protein and their digestive products into the small intestine (111). 
The triangular shape with the apical surfaces
 
oriented toward the intestinal lumen helps 
intestinal nutrients to stimulate I cells to release CCK from the basolateral site into the 
interstitial space where it can bind to CCK receptors located in the gastrointestinal tract. 
CCK presents in the gut and the brain and were found in different molecular forms that 
derive from the same precursor (single CCK gene ) and differ from each other as a result 
of posttranslational processing (112). A range of 4 to 83 amino acids were identified to 
be present in human tissue and blood (113, 114) with CCK-33 and CCK-8 are the most 
predominant forms in human tissue and blood (115, 116). CCK plays a role in diverse 
behaviors and states as anxiety,
 
sexual behavior, learning, and memory and spontaneous 
activity (117). It could also be involved in the functional expression of other gut 
hormones such as ghrelin, insulin and leptin. (118-120). In the pancreas, CCK functions 
as a regulatory peptide that triggers secretion of digestive enzymes.   
 
Figure 1.3 : Primary sequence of the most predominant mammalian forms of CCK: 
CCK-58, CCK-33, and CCK-8 (121).  
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 CCK is one of the most important gut peptides involved in food intake regulation 
by both satiety and satiation induction (122-124). Its physiological action is mediated 
mainly via CCK type 1 receptor (CCK1R) activation. CCK1R is a G-protein coupled 
receptor (GPCR) which is mainly found in the alimentary tract. In human, it is expressed 
in chief cells, D-cells and mucus cells of the gastric mucosa, in glucagon secreting cells 
of the pancreas, in smooth muscle cells of the gall bladder, the pyloric sphincter, the 
intestines and the sphincter of Oddi. Additionally, CCK1R is present on vagal afferent 
fibers and nerve cells of the myenteric plexus. The activation of the receptor is 
responsible for controlling gastrointestinal functions which include delayed gastric 
emptying, inhibition of gastric acid secretion, stimulation of gall bladder contraction, 
slowing down gastrointestinal motility and stimulation of pancreatic exocrine secretion, 
and finally it leads to satiety regulation (125, 126). Although most reports from literature 
indicate to the role of CCK1R in the mediation of satiety, the few evidences that suggest 
the involvement of CCK2R in the control of food intake cannot be ignored when talking 
on CCK signaling [5, 26].  
 
In vitro studies on second messengers involved in the signaling through G-protein 
coupled receptors (GPCRs) revealed the following cascade pathway presented in figure 
1.4. In brief, binding of the agonist to GPCR, results in activation of phospholipase
 
C 
(PLC). Phospholipase
 
C (PLC) hydrolyzes phosphatidyl inositol 4, 5 biphosphate into 
inositol trisphosphate (IP3)
 
and diacylglycerol (DAG). Inositol trisphosphate (IP3) 
stimulates intracellular Ca
+2
 release which acts together with diacylglycerol (DAG) to 
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activate protein kinase (PKC). PKC mediates phosphorylation of other proteins in a cell 
type specific manner which leads to various cellular responses (127). 
 
Figure 1.4: Simplified view of signaling pathway of the CCK1R via the Gq type of G-
protein coupled receptor after binding with an agonist (128). 
 
1.4. Overview of the anti-hypertensive and anti-obesity effects of 
phenolic compounds reported in animal and human studies 
 
1.4.1 Overveiw of the anti-hypertensive effects of phenolic 
compounds 
 
Following a healthy diet is considered an important tool in the management and reduction 
of the risk of hypertension (78). Examples of a healthy diet are the Mediterranean diet or 
the Dietary Approach to Stop Hypertension (DASH) diet, which are both characterized 
by high amounts of fruit and vegetables. Several observational and intervention studies 
reported an inverse association between the risk of hypertension and the high intake of 
foods rich in phenolic compounds such as cocoa beverage, fruits and vegetables, tea and 
virgin olive oil. Indeed, phenolic compounds and food rich in phenolic compounds have 
been extensively investigated in terms of their potential effect on reduction hypertension. 
A lot of studies in different animal models as well quit good number of human 
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interventions proved the potential role of phenolic compounds and mainly flavonoids and 
food rich in phenolic compounds in reducing blood pressure.  
1.4.1.1 Anti-hypertensive effects of phenolic compounds reported in animal studies 
 
The effect of phenolic compounds on hypertension was reported in a lot of studies in 
animal models. In this context, many studies focused on flavonoids and food rich in 
flavonoids (table 1.2 and table 1.3). As such, evidence from many experiments carried 
out with spontaneously hypertensive rats (SHRs) suggest the potential role of pure or 
isolated flavonol compounds in lowering BP with quercetin being the most studied 
compound in terms of its effect on BP. The chronic effect of oral quercetin administration 
on reducing BP in hypertensive animals was reported in many studies in recent years. In 
this context, studies showed that long term oral administration of quercetin in SHRs 
induced a signiﬁcant reduction in BP (129, 130). On the other hand, no effect of quercetin 
was observed in normotensive Wistar Kyoto rats (WKY) in the two studies. More 
recently, Galindo et al. (131) studied the acute effect of quercetin and its conjugated 
metabolites (quercetin-3-glucuronide and isorhamnetin-3-glucuronide) on BP in SHRs. 
They found that BP decreased after 2.5 h of oral administration of quercetin reaching a 
maximum effect 6 h after administration. Quercetin-3-glucuronide and isorhamnetin-3-
glucuronide significantly reduced mean BP, after 1 and 2 h of metabolite injection (1 
mg/kg i.v.), respectively. The maximum reduction induced by both compounds was 
reached after 3 h of injection. However, the inhibitory effect by quercetin and its two 
metabolites was prevented by D-saccharic acid 1.4-lactone (SAL), a β-glucuronidase 
inhibitor. Therefore, they suggested that deconjugation which is expected to occur 
intracellularly might be required for the effect of quercetin metabolites. 
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Some flavonol-rich extracts obtained from plants have been reported to reduce BP 
in animal models. After chronic treatment, Brasil et al. (132) showed that the oral 
administration of methanol extract of C. papya rich in quercetin resulted in a reduction in 
mean arterial pressure (MAP) and serum ACE activity in SHRs. Gasparotto Junior et al 
(133) showed that the acute administration of hydroethanolic extract of Tropaeolum 
majus (10 - 300 mg/kg), and its semi-puriﬁed fraction (12.5 - 100 mg/kg) was able to 
dose-dependently reduce MAP of normotensive and SHRs (maximal hypotensive effect 
around 15–20 mm Hg). Isoquercitrin (quercetin-3-O-glycoside) was found as the main 
compound in the hydroethanolic extract of Tropaeolum majus and its semi-puriﬁed 
fraction and when it was administered at a dose of 4 mg/kg, it induced a significant drop 
in MAP of the normotensive anesthetized rats (around 25 mm Hg).  
With regard to flavan-3-ols, studies in animals have found that flavan-3-ols rich 
plants like grape seed (134, 135) and cocoa (136) are associated with improvement in 
endothelial function and with reduction of BP. The antihypertensive effect of dietary (-)-
epicatechin was investigated in different animal models. However, results were not 
consistent as some reported an antihypertensive effect (137, 138) while some others did 
not (139, 140). 
Concerning flavanones, the short and long-term effects of glucosyl hesperidin (a 
water-soluble derivative of hesperidin) and hesperetin were investigated in SHR as well 
as in normotensive WKY rats. Contrary to results in WKY, glucosyl hesperidin caused a 
significant reduction in blood pressure in short (141) and long term (142, 143) studies in 
SHR. The hypotensive effect of hesperetin was significantly inhibited when SHR were 
injected with L-NAME (141) before hesperetin administration. This indicates that the 
 44 
 
antihypertensive effect of hesperetin might be mediated by the vascular nitric oxide 
synthase (NOS) pathway. On the other hand and in male Wistar rats, naringenin did not 
result in a significant reduction in blood pressure at a single dose (144), while naringin 
(flavanone-7-O-glycoside) caused a significant reduction in SBP when applied for long 
terms (145). 
Some flavones have been reported for having synergistic effects in the reduction 
of BP in animal models. For instance, a mixture of luteolin and buddleoside resulted in 
acute and long term antihypertensive effects in SHRs. In contrast, a single dose of 
luteolin or buddleoside was reported not to induce a significant change in BP (146). In 
diabetic rats, both chrysin and luteolin alleviated diabetes-induced vascular complication 
and hypertension on the long term (147). Additionally, chrysin and luteolin caused 
impaired relaxation responses of aorta in diabetes and ameliorated dyslipidemia 
associated with diabetes.  
The effects of lingonberry juice, rich in flavonoids with anthocyanins being the 
dominant compounds influencing BP, on vascular function and vascular inflammation 
was investigated in SHRs over a period of 8 weeks (148). At low concentrations of 
lingonberry juice, reduction in BP consistent with a decrease in inflammatory markers 
was observed while no change occurred in plasma ACE and aldosterone level. 
Additionally, lingonberry juice caused an increase in the total plasma calcium 
concentration which might have positive effect on BP since experimental and 
epidemiological studies reported a positive effect of dietary calcium on BP (149, 150). 
Although quite good evidences are available for the flavonoids in terms of blood 
pressure lowering potency, few studies investigated the impact of phenolic acids. In this 
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context, Yeh et al reported that an oral daily dose (100 mg/kg) of caffeic acid for 6 weeks 
induced a reduction in blood pressure in SHR compared to the control group (151). 
Another study showed that a chronic treatment (8 weeks) with 50 mg/kg/day of ferulic 
acid significantly reduced SBP in both SHR and in young N (ω)-nitro-L-arginine methyl 
ester –treated Wistar rats (152). Suzuki et al. (153) showed that the single ingestion of 
(30-600 mg/kg) of chlorogenic acid reduced BP in SHR. Additionally, when the rats were 
fed with 300 mg/kg/day for 8 weeks, the development of hypertension was inhibited 
compared with the control diet group. 
 Tannic acid is a polymer that is hydrolyzed in to form gallic acid in the 
gastrointestinal tract. Thekkumkara et al (154) showed that a daily treatment with tannic 
acid (5mg/kg body weight) for 4 weeks of SHR induced a significant reduction in MAP 
in SHR in comparison with animals treated with vehicle control. In addition, withdrawal 
of tanic acid reversed its inhibitory effect on MAP. 
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Table 1.2 The effect of pure or isolated flavonoids on blood pressure reported in animal studies 
Sub-class Pure or isolated 
flavonoids 
Animals Dose Main Results Reference 
Flavonols Quercetin SHRs 10mg/kg BW/d for 13 
weeks 
Signiﬁcant reduction in MAP. 
The chronic treatment with quercetin prevented the 
upregulated eNOS and p47 protein expression, the 
downregulated caveolin-1 expression, the increased NADPH-
induced superoxide production in SHRs compared to non-
treated SHRs 
(129) 
Quercetin One-clip (2K1C) 
Gold blatt (GB) 
hypertensive rats 
Oral administration of 
10 mg/kg BW/d for 5 
weeks 
Significant reduction in SBP since the second week of the 
administration. 
Improve the decreased endothelium dependent 
relaxation to acetylcholine of aortic rings from GB rats. 
Increased endothelium-dependent vasoconstrictor response 
to acetylcholine and overproduction of TXB2 by aortic vessels 
of 
GB rats, being without effect in normotensive animals. 
Increased plasma NOx and TBARS, and decreased liver total 
glutathione 
(GSH) levels and glutathione peroxidase (GPX) activity in GB 
hypertensive rats compared to the control animals 
 
(155) 
 
 
Quercetin 
 
Male Wistar rats 10mg/kg BW /d 
intraperitoneally for 
14 days 
Quercetin treatment induced no significant changes in the 
hypertensive responses to angiotensin I and angiotensin II, as 
well in the hypotensive responses to bradykinin, compared to 
response to captopril. No significant differences were found in 
plasma ACE activity in rats treated with quercetin compared 
with those found in the control group 
(156) 
Quercetin 
 
Male Dahl salt-
sensitive (DSS) 
rats 
10mg/kg BW/d for 4 
weeks 
Quercetin lowered SBP significantly in comparison to baseline. 
The reduction in SBP was in keeping with their increased 
urinary output, increased sodium output, decreased 
aldosterone and decreased AT1a mRNA. 
(157) 
Quercetin Male SHRs 
 
 
10 mg/kg BW/d for 4 
weeks (oral 
administration) 
Quercetin reduced BP, left 
ventricular and renal hypertrophy and improved NO-
dependent acetylcholine relaxation 
(130) 
Quercetin Male SHRs  10 mg/Kg BW/d (oral 
administration): 
 acute effect 
A progressive decrease in mean BP reach maximum level at 6h 
of administration. Incubation of the mesenteric arteries with 
quercetin for 30 min caused a significant concentration 
dependent decrease in the vasoconstrictor response to 
phenylephrine. 
(131) 
Quercetin-3-
glucuronide isolated 
from green bean pods 
isorhamnetin-3 
glucuronide produced 
enzymatically from 
isorhamnetin 
Male SHRs  1 mg/kg BW i.v (acute 
effect) 
A progressive decrease in mean BP with maximum effects seen 
after 3h of administration. Incubation of the mesenteric 
arteries with quercetin-3-glucuronide for 1 and 2h and not for 
30 min caused a significant reduction in the vasoconstriction 
induced by phenylephrine  
(131) 
 
Quercetin Male Sprague 
Dawley rats 
Intragastrically, 25 or 
50mg/kg BW/d for 6 
days 
Quercetin restored the suppressed vascular responsiveness to 
bradykinin, acetylcholine, and phenylephrine in phenyl 
hydrazine control rats in a dose-dependent manner. 
Quercetin partially protected blood glutathione, suppressed 
plasma malondialdehyde levels, and largely suppressed nitric 
oxide metabolites and superoxide anion production 
(158) 
Enzymatically modified 
isoquercetin 
Male SHRs 3, 25mg/kg BW/d for 
50 Days 
SBP Was significantly lower than that in the control on d22, 36 
and 50 of administration 
(159) 
 isoquercitrin Normotensive 
and SHRs 
Intravenous 
administration of 0.5, 
1, 2 and 
4mg/kg BW 
 
Dose dependent reduction in MAP with minor effect on heart 
rate. 
Reduced ACE activity in serum samples at 90 min 
after administration 
(133) 
Baicalein, flavone, or 
quercetin 
SHRs Oral adminstration10 
mg/kg BW for 4 
weeks. 
SBP was measured 24 
hours after the 
last treatment 
Flavone, quercetin but baicalein not reduced SBP compared to 
vehicle group. All the flavonoid-treated animals showed 
remarkably higher endothelium-dependent relaxations to 
acetylcholine. In contrast to other experimental groups, 
flavone pretreatment also enhanced the endothelium 
independent relaxations to sodium nitroprusside 
 
(160) 
kaempferol Normotensive 
and SHRs 
Intravenous 
administration 
 
No effect on MAP (133) 
Synthesized quercetin-
39-sulfate 
Male SHRs 1 mg/kg BW i.v (acute 
effect) 
No effect on BP (131) 
Pentamethylquercetin 
 
Male Sprague-
Dawley rats 
2.5, 5, 10 mg/Kg BW Treatment prevented the increment in SBP after abdominal 
aorta constriction 
(161) 
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Morin Male Wistar rats 50 mg/kg BW/d for 6 
weeks 
Antihypertensive and antioxidant effects against 
deoxycorticosterone acetate (DOCA)-salt induced 
hypertension 
(162) 
Flavan-3ols (-)-epicatechin Rat model of 
HFD induced 
obesity 
1mg/kg BW/d for 2 
weeks 
No change in SBP in both normal and HF diets groups, 
significantly decreased the rate of weight gain, glycemia and 
hypertriglyceridemi. 
(139) 
Epicatechin obese diabetic 
(db/db) mice 
(0.25% in drinking 
water/d for 15 wk 
blood pressure, blood glucose, food intake, and body weight 
gain were not significantly altered 
(140) 
(–)-Epicatechin SHRs, 
Male wistar rats  
3 g/kg diet 
corresponding to 250 
mg/kg BW/d 
For 6 days 
Decreased BP 
Endothelium dependent vascular function improvement 
mediated by NO 
(137) 
(_)-Epicatechin 
 
Male Sprague–
Dawley rats 
0.2–4.0 g/kg/d diet for 
4 days 
Prevented the increase in BP associated with the inhibition of 
NO production in a dose-dependent manner. 
Prevented oxidative stress and restored NO bioavailability 
(138) 
Epicatechin 
 
Male Sprague–
Dawley rats 
10−9–10−5 M Direct 
arterial infusion ( 
Administered directly 
into the artery of the 
hind-limb circulation). 
 
No changes in blood pressure or heart rate were recorded 
(readings were taken immediately 
after compound administration at 0, 0.5, 1, 1.5, and 2 min 
post injection). 
Direct and immediate vasodilatory effect 
(163) 
Dihydrokaempferide 
isolated from Brazilian 
green propolis 
SHRs 10 mg/kg BW/d (oral 
administration) for 
28days 
Significant decrease in blood pressure, especially marked were 
the effects observed in the group that received isosakuranetin 
(164) 
Flavanones Naringin Male Wistar rats Naringenin: 100 
mg/kg BW/d mixed 
with diet  
For 8 weeks 
Reduced SBP in High carbohydrate high fat diet fed group (145) 
Naringin, 
Hesperidin, 
glucosyl Hesperidin 
stroke-prone 
spontaneously 
hypertensive 
(SHRSP) 
Naringin:1000mg/kg 
diet  
Hesperidin:825mg/kg 
diet  
glucosyl 
Hesperidin:250, 500, 
1000 and 2000 mg/kg 
diet for 4 weeks 
Mixed with the diet 
Significant decrease in SBP. Improved endothelial 
function (enhanced endothelium-dependent relaxation 
induced by acetylcholine, increase in the metabolites of NO in 
urine samples after ingestion of naringin, hesperidin and 
glucosyl hesperidin) 
(143) 
Glucosyl hesperidin SHRs and 
normotensive 
Wistar-Kyoto 
rats (WKYs 
A single oral 
administration (10 to 
50 mg/kg/BW 
 Significant dose-dependent reduction in SBP in SHR 9 and 12 h 
after administration in SHRs 
(141) 
Glucosyl hesperidin SHRs and 
normotensive 
Wistar-Kyoto 
rats (WKYs). 
50mg/kg diet (mixed 
with diet) for 8 weeks 
G-Hesperidin had no effects in WKYs. On the other hand and in 
SHRs, the ingestion of G-hesperidin inhibited the development 
of hypertension and enhanced endothelium-dependent 
vasodilation in response to acetylcholine, but had no effect on 
endothelium-independent vasodilation in response to sodium 
nitroprusside. In addition, G-hesperidin decreased mRNA 
expression of nicotinamide adenine dinucleotide phosphate 
oxidase subunits in 
aorta, which are the main source of superoxide anion in the 
vasculature 
 
(142) 
Naringenin 
 
Male wistar rats 100 mg/kg BW i.p. and 
BP was recorded for 
2h (acute effect) 
Naringenin caused a weak and not significant lowering of 
BP. 
(144) 
Isosakuranetin,  
isolated from Brazilian 
green propolis 
SHRs 10 mg/kg BW/d (oral 
administration) for 
28days 
Significant decrease in blood pressure, especially marked were 
the effects observed in the group that received isosakuranetin 
(164) 
Complex dioclein with 
β-cyclodextrin (1:1) 
 
Mice Single oral dose 
(10mg/kg BW) or 
2.5mg/kg BW 
intraperitoneally 
 
The hypotensive 
response was 
obtained during 3h 
monitoring 
 
Induced a pronounced decrease in SBP. 
The onset of the hypotensive effect of complexed dioclein 
after oral administration is observed later and the maximal 
effect takes longer to be achieved compared to i.p. 
administration 
(165)  
Dioclein Mice Single oral dose 
(10mg/kg BW) or 
2.5mg/kg BW 
intraperitoneally 
The hypotensive 
response was 
obtained during 3h 
monitoring 
Opposite to intraperitoneally, no significant change in SBP was 
seen when dioclein administered orally 
(165) 
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Flavones Purified luteolin from 
the outer cover of 
Arachishypogaea 
(Faba- ceae)  
Male SHRs Single dose (25 mg/kg 
BW, p.o), 
 (acute effect) 
No remarkable decrease in SBP and DBP after 2h of 
administration 
(146)   
Buddleoside from the 
dried flower of 
Chrysanthemum mor- 
ifolium Ramat  
Male SHRs Single dose (25 mg/kg 
BW, p.o) 
BP was measured 
after 2 h 
administration (acute 
effect) 
No remarkable decrease in SBP and DBP after 2h of 
administration  
(146) 
Luteolin:Buddleoside 
(1:1) mixture 
 
Male SHRs 25 mg/ kg BW or 
50mg/kg BW of the 
mixture: Blood 
pressure was 
measured after 2 h 
administration 
 
30, 60mg/kg for 30 
days 
 
Acute and long term antihypertensive effects. In addition, on 
the long term there were significant decrease in angiotensin-II 
(Ang-II) levels and the plasma aldosterone. 
No significant influence in rennin levels in the SHR. Endothelin 
level decreased while nitric oxide level increased 
(146) 
 Chrysin  
  
Male wistar rats Chrysin: 25mg/kg 
BW/d for 6 weeks 
(oral administration) 
Attenuated DBP elevation in diabetic induce rats without 
affecting the developed hyperglycemia, prevented 
dyslipidemia (elevated levels of TGs, total and LDL cholesterol), 
attenuate diabetes-evoked impairment in endothelial-
dependent relaxation 
 (147) 
Luteolin 
 
Male wistar rats Luteolin: 100mg/kg 
BW/d for 6 weeks 
(oral administration) 
Attenuated DBP elevation in diabetic induce rats without 
affecting the developed hyperglycemia, prevented 
dyslipidemia (elevated levels of TGs, total and LDL cholesterol), 
attenuate diabetes-evoked impairment in endothelial-
dependent relaxation 
(147) 
Chrysin glucoside 
isolated from 
Calycotome villosa 
 
Anaesthetize 
Male Wistar rats 
Intravenous injections 
of bolus doses (1–3 
mg/kg BW) of the 
chrysin glucoside 
Immediate and dose-dependent decrease in mean arterial 
blood pressure (MABP). 
Pretreatment of the rats with the nitric oxide synthase 
inhibitor reduced partially, but significantly the maximal 
decrease in MABP elicited by chrysin glucoside 
(166) 
Apigenin SHRs Oral administration 0, 
0.007, 0.026, 0.104 
and 0.417 g/kg 
BW/day 
SBP was decreased. 
The transcription level of ACE2 mRNA in captopril positive 
control group and 0.417 g/kg bw apigenin group was 
significantly higher than the control group 
(167) 
 
Artemetin isolated 
from 
Achillea millefolium L. 
(Asteraceae) 
 
Male Wistar rats Oral administration 
(1.5 mg/kg BW) or 
intravenous (0.15–1.5 
mg/kg BW)  
 
Artemetin dose-dependently reduced the MAP at 3h of 
treatment. 
Intravenous injection of artemetin (0.75 mg/kg) significantly 
reduced the hypertensive response to angiotensin I while 
increased the average length of bradykinin-induced 
hypotension. 
Artemetin did not change angiotensin 
II-induced hypertension 
(168) 
Tilianin isolated from 
Agastache 
mexicana 
SHRs Single oral 
administration 50 
mg/kg BW (acute 
effect) 
Significant decrease in systolic and diastolic blood pressures (169) 
Betuletol isolated from 
Brazilian green 
propolis 
SHRs Oral administration 10 
mg/kg BW/d for 28 
days 
Significant decrease in blood pressure, especially marked were 
the effects observed in the group that received isosakuranetin 
(164) 
Chalcones Dihydrospinochalcone-
A isolated 
Lonchocarpus xuul 
Lundell 
SHRs A single intragastric 
dose (50 mg/kg BW). 
 
A significant decrease in SBP and DBP in SHR rats. No change in 
heart rate. Endothelium-dependent vasorelaxant effects. 
(170) 
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Table 1.3 The effect of flavonoids rich plant material on blood pressure reported in animals models 
Plant or plant 
extracts 
Identified flavonoids Animals Dose Main results Reference 
Methanol 
extractof 
C.papya 
(MECP) 
Quercetin 47.11±0.03µg/g extract SHRs 
And wistar 
rats 
100mg/kg BW 
 Twice a day 
For 30 days 
Serum ACE inhibition in both SHRs and in Wistar rats. 
Reduce MAP in SHRs. 
The chronic treatment with MECP reversed both cardiac 
hypertrophy and the reduction of arterial baroreflex sensivity. 
(132) 
Hydroethanolic 
extract (HETM) 
obtained from 
Tropaeolum 
majus L 
 
Isoquercitrin 38.64± 0.30 mg/g dry 
HETM 
Normotensiv
e and SHRs 
Oral administration of 
HETM (10–300 mg/kg 
BW)  
MAP and heart rate 
were measured at 1.5, 
3, 6 and 12 h of 
treatment 
 HETM Significantly reduced, in a dose-dependent 
manner, the MAP in both normotensive and SHR. In addition, 
these preparations significantly decreased 
the MAP for up to 3 h after the administration. Heart rate was 
not affected. Reduced ACE activity in serum samples at 90 min 
after administration 
(133) 
Semi-purified 
fraction (TMLR) 
obtained from 
Tropaeolum 
majus L 
 
Isoquercitrin 93.45 ± 2.80 mg/g dry 
HETM 
Normotensiv
e and SHRs 
Oral administration of 
TMLR (12.5–100 mg/kg 
BW)  
MAP and heart rate 
were measured at 1.5, 
3, 6 and 12 h of 
treatment 
TMLR Significantly reduced, in a dose-dependent manner, the 
MAP in both normotensive and SHRs., MAP decreased for up 
to 3 h after the administration. 
Heart rate was not affected. 
Reduced ACE activity in serum samples at 90 min after 
administration 
(133) 
Carpobrotus 
rossii (CR) 
extract 
31% w/v acylated spinacetin 
Glycosides 
male 
Hooded-
Wistar rats 
35 ± 0.52 mg/kg BW/d 
for 4 weeks 
No change in SBP. 
Total cholesterol was lower but other blood chemistry 
parameters including HDL and triglycerides were similar. 
(171) 
Whole yellow 
passion fruit 
pulp (Passiflora 
edulis 
Sims f. 
flavicarpa Deg.) 
Mg in 100 g in the yellow passion 
fruit pulp:  
Apigenin-3-rhamnoside (4.01±0.17) 
luteolin-3-glucoside(3.63±0.15) 
quercetin (2.21±0.32) 
 kampferol (1.78±0.06) 
SHRs 
 
 
 
 5,6 and 8g of Yellow 
passion fruit pulp/kg 
BW/d for 5 days 
8g from the whole passion fruit significantly decreased SBP. 
Enhancement of the 
antioxidant status 
(172) 
Low molecular 
grape seed 
proanthocyanid
in extract (LM-
GSPE) 
Mg/ g extract: 
Catechin 90.7±7.6 
Epicatechin 55.0±0.8 
Procyanidin dimer 144.2±32.2 
Procyanidin trimmer 28.4±2.0 
Procyanidin tetramer 2.0±0.2 
Quercetin 0.3±0.0 
Quercetin-3-O-gallate 0.2±0.0 
Naringenin-7-glucoside 0.1±0.0 
Kaempferol-3-glucoside 0.1±0.0 
Wistar rats  375mg/kg BW 
(acute effect) 
Decrease in both the SBP and DBP within 6 h from 
administration. Decrement in both the plasmatic and hepatic 
TC and TG levels 
(134) 
Grape seed 
procyanidin 
extract (GSPE) 
Mg/g extract 
Epigallocatechin gallate 0.4±0.1 
Procyanidin trimer28.4±2.0 
Procyanidin tetramer 2.0±0.2 
Epicatechin gallate 55.3±1.5 
Quercetin-3-O-galactoside 0.2±0.0 
Naringenin-7-glucoside 0.1±0.0 
Kaempferol-3-glucosid 0.1±0.0 
Quercetin 0.3±0.0 
SHRS and 
WKY 
375 mg/kg BW 
Acute effect 
GSPE caused a significant decrease in SBP of SHR  
(maximum decrease 6 h post-administration), while did not 
affect BP of Wistar–Kyoto rats. GSPE increased the activity of 
an antioxidant endogen system but did not affect plasma ACE 
value compared to non treated group. 
Improvement of oxidative stress (rapid increase in hepatic 
GSH, observed only 6 h post-administration in the GSPE group 
of SHR) 
 
(135) 
Proanthocyanid
ins fraction 
(PAF) from 
Persimmon 
Leaf Tea 
Content of PAF (% ) 
Catechin 16.1 ± 0.0 
Epigallocatechin 39 ± 1.1 
 
Epigallocatechin-3-O-gallate 3.2 ± 
0.2 
Epicatechin 36.1 ± 0.3 
Epicatechin-3-O-gallate 5.8 ± 1.4 
SHRs 
 
Single dose 100, 300 
mg/kg BW using 
stomach tube. 
BP was measured at 
0,2,4,6 8h  
300 mg/Kg Caused a gradual and significant decrease in SBP 
with minimum value obtained at 4h. 
100mg/kg resulted in a minimum but not significant value of 
SBP at 2h 
(173)  
A natural 
flavonoid-
enriched cocoa 
powder 
(CocoanOX) 
 
 (‏+)-catechin 5.18 ± 0.09 
(-)-epicatechin 19.36 ±0.03 
procyanidin B2 16.85±0.06 
procyanidin B1 1.25±0.07 
SHRs 50, 100, 300, and 
600mg/kg BW. 
BP was measured at 2, 
4, 6, 8, 24, and 48 h 
Post administration 
Does dependent antihypertensive effect up to the dose 
300mg. 
The maximum decrease in the SBP was achieved 4 h post 
administration of 300mg/kg 
 (136) 
Aqueous 
Extract (AE) of 
Cecropia 
glaziovii Sneth 
 
Catechins:12% 
Procyanidins: 19%  
Flavones: 19% 
Female 
normotensie 
Wistar rats 
A single dose of AE (1 
g/kg BW, p.o.) or 
repeatedly (0.5 
g/kg/bid, p.o.) for 60 
days 
The arterial blood pressure, heart rate and plasma ACE 
activity were not significantly modified within 24 h after a 
single dose administration of AE. 
Repeated treatment with AE reduced the mean SBP after 14 
days. 
The plasma ACE activity was unchanged.  
Reduce BP not due to ACE 
(174)  
Tea catechin 
extracts 
56.1% 
(–)-EGCG, 11.0% (–)-
epigallocatechin (EGC), 9.9% (–)-
epicatechin 
(EC), 5.1% (–)-gallocatechin-gallate 
Malignant 
Stroke-
prone 
spontaneous
ly 
0.5% tea catechin 
extract solution as 
driniking water for 
3weeks 
Tea catechin ingestion significantly delayed stroke onset by 10 
days compared to the control group. 
Although there was no difference in blood pressure at 10 
weeks, the rate of in blood pressure increase in the tea 
catechin group was significantly smaller than that in the 
(175) 
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(GCG), 3.2% 
(–)-epicatechin-gallate (ECG), 0.1% 
(–)-catechin-gallate (CG) 
hypertensive 
rats ((M-
SHRSP)) 
control group. 
Green tea 
extract 
Epicatechin (EC) 3.83 ± 0.15 
(−)-Epicatechin-3-gallate (ECG) 
13.50 ± 0.92 
(−)-Epigallocatechin (EGC) 33.49 ± 
1.31 
(−)-Epigallocatechin-3-gallate 
(EGCG) 28.54 ± 1.22 
Diabets 
induced 
Male albino 
rats of 
Wistar strain 
300mg/kg BW for 4 
weeks 
The increase in blood glucose, glycated hemoglobin and 
systolic blood pressure in diabetic rats were reduced upon 
green tea treatment. 
(176)  
Tea catechin 31.7% of 
epigallocatechin gallate, 15.7% of 
epigallocatechin, 
10.0% of epicatechin gallate, and 
8.5% of epicatechin 
Sprague–
Dawley rats 
diabetic 
induced rats 
 
5mg/day (in drinking 
water) for 12 weeks 
No change in blood pressure  (177) 
Lingonberries 
(Vaccinium 
vitis-idaea) 
juice 
Content in juice mg/100g: 
Anthocyanins 5.9 ± 0.1 
Flavonols 3.8 ± 0.1 
Flavan-3-ols 3.0 ± 0.1 
 
SHRs Daily intake per rat: 
 
Anthocyanins 2.2 mg 
Flavonols 1.4 mg 
Flavan-3-ols 1.1mg 
Procyanidins 7 mg 
 
For 8 weeks 
SBP decreased. 
Endothelium-dependent vascular relaxation was not 
improved. 
Slightly affected plasma inflammatory markers (reduction of 
NOx and sICAM-1) and clinical chemistry variables (decreased 
alkaline phosphatase and increased chloride and calcium 
levels). 
No change in circulating ACE between the different groups. 
Plasma aldosterone levels did not differ 
 
(148) 
 
1.4.1.2 Anti-hypertensive effects of phenolic compounds reported in human studies 
 
The potential health benefits of phenolic compounds and phenolic compounds-rich food 
in humans has been addressed over the last decades. In this regard, human intervention 
trials provided indications that consumption of foods rich in phenolic compounds might 
be associated with a reduced risk of coronary heart disease and hypertension.  
Cocoa products are the main sources of flavonoid-rich foods studied for their 
potential to lower BP. Some randomized controlled trials showed no significant effect for 
the daily ingestion of flavonoid-enriched chocolate on BP for 1 year (178, 179). 
However, evidence from other studies supports the health promising effects of 
consumption of flavonoid-rich cocoa products such as dark chocolate in the control of 
SBP and DBP (180-182). In this context, it is worthy to mention is that European Food 
Safety Authority (EFSA) has approved the health claims on consumption of cocoa 
flavanols in the high flavanol cocoa extract (i.e. in capsules or tablets) and maintenance 
of normal endothelium-dependent vasodilation. In order to obtain the claimed effect, 200 
mg of cocoa flavanols should be consumed daily. This amount could be provided by less 
than one gram of high flavanol cocoa extract in capsules or tablets, and can be consumed 
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in the context of a balanced diet.  
Fruits and vegetables are rich sources of anthocyanins and flavanols. Human 
intervention studies using fruits and vegetables for their potential antihypertensive effect 
have been less performed. However, there is a consistency in the results reported in terms 
of positive effects of fruits and vegetables rich in anthocyanins and/or flavanols in 
reducing BP and the potential role in the protection against CVD regardless of the study 
design and study period (183-186). 
Grape and grape seed are rich sources of phenolic compounds. The involvement 
of these sources in promoting BP reduction was reported in many studies. In a placebo-
controlled double-blind study, Park et al. (187) evaluated the effect of daily consumption 
of 5.5ml/kg body weight of grape juice (containing 472.8 mg total polyphenols per 240 
mL) for 8 weeks in hypertensive Korean patients. At the end of the 8 weeks of 
intervention, both SBP and DBP were significantly reduced by 7.2 mm Hg and 6.2 
mmHg, respectively. A meta-analysis of randomized controlled trials showed that a 
polyphenol rich grape seed extract significantly lowered SBP and heart rate (188). Very 
recently, a double-blind, placebo-controlled, randomized intervention study investigated 
the effect of a specific grape seed extract rich in low-molecular-weight polyphenolic 
compounds on ambulatory blood (ABP) in untreated subjects with pre- and stage I 
hypertension. This study showed that consumption of 300 mg/d grape seed extract during 
an intervention period of 8 weeks did not significantly lower the ABP in untreated 
subjects with pre- and stage I hypertension (189). Additionally, the consumption of 
raisins which are rich sources of a wide variety of polyphenols, catechins, resveratrol, and 
isoﬂavones (daidzein and genestein) was reported to be associated with lowering of blood 
 52 
 
pressure (190, 191). 
Until now, only few studies attempted to evaluate the impact of consuming 
isolated or pure phenolic compounds on BP. However, quercetin, which is one of the 
most abundant flavonoids in fruits and vegetables and probably the most studied 
molecule, has been investigated quite thoroughly for its antihypertensive potential. In a 
randomized, double-blind, crossover trial, 4 weeks of supplementation with quercetin 
(730 mg/day) resulted in a reduction in SBP (−7 ± 2 mmHg) and DBP (−5 ± 2 mmHg) in 
stage I hypertensive patients but not in those without hypertension (192). More recent 
studies in overweight–obese subjects with risk for metabolic syndrome showed that 
quercetin consumption (150 mg/day) for 5–6 weeks significantly reduces SBP and 
provides protection against CVD (193, 194). Hesperidin is another flavonoid that has 
been reported to have a beneficial effect on BP as stated in table 3. A randomized cross-
over study with healthy volunteers found that a 4-week consumption of orange juice (500 
ml/day containing 292 mg of flavanon hesperidin) as well as a control drink plus 
hesperidin (146 mg) resulted in a significantly lower DBP (−3.2 ± 1.5 mmHg and -5.5 ± 
1.8 mmHg, respectively) compared to a control drink plus placebo (195).  
With regard to the impact of phenolic acids on blood pressure regulation in 
humans, a double-blind placebo-controlled study evaluated the effect of chlorogenic acid 
from green coffee bean extract on mild hypertensive subjects. It was found that a 
treatment with 140 mg/day of chlorogenic acid for 12 weeks caused a significant 
reduction in SBP and DBP by 10 and 7 mmHg, respectively (196). 
In short, some promising effects on human blood pressure were reported with 
specific compounds and their food sources. However, most results are based on complex 
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food, extracts or beverages and thus the effect of compounds other than phenolic 
compounds cannot be excluded (178, 183, 197, 198). In addition, different designs, 
different intervention times and different doses might result in different results (194, 199, 
200). Therefore, more human interventions using specific pure phenolic compounds are 
needed to confirm the role of these compounds in lowering blood pressure. 
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Table. 1.4 Recent trials on the effect of flavonoids and flavonoids rich food on blood pressure in humans 
Authors Participants Study design Intervention 
duration 
Dose and treatment Results 
Edwards et al. 
(192) 
Men and women with 
prehypertension (n = 
19) and stage 1 
hypertension (n = 22 
Randomized, double-
blind, placebo-
controlled, crossover 
study 
4 weeks 730 mg quercetin/d vs. 
placebo. 
Blood pressure was not altered in prehypertensive 
patients after quercetin supplementation. In contrast, 
reductions in (P < 0.01) systolic (-7 +/- 2 mm Hg), 
diastolic (-5 +/- 2 mm Hg), and mean arterial pressures (-
5 +/- 2 mm Hg) were observed in stage 1 hypertensive 
patients after quercetin treatment 
Larson et al. 
(200)  
 
Normotensive men (n = 
5) and stage 1 
hypertensive men (n = 
12) 
Randomized, 
double-blind, cross-
over, placebo-
controlled study 
Acute effect  1095 mg quercetin (single 
dose) 
In stage 1 hypertensive Individuals, mean BP decreased 
significantly 10 hours after administration. Plasma ACE 
activity, nitrites and brachial artery flow-mediated 
dilation were unaffected  
Dower et al. 
(201) 
Healthy men and 
women (n=37) 
a randomized, 
double-blind, 
placebo-controlled, 
crossover trial 
4 Weeks Participants received (-)-
epicatechin (100 mg/d), 
quercetin-3-glucoside 
(160 mg/d), or placebo 
capsules 
Both epicatechin and quercetin-3-glucoside 
supplementation did not change flow-mediated dilation, 
blood pressure (office BP and 24h ambulatory BP), NO, 
endothelin 1, and blood lipid profile.  
Perez et al. (199) 
  
 
 
 
15 Healthy volunteers ( 
6 female) 
Randomized, double 
blind, placebo-
controlled trial 
3 Weeks Participants were given a 
capsule containing placebo or 
200 or 400 mg of quercetin 
daily 
No changes were observed in BP 
Brüll et al. (202) 70 overweight-to-obese 
patients with pre-
hypertension and stage I 
hypertension. 
Randomized double-
blinded placebo-
controlled cross-over 
trial 
6-week 
treatment 
periods 
separated by 
a 6-week 
washout 
period 
Patients were randomized to 
receive 396 mg of onion skin 
extract powder /d which 
contains 162 mg quercetin or 
placebo 
In the total group, quercetin did not significantly affect 
24 h ABP parameters and office BP. In the subgroup of 
hypertensives, quercetin significantly decreased 24h, 
day-time and night-time SBP when compared with 
placebo. 
In total group and also in the subgroup of hypertensives, 
vasoactive biomarkers including endothelin-1, soluble 
endothelial-derived adhesion 
molecules, asymmetric dimethylarginine, angiotensin-
converting enzyme activity, endothelial function, 
parameters of oxidation, inflammation, 
lipid and glucose metabolism were not affected by 
quercetin supplementation 
Schroeter et al. 
(203) 
Healthy individuals n=6 Randomized cross 
over study 
Acute effects (-)-Epicatechin ( 1 or 2 mg/kg 
BW 
Both doses resulted in similar and significant increase in 
FMD after 2h of ingestion compared with baseline and 
water controls. 
Schroeter et 
al.(203) 
 
 
Healthy individuals n=10 Randomized, double-
blind, cross over 
study 
Acute effects Cocoa powder with high (917 
mg) or low flavanol content 
(37 mg) was given on 2 
separate days with >days 
washout 
The oral ingestion of the high-flavanol cocoa resulted in 
a significant transient increase of the FMD response at 
1–4 h postconsumption compared with baseline of the 
same day. The high-flavanol cocoa -mediated increase in 
FMD was paralleled by an augmentation of plasma 
nitroso species (RXNO) concentrations at 1–3 h 
Blazer et al. (204) Medicated diabetic 
patients (n=41) 
Double-masked 
randomized, 
controlled trial 
30 day 3 doses per day of Flavanol-
rich cocoa (321 mg flavanol) 
per dose or a nutrient-
matched control (25 mg 
flavanol) per dose 
FMD was significantly increased compared to baseline. 
Endothelium-independent response, blood pressure, 
heart rate were not affected. 
Curtis et al. (178)  
 
118 Postmenopausal 
women with type 2 
diabetes 
Randomized double-
blind, controlled trial 
1 Year 27 g/day of flavonoid-enriched 
chocolate 
(850 mg flavan-3-ols, 90 mg 
epicatechin] and 100 mg 
isoflavones/ 
day) 
Significant reduction in estimated peripheral insulin 
resistance and improvement in insulin sensitivity. 
Significant reductions in total cholesterol. 
No effect on BP, HbA1c, or glucose was observed. 
Davison et 
al.(205) 
52 Subjects with 
untreated mild 
hypertension 
Randomized double-
blind, parallel study 
6 Weeks Reconstituted cocoa beverage 
containing 33, 372, 712 or 
1052 mg/ day 
There were significant reductions in 24-h systolic, 
diastolic and mean arterial BP only at the highest dose 
Terauchi et al. 
(206) 
 
96 Women Randomized, double-
blind, placebo-
controlled 
pilot study 
8 Weeks Either low-dose (100 mg/d) or 
high-dose (200 mg/d) 
proanthocyanidin, or placebo 
Cardiovascular parameters, were similar among the 
groups. 
SBP and DBP decreased in the low-dose and high-dose 
groups after 4 weeks. 
 
Hassellund et a.  
(207) 
31 Men with screening 
blood pressure 
4140/90mmHg without 
anti-hypertensive or 
lipid-lowering 
medication 
Randomized double-
blind placebo-
controlled crossover 
study 
4 Weeks 
with 1 week 
washout 
 640mg Anthocyanins daily 
versus placebo 
High-density lipoprotein (HDL)-cholesterol and 
blood glucose were significantly higher after 
anthocyanin versus placebo treatment. 
No effects were observed on inflammation or oxidative 
stress in vivo 
Curtis et al. 
(208) 
52 healthy 
postmenopausal women 
Randomized, 
placebo-controlled 
study 
12 Weeks 500 mg/d anthocyanins 
as cyanidin glycosides (from 
elderberry) or placebo (2 
capsules twice/d 
No effects on biomarkers of CVD risk as there was no  
change in plasma levels of inflammatory biomarkers 
(CRP, TNFa, IL-6, TNF RI and RII, and RANTES), vascular 
activity (endothelin-1, platelet reactivity, 
blood pressure, pulse). In addition, plasma lipids and 
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lipoproteins (total cholesterol, HDL cholesterol, LDL 
cholesterol, triglycerides), or glucose concentrations, 
were all within the anticipated physiological range 
Barona et al. 
(184)  
 
Men classified with 
metabolic syndrome (n 
= 24) 
Randomized double-
blind, cross-over 
study 
30 days Participants were randomized 
and allocated to 46 g/d of the 
grape polyphenols extract 
supplement ( flavonoids 
content mg/kg freeze dried 
powder: Flavans 4100; 
Anthocyanins 770; Quercetin 
30.8; Myricetin 2,55; 
Kaempferol 3,15 or to a 
placebo  
SBP and plasma soluble intercellular adhesion molecule-
1 (sICAM-1) concentrations were lower, whereas the 
response of the vascular endothelial function marker 
FMD was higher, during the GRAPE compared with the 
placebo period. Plasma NOx concentration did not differ 
after grape powder treatment. Changes in systolic BP 
were negatively correlated with changes in NOx 
concentrations 
Habauzit et al. 
(209) 
Healthy 
postmenopausal women 
(n= 48) 
Randomized, double-
blind, controlled, 
crossover trial 
6 months Participants were randomly 
assigned to consume 340 mL 
grape fruit juice (GFJ)/d, 
providing 210 mg 
naringenin glycosides, or a 
matched control drink without 
flavanones with 2 months 
washout between beverage 
Endothelial function in macro- and microcirculation, 
blood pressure, glucose metabolism, and biomarkers 
of inflammation and oxidative stress were not affected 
by the intervention. The mean carotid-femoral pulse 
wave velocity, which reflects central aortic stiffness, was 
statistically significantly lower after consumption of GFJ 
than after consumption of the matched control drink 
without flavanones 
Johnson et al. 
(210) 
Postmenopausal women 
with pre- and stage 1- 
Hypertension (n=48) 
Randomized, double-
blind, placebo-
controlled clinical 
trial 
8Weeks 22 g freeze-dried blueberry 
powder (469.48 anthocyanins) 
or 22 g macronutrient-
matched control powder 
SBP and DBP significantly lowered. Nitric oxide level 
increased in the blueberry group compared with the 
baseline level, whereas there were no changes in 
the control group. 
Basu et al. (211) 60 volunteers (5 men 
and 55 women) 
Randomized 
dose-response 
controlled trial 
12 Weeks 1 of the following 4 beverages: 
1) low-dose freeze dried 
strawberries (LD-FDS; 25 g/d) 
containing 78 mg 
antocyanins/g; 2) low-dose 
control (LD-C); 3) high-dose 
freeze dried strawberries (HD-
FDS; 50 g/d containing 155mg 
anothcyanins/g); and 4) high-
dose control (HD-C).  
Significantly greater decrease in total and LDL 
cholesterol in the HD-FDS compared to LD-FDS. 
The decrease in LDL and total cholesterol remained 
significant over the 12 week treatment compared to 
control group. Both LD-FDS and HD-FDS treatments did 
not affect any measures of adiposity, blood pressure, 
glycemia, and serum concentrations of 
HDL cholesterol and triglycerides, C-reactive protein, 
and adhesion molecules. 
Curtis et al. (179) 
 
93 Postmenopausal 
women with diabetes  
Randomized double-
blind controlled 
study 
1 Year Either 27 g flavonoid-enriched 
chocolate/d [850 mg flavan- 
3-ols (90 mg epicatechin) + 
100 mg isoflavones (aglycone 
equivalents)/ 
d] or matched placebo 
no significant change in BP 
Erlund et al. 
(183)  
 
72 Subjects Single-blind, 
randomized, 
placebo-controlled 
8 Weeks 160 g/day of different berries 
for 8 weeks, providing 837 
mg/day of polyphenols of 
which 60% were anthocyanins 
Berry consumption decreased BP and increased HDL 
concentration. 
Total cholesterol and triacylglycerol did not change 
Naruszewicz et 
al. (186) 
44 Coronary artery 
disease patients 
A double-blind, 
placebo-controlled, 
parallel trial 
6 Weeks Subjects were given either 
chokeberry flavonoid extract 
(255 mg/day; of which 25% 
anthocyanins, 50% monomeric 
and polymeric procyanidins) or 
a placebo  
Flavonoids significantly reduced serum 8-isoprostans 
and Ox-LDL levels. Significant increase in adiponectin 
levels and reduction in SBP and DBP by a mean average 
of 11 and 7.2 mmHg, respectively. 
Egert et al. (194) 
 
93 Overweight or obese 
subjects with 
metabolic syndrome 
traits 
A double-blinded, 
placebo-controlled 
cross-over trial 
6 Weeks Either 150 mg quercetin/day 
or placebo 
In contrast to placebo, quercetin decreased SBP by 
2·6mmHg in the entire study group. 
Quercetin decreased serum HDL-cholesterol 
concentrations , while total cholesterol, TAG and the 
LDL:HDL-cholesterol and TAG:HDL-cholesterol ratios 
were unaltered. Quercetin significantly decreased 
plasma concentrations of atherogenic oxidised LDL, but 
did not affect TNF-a and C-reactive protein when 
compared with placebo. 
Egert et al. (193) 93 Overweight-obese 
volunteers with 
metabolic syndrome 
traits in relation to 
apolipoprotein (apo) E 
genotype 
Adouble-blinded, 
placebo-controlled, 
crossover trial 
6 Weeks Either 150 mg quercetin/day 
or placebo  
Quercetin decreased SBP by 3.4 mm Hg in the apoE3 
group, whereas no significant effect was observed in the 
apoE4 group. Quercetin decreased serum HDL 
cholesterol and apoA1 and increased the LDL:HDL 
cholesterol ratio in the apoE4 subgroup, whereas the 
apoE3 subgroup had no significant changes in these 
variables. Quercetin significantly decreased plasma 
oxidized LDL and tumor necrosis factor-α in the apoE3 
and apoE4 groups.  
 
Reshef et al. 
(212) 
12 Patients with stage I 
hypertension, 
Randomized Double-
blind, cross-over 
study 
12 Weeks Each patient received 0.5 
L/day alternately 
high-flavonoid sweetie juice 
(677 
mg/L of naringin and 212 mg/L 
of narirutin) and low-flavonoid  
The high flavonoid sweetie juice was more effective 
than low flavonoid sweetie juice in reducing DBP.  
SBP declined with no significant difference 
between subjects in both groups. 
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sweetie juice (166 mg/L of 
naringin and 64 mg/L of 
narirutin), each for a 5-week 
period 
Naomi et al. 
(197)  
34 Healthy subjects 
devided in 2 groups 
(young and older 
groups) 
- 4-6 Days 920 ml of flavanol-rich cocoa 
in four 230-ml doses/day. 
The cocoa beverage contained 
the following flavanols/100 ml: 
epicatechin 
9.2 mg, catechin 10.7 mg, and 
flavanol oligomers 
69.3 mg 
Cocoa alone induced no significant changes in BP at day 
5 compared to baseline in both groups. 
Flow mediated vasodilation, measured by tonometry in 
the finger was enhanced with flavanol-rich cocoa in 
both groups, but significantly more among the old.  
Four to six days of flavanol-rich cocoa caused a rise in 
pulse wave amplitude in both groups. 
Morand et al. 
(195) 
24 Healthy overweight 
men 
Randomized, 
crossover controlled 
study 
4 Weeks 500 ml Orange juice (292 mg 
of hesperidin and 47 mg of 
nariratin) or 500 ml control 
drink plus capsules of pure 
hesperidin (2 × 146 mg) or 500 
ml control drink daily capsules 
of pure hesperidin (2 × 146 
mg) 
DBP was significantly lower and postprandial 
microvascular endothelial reactivity was significantly 
improved after 4 wk consumption of orange juice or 
control plus hesperidin compared with control. 
Rizza et al. (213) 24 individuals with 
metabolic syndrome  
Randomized, 
placebo-controlled, 
double-blind, 
crossover trial 
3 weeks 500 mg Hesperidin orally per 
day 
Hesperidin treatment increased flow-mediated dilation 
and reduced concentrations of circulating inflammatory 
biomarkers (high-sensitivity C-reactive protein, serum 
amyloid A protein, soluble E-selectin). 
Desideri et al. 
(198) 
90 Elderly men and 
women with mild 
cognitive impairment 
Double-blind, 
randomized, parallel 
arm study 
8 weeks Cocoa drink with flavan-3-ols 
at high (990mg flavan-3-ols), 
intermediate (520 mg) or low 
level (45 mg) 
BP, insulin resistance, , and lipid peroxidation decreased 
among subjects in the high-flavanol and intermediate-
flavanol groups compared with the low flavonoid group. 
Asgary et al. 
(185) 
21 hypertensive patients Single blind clinical 
trials 
2 weeks Either 150 ml (8.7 mg 
anthocyanin )/ day of 
pomegranate juice or water 
Both SBP and DBP decreased. A significant reduction in 
serum vascular cell adhesion molecule-1. Serum levels 
of E-selectin were elevated by the end of trial in the PJ 
group. 
Differentials for other parameters intracellular adhesion 
molecule-1 (ICAM-1), high-sensitivity C-reactive protein 
(hs-CRP) and interleukin-6 ( IL-6) were not found to be 
significantly different between the study group. 
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1.4.1.3 Possible mechanisms of action 
 
Figure 1.5 sumarizes proposed actions of phenolic compounds underlying their potential 
antihypertensive activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Proposed mechanisms involved in the potential role of phenolic compounds 
on blood pressure. ROS, reactive oxygen species; SOD, superoxide dismutase; GPx, 
glutathione peroxidase; NADPH, nicotinamide adenine dinucleotide phosphate; eNOS, 
endothelial nitric oxide synthase; NO, nitric oxide; ET, endothelin-1; EDHF, endothelium 
derived hyperpolarizing factor; ACE, angiotensin converting enzyme; ACE2, angiotensin 
converting enzyme 2. 
 
 1.4.1.3.1Phenolic compounds and oxidative stress  
 
During the course of oxygen metabolism, significant amounts of reactive oxygen species 
(ROS) such as superoxide are produced under normal conditions. Superoxide, which is 
the primary ROS produced in the body, is a short-living, highly reactive, and cytotoxic 
molecule that can attack and modify adjacent molecules. The natural antioxidant system 
neutralizes ROS under normal conditions. However, the imbalance between the 
production of ROS and antioxidant capacity which can result from heightened ROS 
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generation, an impaired antioxidant system, or a combination of both, causes oxidative 
stress (214).  
Although the connection between free radicals and hypertension has been known 
since the 1960’s, the role of oxidative stress in the development of hypertension began to 
be fully investigated in the 1990’s (215). Studies in animals suggests that the reduction in 
the bioavailability of nitric oxide (NO) can be one of the most important mechanisms by 
which oxidative stress can raise BP (216). When NO is released from endothelial cells, it 
causes smooth muscle relaxation, resulting in vasodilation, increased blood flow and a 
reduction in BP. NO is synthesized by various nitric oxide synthase (NOS) enzymes. 
Heightened ROS generation leads to a decrease in NO bioavailability by direct 
inactivation in the reaction that forms peroxynitrite (217, 218). Peroxynitrite oxidizes and 
destabilizes NOS which in turn results in more production of superoxide. The ROS such 
as superoxide can reduce NO production by uncoupling endothelial NOS by 
tetrahydrobiopterin oxidation (cofactor essential for NOS function) or by inhibition of 
dimethylarginine dimethylaminohydrolase (enzyme that degrades the NOS inhibitors, 
methylarginines) (215). Another mechanism that could be involved in the development of 
hypertension caused by oxidative stress is nonenzymatic oxidation of arachidonic acid 
and formation of isoprostanes, which have potent vasoconstrictor, proinflammatory and 
antinatriuretic activity (219). Additionally, ROS can increase vascular smooth muscle 
tone by increasing cytoplasmic ionized calcium concentration ([Ca
2+
]i) (214). Several 
studies reported that essential hypertensive patients and various animal models of 
hypertension to have excessive amounts of ROS and a diminished antioxidant status 
(215, 220, 221). Studies with mice with a genetically engineered deficiency in ROS-
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generating enzymes showed that these models have lower blood pressure than wild type 
mice (222, 223). In addition, Ang II infusion in these mice did not cause hypertension 
(223). Therefore and due to the antihypertensive effect of inhibition of ROS-producing 
enzymes or the antioxidant therapy and ROS scavengers, it was proposed that ROS can 
be causative in the development of hypertension (224) and that oxidative stress can play a 
critical role in the pathogenesis of hypertension and its related complications (225-228). 
As a result, amelioration of oxidative stress was one of the important elements in the 
prevention and treatment of hypertension (215).  
Phenolic compounds are well known as natural antioxidants. Thus, their reported 
effects in the prevention of cardiovascular disease might be partially attributed to their 
potential to reduce vascular oxidative stress through their direct superoxide anion 
scavenging activity or through interaction with other ROS such as hydroxyl radicals and 
peroxy radicals. Additionally, they have the potential to stimulate endogenous antioxidant 
enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GPx) (229, 
230). On the other hand, it is reported that they inhibit the two major enzymes generating 
ROS namely, xanthine and NAD(P)H oxidases, which promote NO availability and 
thereby lower BP (231, 232). The antioxidant capacity of phenolic compounds could be 
attributed to scavenging ROS, chelating redox active transition- metal ions, inhibiting 
pro-oxidant enzymes, inhibiting redox sensitive transcription factors, and inducing 
antioxidant enzymes. Flavonoids are good electron donors and efficient scavengers of 
free radicals such as superoxide anions, NO, singlet oxygen, and peroxynitrite. The 
number of ortho-dihydroxyl and ortho-hydroxyketol groups, C2-C3 double bonds, 
concentration, solubility, and the accessibility of the active group to the oxidant are 
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important factors that determine the scavenging capacity of the molecules. The number of 
hydroxyl groups on the B ring contributes significantly to the hydroxyl scavenging 
activity and thereby to the antioxidant capacity. Moreover, flavonoids have a saturated 
heterocyclic ring, which might help ROS predominantly to attach to the ortho-dihydroxy 
site on the B ring. This results in electron delocalization and confers a higher stability to 
the resulting radical semiquinones. Next, the hydroxyl groups at C5 and C7 of the A ring; 
C3′ and C4′ of the B ring; and C3 of the C ring might enhance the inhibition of lipid 
peroxidation (233). 
Cocoa extract rich in flavanols and procyanidins showed a positive effect on 
different oxidative stress parameters such as delaying low-density lipoprotein (LDL) 
oxidation and a reduction in the production of ROS in activated leukocytes and an 
inhibition of ultraviolet-induced DNA oxidation in vitro. However, it is worth mentioning 
that despite the huge number of studies in vitro that show the antioxidant activity of 
flavonoids, the evidence is still limited in vivo (234, 235). In hypercholesterolemic 
patients, flavanol-rich cocoa was reported to counteract lipid peroxidation and lower 
plasma levels of oxidized LDL and increases overall antioxidant capacity (236, 237). 
Green tea catechins were reported to decrease the biomarkers of oxidative stress and lipid 
peroxidation and to increase the plasma antioxidant capacity as well as protect human 
plasma against oxidation (233).  
Generally, several factors influence the antioxidant activity of phenolic compounds in 
humans (238). First, absorption of phenolic compounds in the human gut, and uptake in 
the blood and brain is very low. After the consumption of flavonoid-rich foods, the 
maximum plasma level from these flavonoids is usually reached between 1 and 3 h. 
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These levels range between 0.06 and 7.6 µM for flavonols, flavanols and flavanones, and 
less than 0.15 µM for anthocyanidins. Also, the half-lives of flavonoids in human plasma 
are in the range of a few hours. In addition, they are extensively metabolized in the 
intestine and liver (232). Moreover, important to mention is that the majority of the in 
vitro studies are based on the use of phenolic compounds present in foods and not in the 
form they are present in the circulation. Therefore, it can be concluded that extrapolate 
the results to humans should be very critical. Next, the blood or brain levels of phenolic 
compounds are unlikely to be high enough to neutralize free radicals chemically.  
Accordingly, phenolic compounds may act as antioxidants in vivo in a more broad sense 
by interfering with prooxidant processes or by inhibition of prooxidant enzymes such as 
NADPH oxidases, lipoxygenases and myeloperoxidase-mediated modifications of LDL 
(232). 
 1.4.1.3.2 Phenolic compounds and endothelium 
 
The endothelium plays a very important role in BP and blood flow regulation by 
synthesis and release of the vasorelaxing factor NO and the endothelium derived 
hyperpolarizing factor (EDHF) (231). Endothelial dysfunction which is a common 
feature in all forms of cardiovascular disease, including hypertension, is characterized by 
a decrease in vasodilator NO bioavailability which results in less endogenous opposition 
to circulating vasoconstrictor endothelin-1 and in an increase in levels of oxidized-low-
density lipoprotein (239). 
Flavonoids were reported to interact with pathways leading to generation of NO 
from vascular endothelium. Several in vitro studies were done using isolated vessels from 
animals to assess the endothelial function. Results from these studies showed that 
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flavonols, flavones, flavanols, flavanones, and anthocyanins can cause endothelium 
dependent vasorelaxation of isolated arteries via NO release from the endothelium (240, 
241). Stangl et al. (242) reported that the endothelium dependent vasorelaxation induced 
by tea catechin occurs in response to significant dose dependent activation of endothelial 
nitric oxide synthase (eNOS) in the endothelial cells. Quercetin at physiologically 
relevant concentration also increases eNOS mRNA expression in HUVEC (243). In 
addition to the NO dependent pathway, the vascoprotective effect of flavonoids could be 
due to EDHF-mediated responses in porcine coronary arteries and aortic vessels (231, 
244). 
In animal models, studies reported that the BP reducing effect of quercetin was 
accompanied by improvements in the endothelial function induced by an increased NO 
bioavailability and NO production. In addition to the NO-dependent vascular function 
improvement pathway, other studies reported that quercetin decreases plasma ET-1 
(vasoconstrictor) in rats (234). Gómez-Guzmán et al. (245) reported that the protective 
effect of epicatechin in deoxycorticosterone acetate (DOCA)-salt-induced hypertension 
was mediated by the improvement in endothelium function and the reduction in plasma 
ET-1 levels. Additionally, the study showed that the effects on aortic endothelial function 
were associated to an attenuation of vascular oxide content and an increased 
phosphorylation of endothelium NO synthase. Yamamoto et al. (141) suggested that the 
hypotensive effect of hesperetin in SHR involved NO-mediated vasodilation. This is 
because hesperetin enhanced endothelium-dependent relaxation had no effect on 
endothelium-independent relaxation. Moreover, in the presence of nitric oxide synthase 
inhibitor, the depressor effect of hesperetin was significantly inhibited. 
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In humans, accumulating data on tea, cocoa, dark chocolate and other related 
sources suggest that phenolic compounds can improve endothelial function (240, 246). 
Acute and chronic green and black tea consumption by healthy subjects resulted in a 
significant improvement in flow-mediated endothelium dependent vasodilatation (FMD) 
of the brachial artery (247, 248). Similarly, the short (hours) and long term (weeks) 
intake of flavonoids derived from chocolate or cocoa resulted in an increase in FMD of 
conduit arteries and microcirculation, the subcutaneous vessels and the coronary arteries 
(204, 249). Most studies suggest that catechins present in tea and chocolate, at least in 
part, attribute to the observed vascular effects and this effect is NO mediated. In 
accordance, Schroeter et al (203) showed that the oral administration of pure (−)-
epicatechin showed similar acute vascular effects as flavanol-rich cocoa as both 
administration of catechin-rich cocoa or pure epicatechin enhanced FMD with acute 
elevation in the level of circulating NO species. The chronic consumption of flavanol-
rich cocoa correlated with the increase in the urinary excretion of NO metabolites, 
suggesting a prolonged and augmented NO synthesis. In addition, the administration of 
L-NG-monomethyl arginine, a competitive NO synthase inhibitor, significantly decreased 
the increase in blood flow, supporting the concept of NO-dependent effects (203, 204). A 
randomized controlled study in healthy men showed that quercetin and (-)-epicatechin 
resulted in a significant increase in plasma S-nitrosothiols, plasma nitrite and in a 
significant reduction in plasma endothelin-1 concentration, a potent vasoconstrictor after 
2h of oral administration (250). In contrast, a very recent study showed that consumption 
of quercetin or epicatechin for 4 weeks did not change FMD, NO and endothelin-1 (201). 
However, there was a difference in the dosages and duration of administration used in 
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both studies which might attribute to the difference in the results. 
Flavonoid-rich vegetables and fruit diets were reported to increase endothelium 
dependent microvascular reactivity and plasma NO levels as well as to improve 
inflammatory status in people with an increased risk of CVD (251). A study on 
individuals classiﬁed with metabolic syndrome demonstrated that, compared with 
placebo, the daily consumption of freeze dried grape rich in flavans, anthocyanins and 
flavonols for 30 days signiﬁcantly improved vascular endothelial function and decreased 
circulating inﬂammatory molecules in addition to lowering SBP (184). Very recently, 
daily intake of fresh pomegranate drink rich in anthocyanin by hypertensive patients for a 
period of 2 weeks resulted in a significant reduction in both SBP and DBP which was 
accompanied by a significant reduction in serum vascular cell adhesion molecule-1, 
which is a biomarker of endothelial dysfunction and vascular inflammation (185). 
Contrary to these results, consumption of onion extracts rich in quercetin for 6 weeks did 
not change endothelin-1, soluble endothelial-derived adhesion molecules, endothelial 
function and parameters of oxidation in hypertensive individuals (202). 
Collectively, evidences from some studies might suggest that one potential 
mechanism by which phenolic compounds or food rich in phenolic compounds decrease 
BP could be through improvement of the NO dependent endothelial function. However, 
the contradiction seen between results from different studies using pure compounds or 
different food sources rich in phenolic compounds cannot be ignored. The reasons behind 
this inconsistency could be attributed to differences in doses used, study duration, and the 
characteristics of individuals participating in the studies at baseline. In addition, phenolic 
compounds rich extracts can also contain other compounds interfering with the results, 
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and partly explain differences compared to studies with pure flavonoids. Moreover, the 
possible synergistic effect that can be seen because of the presence of several phenolic 
compounds in phenolic compounds rich extracts. This highlights the importance of 
conducting more studies to investigate pure compounds individually and the relation 
between lowering BP and biomarkers of endothelial function.  
 1.4.1.3.3 Phenolic compounds and RAAS 
 
RAAS has been recognized for decades for its major role in the regulation of BP and 
fluid balance in the body. Renin, which is released by the kidney in response to a 
decrease in blood volume and renal perfusion, cleaves angiotensinogen to form the 
inactive decapeptide Ang I. ACE metabolizes Ang I into the active octapeptide AngII 
which is known as a vasoconstrictor. AngII promotes the kidney to secrete aldosterone 
which causes sodium and water retention and potassium excretion. This altogether results 
in an increased BP. Overactivation of RAAS leads to hypertension and other 
cardiovascular diseases (252). It is already known that the use of ACE inhibitors or 
specific angiotensin receptor blockers that can interfere with RAAS is one of the 
approaches used to decrease BP (234). The detailed effects of phenolic compounds on 
RAAS are still not clear. There are some indications from in vitro studies which suggest 
that the inhibition of ACE enzyme activity could be one of the mechanisms in which 
flavonoids could reduce BP (97, 98, 253). Very few studies checked the role of phenolic 
compounds in RAAS in vivo. With the data available, no consistency in the results was 
obtained so far. In SHRs, the reduction in ACE activity was reported by the application 
of quercetin-rich extracts (132), the 3-O-glucoside of quercetin and plant extracts rich in 
this flavonoid glucoside (133) after 30 days, and 90 min of administration, respectively. 
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Mackraj et al. (157) indicated that the effect of quercetin in lowering BP in Dehal salt 
sensitive hypertensive rats is probably due to a modulation of renal function. On the other 
hand, Neto Neves et al. (156) suggested that other mechanisms than ACE inhibition are 
probably involved in the antihypertensive and protective cardiovascular effects associated 
with quercetin. In agreement, treatment with procyanidins and catechins-rich extract for 
60 days did reduce BP but did not change plasma ACE activity in female normotensive 
Wistar rats (174). In stage1 hypertensive men, the decrease in BP caused by quercetin 
application was not accompanied by a change in plasma ACE activity (200). Worthy to 
mention is that rennin is the ﬁrst enzyme involved in the cascade of RAAS activation and 
thus it plays a crucial role in hypertension. However, very few reports on renin inhibition 
by phenolic compounds are available. Recent results from in vitro studies provided 
evidence that some phenolic compounds might have an antihypertensive potential 
through renin inhibition. Deng and his colleagues (254) showed that baicalin inhibited the 
activity of ACE and rennin and the fluorescence emission of both renin and ACE were 
efficiently quenched by baicalin. In addition, they showed that baicalin–renin complex 
formed through three-sites binding including the active site, but there was only one 
binding site for the baicalin–ACE complex with a much smaller binding constant. 
Another study reported that epigallocatechin gallate, (-)-epicatechin gallate and (-)-
epigallocatechin inhibited rennin activity, with epigallocatechin gallate showing the 
strongest inhibitory activity (255). 
Recently, RAAS has been extended by including new components, such as the 
angiotensin-converting enzyme 2 (ACE2), the heptapeptide angiotensin (1–7) (Ang-(1–
7)), and Mas receptor. ACE2, a homologue of ACE, is mainly expressed in endothelial 
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cells and vascular smooth muscle cells of the vascular wall. It converts Ang II to Ang-(1-
7), and thereby causing vascular protective effects (256). A very recent in vitro study 
showed that baicalin could protect endothelial cells from Ang II-induced endothelial 
dysfunction and oxidative stress via activating ACE2/Ang-(1-7)/Mas axis and modulating 
the expression of other factors (257). 
To conclude, the detailed effects of phenolic compounds on RAAS are still not 
enough to make a firm conclusion. Some indications from in vitro studies suggest that 
ACE inhibitory activity could be one of the mechanisms involved in the reduction of BP 
caused by phenolic compounds. However, more studies are still important to confirm this 
effect. 
 1.4.1.3.4 Other mechanisms 
 
Phenolic compounds might influence other responses involved in BP regulation. For 
instance, increased alpha-adrenergic response in small mesenteric arteries has been 
involved in increased BP in SHR. Quercetin and isorhamnetin incubated with mesenteric 
vessels from SHR for 30 min, were reported to cause a significant reduction in the 
vasoconstrictor response induced by the alpha-adrenergic receptor agonist phenylephrine 
(131). The epithelial Na
+
 channel (ENaC) in the kidney plays a key role in the regulation 
of blood pressure by contributing to the Na
+
 reabsorption in renal tubules. In salt 
sensitive hypertensive animals, the BP-lowering effects of flavonoids might be mediated 
by a modulation of renal function. Quercetin was reported to cause reduction in the SBP 
elevated by high salt diet associated with diminishing of the alphaENaC mRNA 
expression in the kidney (258). There is also evidence that quercetin may decrease blood 
pressure through endothelium independent vasorelaxation by directly acting on the 
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vascular smooth muscle. However, it remains unclear how quercetin evokes endothelium-
independent relaxation, but it has been suggested that it results from inhibition of protein 
kinases involved in the Ca
2+
-sensitizing mechanisms responsible for smooth muscle 
contraction (259).  
It is known from human and animal studies that inflammation might play an 
important role in the development of hypertension (260). Flavonoids have been reported 
to have anti-inflammatory activity in vitro through inhibition of different mediators of the 
inflammatory process such as reactive C protein or adhesion molecules and NOS. In 
addition, the molecular activities of flavonoids include inhibition of transcription factors 
such as NF-kappaB and activating protein-1 (AP-1), as well as activation of nuclear 
factor-erythroid 2-related factor 2 (Nrf2) (261-263). Droke et al. (264) showed that 
administration of soy isoflavone in C57BL/6J mice reduces the risk of cardiovascular 
disease associated with chronic inflammation, by down-regulating the expression of the 
proinflammatory mediator tumor necrosis factor (TNF)-alpha at endothelial level. In 
human, a study assessing associations between flavonoid intake and inflammatory 
biomarkers reported that total flavonoids, flavanones, and flavones were inversely 
associated with IL-18 concentrations and that flavonols were inversely associated with 
soluble vascular cell adhesion molecule concentrations (265). Another study reported that 
habitual intakes of anthocyanins are associated with inflammatory biomarkers involved in 
the regulation of glucose homeostasis, β-cell function, and insulin signaling (266). So far, 
more investigation is still important and needed to suggest that anti-inflammatory activity 
might be one of the mechanisms that could be involved in the antihypertensive potential 
of phenolic compounds. 
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Indeed, we have to be critical when we discuss the possible mechanisms of action 
that might be involved in the antihypertensive potential of phenolic compounds. At this 
moment, there is no much information on all possible mechanisms that can mediate the 
effect of phenolic compounds on hypertension. New drug classes eg, inhibitors of 
vasopeptidases, aldosterone synthase and soluble epoxide hydrolase, agonists of 
natriuretic peptide A and vasoactive intestinal peptide receptor 2, and a mineralocorticoid 
receptor antagonist are used in phase II/III of development. On the other hand, inhibitors 
of aminopeptidase A, dopamine β-hydroxylase, and the intestinal Na+/H+ exchanger 3, 
and agonists of components of the angiotensin-converting enzyme 2/angiotensin(1–
7)/Mas receptor axis are used in phase I or preclinical development (267). Accordingly, it 
is important to investigate the effects of flavonoids on these therapeutic targets. To our 
knowledge and based on research we did, very little information is reported on the effects 
of phenolic compounds on these pathways (257, 268, 269).  
1.4.1.4 Conclusion 
Data from in vitro and in vivo studies suggest a potential role of phenolic 
compounds and food rich sources in a reduction of the blood pressure. Results from some 
randomized control trials in human confirmed the beneficial effects of flavonoid-rich 
food towards blood pressure control and influence on cardiovascular risk factors. 
However, further research with well-designed and long-term studies to optimize the doses 
of phenolic compounds in different food matrices and to confirm the observed clinical 
benefit, is still required. Plausible mechanisms supported by different studies are a 
decrease in oxidative stress, improving the endothelial function and interference with 
RAAS. However, the exact mechanism(s) of action by which phenolic compounds might 
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decrease the BP in humans still needs more investigation and confirmation. Lastly and in 
parallel to focus on phenolic compounds rich food, attention should be given to study 
pure and individual phenolic compounds through feeding studies in animal models and 
further in humans. This could help in better understanding of the possible beneficial 
effects of individual compounds. Moreover, it allows not only to evaluate exactly the role 
phenolic compounds in the treatment and management of hypertension but also to 
determine the exact mechanism(s) responsible for the action.  
 
1.4.2 Overview of the anti-obesity effects of phenolic compounds 
 
Because of the side-effects accompanied by the medication, the use of supplements and 
alternative forms from natural products became of medical interest and is considered as a 
promising tool in management and treatment of obesity (270-272). Within the plant 
metabolites, phenolic compounds are one of the important phenolic compounds that have 
been investigated for possible anti-obesity effects and that are still gaining considerable 
interest. Although not consistent in all studies, results from many animal and human 
studies suggest the positive role of phenolic compounds and phenolic compounds-rich 
food in the fight against obesity. Here in the following section we give an overview of 
data reported from previous studies on the role of phenolic compounds in obesity 
prevention and treatment.  
1.4.2.1 Anti-obesity effect of phenolic compounds and phenolic compounds-rich food 
reported in animals 
 
The potential anti-obesity effects of phenolic compounds and phenolic compounds-rich 
food in animals have been reported in several studies. Flavonoids such as catechins and 
anthocyanins have been considered to play an important role in the treatment of obesity. 
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Chan et al. (273) showed that the consumption of epicatechins isolated from jasmine tea 
(Camellia sinensis) leaves (5.7 g/kg diet) for 4 weeks caused a reduction in body weight, 
serum parameters (total cholesterol and triacylglycerols) and hepatic lipid levels in 
hamsters. The purity of the isolated tea epicatechins was 95% in which epigallocatechin 
gallate, epigallocatechin, epicatechin gallate and epicatechin made 62.3, 19.2, 8.3 and 
4.6%, respectively. Murase et al. (274) reported that long-term consumption of tea 
catechins is beneficial for the suppression of diet-induced obesity. In this study, the 
composition of the isolated tea catechins was epigallocatechin gallate (74%), epicatechin 
gallate (18%), gallocatechin gallate (6%) and others (2%). They showed that male 
C57BL/6J mice fed a high fat diet supplemented with catechins isolated from green tea 
(Camellia sinensis) (5 g/kg diet) for 11 months, presented a significant reduction in body 
weight gain compared with male C57BL/6J mice fed a high fat diet without 
supplementation of catechin. Supplementation of epigallocatechin gallate purified from 
green tea (10 g/kg diet) for 4 weeks resulted in a dose-dependent attenuation of body fat 
accumulation in male New Zealand black mice (275). Similarly, another study showed 
that feeding male C57BL/6J mice with cyanidin 3-glucoside-rich purple corn color (PCC) 
at a cyanidin 3-O-β-D-glucoside concentration of 2 g/kg diet for 12 weeks significantly 
suppressed the high fat diet-induced increase in body weight gain in addition to white and 
brown adipose tissue weights (276). Anthocyanin-treated mice (1 g/kg of high-fat diet) 
showed a significant decrease in weight gain as reported by Jayaprakasam (277). 
Moreover, a decreased lipid accumulation in the liver, including a significant decrease in 
liver triacylglycerol concentration, was observed in these mice.  
The beneficial effects of isoflavones in preventing the development of obesity 
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were reported in many studies. Kishida et al. (278) examined whether the estrogenic 
property of soy isoflavone, containing 155 mg/g genistein and 127 mg/g daidzein, can 
affect food intake and body weight in Sprague-Dawley rats. It was found that isoflavone 
supplementation at 100-300 mg/kg diet attenuated food intake and body weight gain in 
female rats, whether or not the animals had undergone ovariectomy. Therefore, they 
suggested that other mechanisms, next to the estrogenic effect, could be behind the effect 
on body weight reduction. In agreement with these results, another study showed that 
reduced food intake resulting from isoflavone supplementation was accompanied by 
reducing ghrelin and NPY levels and increased CCK and PYY levels (279). Kim et al. 
(280) showed that genistein supplementation (2 g/kg diet) for 12 weeks in male 
C57BL/6J mice resulted in low body weight gain as well as improved lipid profiles and 
hepatic steatosis. Similarly, female C57BL/6 mice that were fed genistein-supplemented 
(1.5 g/kg) diet for 3 weeks, showed a decrease in food intake of 14% and in body weight 
of 9% (281).  
Quercetin is one of the most studied flavonoids. It might exhibit a wide range of 
biological functions from which the anti-obesity effect has been reported in many studies. 
Revera et al. (282) analyzed effects of chronic administration of quercetin (2 or 10 mg/kg 
of body weight for 10 weeks) on metabolic syndrome abnormalities in obese Zucker rats. 
It was found that the chronic oral administration of high doses of quercetin caused a 
reduction in the final body weight and body weight gain in both obese rats and their lean 
littermates. Kobori et al. (283) reported that administration of diets containing 0.1 and 0.5 
% quercetin for 2 weeks significantly reduced body weight and visceral and hepatic fat in 
male C57/BL6J mice. Another study showed that quercetin supplementation (66 mg/kg 
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body weight/day) protected C57BL/6J mice against weight gain induced by a high fat 
diet (284). On the contrary, the effect of quercetin on body weight was not confirmed by 
some other studies. Steward et al. (285) evaluated the effect of dietary supplementation 
with quercetin (0.8 % of the diet) for 3 weeks and 8 weeks in C57BL/6J mice fed a high-
fat diet. No effect on mean body weight was observed during the experiment. Dietary 
supplementation with quercetin resulted in transient increases in energy expenditure at 3 
weeks and not at 8 weeks. However, quercetin at the levels provided was effective in 
reducing circulating markers of inflammation (TNF-alpha, IFN-gamma, IL1 and IL4) in 
animals on a high fat diet after 8 weeks of treatment. Mice that were fed a mild-high fat 
diet supplemented with quercetin (400 mg/ Kg BW) for 12 weeks did not show a 
significant difference in body weight and energy intake compared to the control group 
fed only a mild-high fat diet (286). A very recent study evaluated the effect of quercetin 
supplementation on weight gain, caloric intake and feed efficiency in exercised and 
sedentary rats (287). Rats were exercised and/or orally supplemented with quercetin (25 
mg/ kg on alternate days) during six weeks. It was concluded that quercetin did not 
induce a reduction in weight gain as there were no differences between the placebo and 
quercetin condition either in the sedentary or in the training condition. In an experiment 
carried out with Wistar rats fed on a high fat diet, treatment with 25 mg of quercetin/kg 
body weight/day did not alter body weight gain and body composition as well as leptin 
level (288). Another experiment performed in db/db mice showed that treatment with 
quercetin (100 mg/kg of body weight/d) for 7 weeks caused a reduction in plasma 
glucose without changes in body weight (289).  
Contrary to quercetin, less information is available on kaempferol and rutin. The 
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anti-obesity effect of 3-O-beta-D-glucosyl-(1-->6)-beta-D-glucosyl-kaempferol isolated 
from Sauropus androgynus on male Wistar rats was studied by Shih-Fing et al. (290). A 
dose of 60 mg/kg/day for 4 weeks resulted in 15% reduction in food intake. This 
corresponded to a decrease in body weight as well as serum-free triglyceride. An 
investigation of the anti-obesity effects of kaempferol in high fat diet-fed rats was carried 
out by Chang et al. (291). Oral administration of kaempferol (300 mg/kg/day) for eight 
weeks caused a reduction in body weight gain, visceral fat-pad weights and plasma lipid 
levels. Hence, kaempferol resulted in reductions in hepatic triglyceride and cholesterol 
content and lowered hepatic lipid accumulation in high fat diet-fed rats. Choi et al. (292) 
investigated the anti-adipogenic activity of rutin in C57BL/6 mice fed with high-fat diet 
(64.4% of total calories as fat). The oral administration (25 and 50 mg/kg body 
weight/daily) of rutin with high fat diet for 4 weeks resulted in less body weight gain and 
significantly lower total cholesterol contents in blood in comparison to the high-fat diet 
alone fed group.  
 
With regard to phenolic acids, fewer studies were reported. Gallic acid (293) and 
p-coumaric acid (294) supplementation at a dose of 100 mg/kg BW for 10 and 8 weeks, 
respectively, caused a significant decrease in body weight, organ weight of the liver, and 
adipose tissue weights of peritoneal and epididymal in Wistar rats with high fat diet-
induced obesity. In addition, dyslipidemia, hepatosteatosis, and oxidative stress reduced 
in the animal group with gallic acid and p-coumaric acid supplementation. Another study 
reported that addition of galic acid (50 or 100 mg/kg BW) to the high fat-diet of male 
C57BL/6 mice OVWE during a period of 16 weeks caused as significant reduction in 
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body weight gain (295) and this could be attributed to gallic acid (296).  
In summary, results obtained from animal studies provide indication on the 
positive role of phenolic compounds in obesity prevention and treatment in spite of the 
absence of effect from some studies. Additionally, many studies showed that application 
of phenolic compounds inhibited the high fat diet induced obesity. This might help 
further the mechanisms by which phenolic compounds could reduce obesity in human.  
 
1.4.2.2 Anti-obesity effect of phenolic compounds and phenolic compounds-rich food 
reported in human 
 
Although there is much evidence about the potential effect of phenolic compounds 
against obesity from in vitro experiments and in vivo studies using animal models, little 
data is available from human intervention studies. Green tea and green tea extracts rich in 
flavonoids have been studied extensively with respect to body weight regulation. 
Catechins are major polyphenols in green tea which accounts for about 35% of its total 
dry weight (297). Data from human studies suggest the positive effect of green tea and 
green tea extracts on body weight and energy expenditure (298-300). Caffeine content is 
not the only factor responsible for this effect on energy expenditure because the 
thermogenic effect of green tea extract containing caffeine and catechins was found to be 
greater than that of an equivalent amount of caffeine (301). A cross-sectional survey, 
where 1210 adults were enrolled, reported that habitual drinkers of tea for 10 years 
showed a 19.6% reduction in body fat percentage and a 2.1% reduction in the waist to hip 
ratio compared to non-habitual tea drinkers (302). A meta-analysis study evaluated the 
anti-obesity effects of green tea supplementation based on 11 selected long-term studies. 
From this analysis, it was concluded that catechins have a small positive effect on body 
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weight loss and body weight maintenance. However, caffeine intake seemed to be a 
moderator influencing the effects of catechins (303). This could be attributed to the 
increase and more sustained effect of norepinephrine on thermogenesis resulting from 
inhibition of catechol O-methyltransferase (COMT), the enzyme that degrades 
norepinephrine, by catechins and prolonging the life of cAMP in the cell by caffeine 
(301). Similarly, another meta-analysis study addressed that the administration of green 
tea catechins with caffeine is associated with reductions in BMI, body weight, and waist 
circumference (304). On the other hand, many studies with green tea and green tea 
catechins did not report positive results related to obesity measures. Diepvens’s study 
found that supplementation of a low-energy diet with green tea for 12-weeks, 
independent of habitual caffeine intake, had no effect on measures of body weight or 
body composition in overweight women at 4 weeks or 3 months (305). Similarly, Hill et 
al. observed that there was no significant difference in body weight, BMI, waist 
circumference, abdominal fat and intra-abdominal adipose tissue between the placebo 
group and the EGCG-supplemented group in overweight/obese postmenopausal women 
(306). In addition, a randomized, double-blinded, placebo-controlled trial in Taiwan 
reported that there was no statistical difference in % reduction in body weight, BMI and 
waist circumference in the green tea catechins-supplemented (491 mg catechins) group 
after 12 weeks of treatment compared to the placebo group (307). The association 
between 3 flavonoid subgroups and BMI over a 14-year period with 4280 men and 
women aged 55-69 years in a prospective cohort study was assessed in the Netherlands. It 
was found that women with the highest intake of total flavonols/flavones and total 
catechins experienced a significantly lower increase in BMI of 0.40 and 0.31, 
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respectively (308). Recently, a randomized, double-blind, placebo-controlled trial showed 
that 118.5 mg/day of anthocyanins for 4 weeks resulted in significant changes in body 
mass, body composition, appetite and dietary intake (309). In contrast, a study on 
subjects exhibiting a BMI between 25 and 35 kg/m
2
 showed no effects on the nutritional 
status (body weight, waist circumference, fat mass and fat-free mass) after 6 weeks of 
treatment with 150 mg/day of quercetin (193). Very recently, a randomized, double-
blind, placebo-controlled study was performed on pre-menopausal obese women. They 
found that dietary supplementation with 300 mg/day of EGCG for 12 weeks did not 
enhance energy-restricted diet-induced adiposity reductions, and did not improve weight-
loss-induced changes in cardiometabolic risk factors in obese Caucasian women (310).  
To summarize, evidence on the beneficial effects of phenolic compounds and 
food rich in phenolic compounds in fighting obesity is increasing. However, more human 
studies are required to provide consistent data. These data can be used to establish the 
exact anti-obesity effect of phenolic compounds. Further, this will help in getting these 
health claims approved.  
 
1.4. 2.3 Possible mechanisms of action  
 
Energy surplus over time which is stored in the body as fat, is an important etiological 
factor for obesity. The beneficial or preventive effect of natural compounds against 
obesity is suggested in many studies (270-272, 311-313). The potential of phenolic 
compounds in weight loss and obesity management could be through influencing one or 
more of the following pathways as illustrated in figure 1.6: lipid absorption, food intake 
and energy expenditure, pre-adipocyte differentiation and proliferation, lipogenesis and 
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lipolysis and inflammatory response (270).  
 
 
Figure 1. 6: Diagram illustrates the possible mechanisms of action behind the anti-
obesity effects of phenolic compounds. HSL, hormone sensitive lipase; PL, pancreatic 
lipase; UCPs, uncoupling proteins. 
 
At the cell biological level, obesity is characterized by an increase in the number and size 
of adipocytes differentiated from fibroblastic pre-adipocytes in adipose tissue. Therefore, 
regulation of the size and number of adipocytes is a valuable path in combating obesity. 
Phenolic compounds can inhibit adipogenesis. Studies indicated that catechins such as 
catechin gallate and epigallocatechin gallate (298, 314-317), quercetin (318), rutin (319), 
luteolin (320), genistein and naringenin (321) might prevent obesity by suppression of the 
adipocyte differentiation which could be attributed to the down-regulation of the 
expression of adipogenic transcription factors (C/EBPα, PPARγ) (322, 323) and 
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activation of the AMPK signal pathway (319, 324, 325). Phenolic acids were reported to 
inhibit the preadipocyte population growth as the treatment of 3T3-L1 preadipocytes with 
chlorogenic acid, o-coumaric acid, and m-coumaric acid caused cell cycle arrest in the 
G1 phase (326). This might attribute to their antiobesity effects in vivo. Phenolic 
compounds were reported to induce apoptosis of mature adipocytes (281, 327, 328) via 
modulation of the ERK and JNK pathways (327). Catechins suppress fat accumulation in 
differentiated 3T3-L1 cells via activating AMPK and inhibiting acetyl-CoA carboxylase 
(329). In addition, catechins can also decrease lipid digestion and absorption by the 
inhibition of digestive lipases (330). The effect on obesity prevention and management 
could be due to interferences with lipid metabolism. Catechins were reported to stimulate 
hepatic lipid metabolism (274). Kaempferol was shown to increase lipid metabolism 
through down regulation of SREBPs and promoting the hepatic expression of ACO and 
CYP4A1 (291). Cyanidin 3-glucoside-rich purple corn color (PCC) suppressed the 
mRNA levels of enzymes involved in fatty acid and triacylglycerol synthesis and lowered 
the sterol regulatory element binding protein-1 mRNA level in white adipose tissue 
(276). Since adipocyte dysfunction plays an important role in the development of obesity 
and insulin resistance, regulation of adipocytokine secretion or the adipocyte-specific 
gene expression can be one of the important targets for the prevention of obesity and 
amelioration of insulin sensitivity. Tsuda et al. (331) showed that treatment of isolated rat 
adipocytes with the anthocyanin cyanidin stimulates adiponectin and leptin 
(adipocytokine) secretion which is reported to activate AMPK that is associated with the 
enhancement of fatty acid oxidation and suppression of triacylglycerol accumulation. In 
addition, treatment with anthocyanin up-regulated the adipocytes-specific gene 
 80 
 
expression.  In another study, Tsuda et al. showed that both cyanidin 3-glucoside and its 
aglycone up-regulated the hormone-sensitive lipase which mediates the mobilization of 
stored triacylglycerol and enhanced the lipolytic activity (332). The pancreatic lipase 
(PL) is responsible for the hydrolysis of 50-70% of the triacylglycerols, 
monoacylglycerides and free fatty acids which are absorbable by enterocytes. Therefore, 
the inhibition of PL could result in a reduced fat absorption and in turn energy uptake 
which is one of the key targets in obesity management (333). Phenolic compounds-rich 
extracts from teas, herbal and fruit sources were reported as PL inhibitors during in 
vitro experiments (312, 334-338). Their high PL inhibitory activity was usually attributed 
to the proanthocyanidins such as gallocatechin gallate, epigallocatechin gallate and 
catechin gallate (312, 334-336) or to phenolic acids (296, 337). The significant decrease 
in PL activity caused by gallic acid and black tea extracts in vitro was accompanied by 
suppression of the elevation of blood triglyceride after oral administration of a corn oil 
emulsion in male mice (296). Recently, a study showed that epigallocatechin-3-gallate, 
kaempferol, quercetin, genistein and luteolin could be potent PL inhibitors, with 
epigallocatechin-3-gallate being the most active (339). Additionally, phenolic compounds 
might increase the energy expenditure via up-regulating different uncoupling proteins 
(UCPs). Many studies showed that catechins interfere with the gene expression of UCPs 
(275, 340, 341). Phenolic compounds might interfere with enterocyte glucose absorption. 
Studies indicated that epicatechin gallate and epigallocatechin gallate interact with 
glucose transporters as antagonist-like molecules, thereby playing a role in controlling the 
dietary glucose uptake in the intestinal tract (342, 343). Cyanidin was also reported by 
Sasaki et al. (344) to reduce the blood glucose levels in mice. Some studies provided 
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evidence on the protective effect of phenolic compounds against obesity-related 
inflammations. For example, quercetin was shown not only to reduce markers of 
inflammation, macrophages and insulin resistance in adipocytes but also it attenuated 
circulating markers of inflammation in animal models (345, 346). Anthocyanins were 
reported to down-regulate inflammatory protein cytokines such as monocyte 
chemoattractant protein-1 (MCP-1) in the adipose tissue of mice (344). Green tea 
catechins were also reported to influence the inflammatory response via inhibition of the 
expression and secretion of proinflammatory resistin, PAI-1, IL-6, TNF-α, MCP-1 and 
MMPs (340, 347). Phenolic compounds might influence obesity by decreasing food 
intake through satiety-inducing hormones. However, this pathway has not been well 
studied yet and only a few data are available. Zhang et al. reported that the effects of 
isoflavones on food intake were accompanied by a reduction of ghrelin and NPY levels, 
and an increase of CCK and PYY levels (279). An in vitro study proved that the 
flavonoid hesperetin stimulates CCK secretion in enteroendocrine STC-1 cells (348). 
Very recently, epigallocatechin-3-gallate (EGCG) was found to induce CCK, GLP-1 and 
PYY secretion from Caco-2 cells (349). The same study showed that EGCG also released 
CCK from the duodenum, and GLP-1 from the ileum using murine intestines. 
1.4.2.4 Conclusion 
 
The effect of phenolic compounds against obesity has been reported in several studies. 
However, results are still inconsistent and incomplete. Therefore, more data on the 
putative beneficial effects of phenolic compounds on body weight management and their 
efficacy in combating obesity are required. Most studies showed that anti-adipogenesis 
and influencing lipid metabolism are the main mechanisms underlying the anti-obesity 
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effect of phenolic compounds. Additionally, the involvement of other mechanisms like 
affecting glucose uptake and gastrointestinal hormones were suggested. Further studies 
are still needed to investigate and better characterize exact mechanisms that can possibly 
mediate the potential anti-obesity effects of phenolic compounds. 
1.5 Other bioactivities of phenolic compounds 
 
Except for the above extensively discussed bioactivities, phenolic compounds have 
shown several other health-beneficiary effects such as antimicrobial, antiageing, and 
anticancer effects (350). However, the aim of this work is only to focus on bioactivities 
of phenolic compounds with regard to hypertension and obesity prevention and treatment. 
As it was stated clearly above in previous sections based on reported studies in animal 
and humans models, phenolic compounds might play an important role in the prevention 
and treatment of hypertension and obesity. Several pathways are already included in BP 
and food intake control. Many were already discussed in previous studies. However, 
some pathways still demand more work to be fully understood. 
In this work we focus on ACE as crucial enzyme involved in BP and CCK and CCK1R 
as important pathways influencing food intake. Data from this work could help in better 
understanding of mechanisms involved in the reported antihypertensive and antiobesity 
effects of phenolic compounds. Discussing the results obtained from the phenolic 
compounds in terms of their structures might give a deep insight to the structure-activity 
relationships of these compounds and further help in developing new drugs based on 
natural compounds. 
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Chapter 2 Angiotensin-Converting Enzyme Inhibitory Effects by 
Plant Phenolic Compounds: A Study of Structure Activity 
Relationships 
 
2.1 Abstract 
 
In this study, 22 phenolic compounds were investigated to inhibit angiotensin-converting 
enzyme (ACE). Tannic acid showed the highest activity (IC50=230 µM). The IC50 values 
obtained for phenolic acids and flavonoids ranged between 0.41-9.3 mM. QSAR analysis 
confirmed that the numbers of hydroxyl groups on the benzene ring play an important 
role for activity of phenolic compounds, and that substitution of hydroxyl groups by 
methoxy groups decreased activity. Docking studies indicated that phenolic acids and 
flavonoids inhibit ACE via interaction with the zinc ion and this interaction is stabilized 
by other interactions with amino acids in the active site. Other compounds such as 
resveratrol and pyrogallol may inhibit ACE via interactions with amino acids at the active 
site and thereby blocking the catalytic activity of ACE. These structure-function 
relationships are useful to design new ACE inhibitors and potential blood pressure-
lowering compounds based on phenolic compounds. 
2.2 Introduction 
 
Hypertension medication includes the use of drugs of which inhibitors of angiotensin 
converting enzyme (ACE) are considered as one of the most important classes (77). As 
we already mentioned in paragraph 1.2.2, ACE catalyzes the conversion of the precursor 
angiotensin I into angiotensin II, which is a peptide responsible in triggering 
vasoconstrictive effects, (82, 83). Therefore, inhibition of ACE has become a promising 
way for regulation and treatment of high blood pressure. Although several synthetic ACE 
inhibitors as lisinopril, captopril and enalapril are widely used for successful treatment of 
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hypertension, the chronic use of these synthetic inhibitors may be associated with many 
undesirable side-effects such as persistent cough, postural hypotension, renal failure and 
angioedema (351, 352). Extensive research has been carried out to look for ACE 
inhibitors from natural products as the latter might have better drug profiles and less side-
effects. We already indicated in paragraph 1.2.4 to the natural substances that have been 
described in literature and targeting ACE inhibition such as peptides and triterpenes. 
Also, recent studies demonstrated the effect of some phenolic compounds as effective 
ACE inhibitors in vitro (95-97). Although these compounds have a poor solubility and 
subsequent restriction in bioavailability, studies in animal and human showed a potential 
effects on the reduction of blood pressure as already extensively discussed and stated in 
paragraph 1.4.1.1 and paragraph and 1.4.1.2. These confirming data form a basis for our 
study with phenolic compounds and also underline the interest to investigate the 
structural differences in terms of ACE inhibition and thereby blood pressure-reducing 
potency, especially because only a few studies have been done to address the relationship 
between the activity of phenolic compounds and their structures. Recently, Guerrero et 
al.(98) reported on the key structural elements of flavonoids which contribute to their 
ACE inhibitory activity. 
The objectives of this study were first to evaluate the ACE inhibitory activity of a 
wide range of 22 phenolic compounds belonging to different classes and subclasses 
(Figure 2.1). Second, results were used to identify possible mechanisms of action based 
on structure-activity relationships and molecular docking. We believe these new insights 
about the structure-function relationships may be useful for designing new ACE 
inhibitors based on phenolic compounds.  
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1 Tannic acid 
 
2 Benzoic acid, R1 = COOH, R3 = R4 = R5 = H 
3 p-Hydroxybenzoic acid, R1 = COOH, R3 = R5= H, R4 = OH 
4 Protocatechuic acid, R1 = COOH, R3 = R4 = OH, R5 = H 
5 Gallic acid, R1 = COOH, R3 = R4 = R5 = OH 
6 Vanillic acid, R1 = COOH, R3 = OCH3, R4 = OH, R5 = H 
7 Syringic acid, R1 = COOH, R3 = R5 = OCH3, R4 = OH 
 
8 Ellagic acid 
 
 
9 trans-Cinnamic acid, R1 = CH2=CHCO2H, R3 = R4 = R5 = H 
10 Ferulic acid, R1 = CH2=CHCO2H, R3 = OCH3, R4 = OH, R5 = H 
11 p-Coumaric acid, R1 = CH2=CHCO2H, R3 = H, R4 = OH, R5 = H 
12 Caffeic acid, R1 = CH2=CHCO2H, R3 = R4 = OH, R5 = H 
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13 Catechol, R1 = R5 = H, R3 = R4 = OH 
14 Pyrogallol, R1 = H, R3 = R4 = R5 = OH 
 
15 Quercetin, R1 = R2 = R3 = OH 
16 Kaempferol, R1 = R3 = OH, R2 = H 
17 Rutin, R1 = Glycoside, R2 = R3 = OH 
 
18 Apigenin, R1 = R3 = OH, R2 = H 
 
19 Epicatechin, R1 = R2 = OH 
 
20 Phloretin 
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21 Resveratrol, R1 = R2 = R3 = OH 
22 trans-Stilbene, R1 = R2 = R3 = H 
 
Figure 2.1: Structure of the 22 phenolic compounds tested in this study. 
 
2.3 Materials and Methods 
 
2.3.1 Products 
 
ACE from rabbit lung, hippuryl-histidyl-leucine (HHL), o-phthaldialdehyde (OPA), HCl, 
BSA, tannic acid, gallic acid, benzoic acid, p-hydroxybenzoic acid, syringic acid, vanillic 
acid, ellagic acid, protocatechuic acid, catechol, pyrogallol, caffeic acid, ferulic acid, p-
coumaric acid, trans-cinnamic acid, quercetin, rutin, kaempferol, resveratrol, trans -
stilbene, apigenin, epicatechin, phloretin and ninhydrin were purchased from Sigma-
Aldrich (Bornem, Belgium; St. Louis, MO). Lisinopril was provided by Merck & Co. 
(Rahway, NJ, USA). Sodium tetraborate (Na2B4O7.10H2O) was purchased from Acros 
Organics (Geel, Belgium), while NaOH and NaCl from Chem Lab (Lichtervelde, 
Belgium).  
2.3.2 In vitro ACE inhibitory activity assay 
 
For the selection of 22 phenolic compounds, the ACE inhibitory activity was measured 
using the colorimetric method previously described (353) with slight modifications. In 
brief, the ACE catalyzed reaction was performed in cuvettes containing 100 µL of sample 
solution, 100 µL of ACE solution, and 100 µL of HHL solution. The phenolic 
compounds were dissolved in 100% ethanol and different concentrations tested with a 
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maximum of 10% ethanol in the final reaction volume; tannic acid was dissolved in 
water. Appropriate control and blank reactions were performed concurrently. The 
reaction mixtures were incubated for 2 h at 37 °C, and the reaction was stopped by 
adding 2 ml of o-phthaldialdehyde reagent. After incubation for 20 min at 25 ºC, the 
absorbance was measured at 390 nm.  
The concentrations of the phenolic compounds (mM) were plotted versus the 
corresponding ACE inhibitory activity values (%) and the dose-response curves were 
obtained by the nonlinear sigmoid regression with Prism v4 (GraphPad Prism, La Jolla, 
CA). The IC50 value, expressing the concentration of the phenolic compound inhibiting 
50% of ACE activity, together with the corresponding 95% confidence interval and the 
R
2
 of the curve fitting were determined as previously described (354). However, 50% 
inhibition was not always reached due to a lower solubility of some phenolic compounds 
at high concentrations. In that case, IC50 values were extrapolated from the linear 
regression plot of the percentage of ACE inhibition versus the concentrations used (355). 
2.3.3 Molecular docking and quantitative structure-activity 
relationship analysis 
 
Molecular docking of the phenolic compounds 1-7, 9-15, 17, 19 and 21-22 into testis 
ACE (tACE) was performed with Discovery Studio (DS) 2.5 (Accelrys, San Diego, CA) 
using a CHARMm-based protocol, CDOCKER. The crystal structure of tACE (1UZF) 
was obtained from the Protein Databank and the ligands (phenolic compounds) were 
sourced from PubChem. The receptor protein and the ligands were subjected to protein 
and ligand preparations to simulate the conditions used in the in vitro analysis (pH 8.3) 
using the Prepare Protein and Prepare Ligand protocols. The best conformation based on 
docking score and literature reports were used in subsequent analyses. In an attempt to 
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establish a linear relationship between the IC50 values and docking scores, the generated 
docking poses were ranked by each of the four individual scores (shape, hydrogen bound, 
protein desolvation and ligand desolvation). The sum of the normalized scoring functions 
generated the FRED Chemgauss4 score, using OEDocking suite for OSX (ver. 3.0.1) 
(OpenEye, Santa Fe, NM). 
Multiple linear regression (MLR) analysis of the tested phenolic compounds was 
used to determine the molecular properties influencing the ACE inhibitory activity of the 
test phenolic compounds. However, only the structure-activity relationship of phenolic 
acids was analyzed due to the limited number of flavonoids tested in this study because 
of their low solubility. Molecular descriptors consisting of 2D molecular properties and 
functional group counts were obtained from DS and E-Dragon 1.1(356). MLR was 
performed using SPSS 20 (IBM, Armonk, NY).  
2.4 Results 
 
2.4.1 Selection of solvent to dissolve phenolic compounds 
  
Since many phenolic compounds are poorly soluble in water, a suitable organic solvent to 
dissolve the phenolic compounds was needed. With the use of 10% methanol and 10% 
DMSO in the enzyme solution, there was an inhibition of the ACE enzyme activity by 25 
and 16%, respectively. In contrast, no loss of ACE enzyme activity was recorded with 
10% ethanol in the reaction mixture. Therefore, the phenolic compounds were dissolved 
in 100% ethanol and their effect on ACE inhibition was tested with an amount of 10% 
ethanol present in the final reaction mixtures. Tannic acid having higher water solubility 
was dissolved in water. 
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2.4.2 ACE inhibitory activity by tannic acid, different phenolic 
acids, pyrogallol and catechol  
 
Before testing the phenolic compounds, we evaluated the ACE inhibitory activity of 
different concentrations of the synthetic ACE inhibitor lisinopril that were prepared in 
water. After sigmoid curve fitting (figure 2.2), the IC50 of lisinopril was 1.00 nM (95% 
confidence interval=0.85-1.26 nM; R
2
=0.99), confirming the reliability of the ACE 
inhibitory bioassay.
  
-2 -1 0 1 2 3
20
40
60
80
100
Log conc (nM)
%
 i
n
h
ib
it
io
n
 
Figure 2.2: Sigmoid dose-response curve of ACE inhibition by lisinopril as calculated in 
Prism.  
 
Table 2.1 demonstrates the ACE inhibitory effects by tannic acid, phenolic acids, 
pyrogallol and catechol. It was clear that among the 22 different phenolic compounds 
tested, tannic acid, 1, was the most active with the lowest IC50 value (230 µM). Both 
subgroups of phenolic acids, i.e. hydroxybenzoic acids (Compounds 2-8) and 
hydroxycinnamic acid (Compounds 9-12), showed ACE inhibition in a range from 2 to 
9.3 mM. Among all hydroxybenzoic acids, only ellagic and gallic acid showed some 
ACE inhibition at a concentration between 0.75 and 1.5 mM, while the other 
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hydroxybenzoic acids at this concentration range did not affect the ACE activity. 
However, at a concentration in the range of 10-14 mM, all hydroxybenzoic acids, except 
syringic acid, resulted in ≥84% ACE inhibition. Among the hydroxycinnamic acids, 
caffeic acid caused the highest ACE inhibition at a concentration in the range of 0.85 and 
1.5 mM. As the hydroxycinnamic acids have a poor solubility at high concentrations, 
even in a 10% ethanol solution, a concentration in the range of 10-14 mM could not be 
tested. Furthermore, catechol and pyrogallol, 13-14, were also tested. While these 
compounds both showed a concentration-dependent ACE inhibition, the IC50 value 
obtained for pyrogallol was 7-fold lower than that of catechol. 
Table 2.1: Percent Inhibition of ACE Activity at Different Concentrations Together with 
Calculated IC50 Values Obtained for Tannic Acid, Phenolic acids, Catechol and 
Pyrogallol. 
 
Class Subclass Compound 
% Inhibition 
(Conc., mM)) 
% Inhibition 
(Conc., mM) 
IC50 value 
(mM) 
95% CI 
(mM) 
R2 
Tannins Tannins Tannic acid 88±2 (0.90) 97±1 (1.9) 0.23 0.08 - 0.69 0.79 
Phenolic acids 
Hydroxybenzoic acids 
Benzoic acid 1±4 (0.85) 90±4 (13.6) 6.20 5.78 - 6.66 0.99 
p-
Hydroxybenzoic 
acid 
3±9 (0.75) 94±2 (12.0) 5.95 5.65 - 6.26 0.99 
Protocatechuic acid 9±1 (0.80) 91±2 (10.8) 5.07 2.70 - 9.24 0.97 
Gallic acid 26±2 (0.80) 84±1 (10.0) 3.70 1.86 - 7.29 0.93 
Vanillic acid 9±7 (1.50) 85±3 (11.8) 8.00 7.60 - 9.23 0.98 
Syringic acid 4±3 ( 1.50) 54±4 (10.0) 9.30 8.35-10.42 0.98 
Ellagic acid 32±1 (1.00) ND 2.00*  0.78 
Hydroxycinnamic acids 
trans-Cinnamic acid 10±4 (1.50) ND 8.50*  0.54 
Ferulic acid 18±2 (0.85) ND 4.40*  0.82 
p-Coumaric acid 19±1 (1.00) ND 2.80*  0,76 
Caffeic acid 34±2 (0.93) ND 2.10*  0.56 
Other 
polyphenols 
Other polyphenols 
Catechol 18±1 (1.50) 64±3 (12.0) 7.70 5.96 – 9.90 0.98 
Pyrogallol 47±5 (1.20) 90±4 (10.0) 1.12 0.76 - 1.64 0.98 
Data are expressed as means ± SD based on three biological replicates. * indicates that IC50 values were 
extrapolated from the linear regression plot of the percentage of ACE inhibition versus the concentrations 
used. ND, not determined due to poor solubility of the sample at a concentration in the range of 10-14 mM. 
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2.4.3 ACE inhibitory activity of flavonoids and stilbenes 
 
Six flavonoids representing 4 subclasses (flavonol, flavanol, flavones and 
dihydrochalcone) (Compounds 15-20) and two stilbenes (Compounds 21-22), were 
tested. As presented in Table 2.2, all tested flavonoids showed ACE inhibitory activity 
with IC50 values ranging between 0.415 and 1.381 mM. At a concentration of 0.075 mM, 
quercetin and kaempferol showed the highest activity. Rutin and epicatechin appeared to 
have an intermediate ACE inhibitory activity, while the lowest ACE inhibitory activity 
was observed with apigenin and phloretin.  
Regarding stilbenes, resveratrol showed a concentration-dependent ACE 
inhibition, giving an IC50 value of 0.970 mM (Table 2.2). trans-Stilbene did not show any 
activity at the concentrations tested (0.05 to 0.1 mM). 
Table 2.2. Effect of Different Flavonoids and Stilbenes on ACE Activity 
 
Class Subclass 
Phenolic 
compounds 
% of ACE Inhibition 
at 0.075 mM 
1 
IC50 value 
(mM) 
2
 
95% CI (mM) R
2 
Flavonoids 
Flavonols 
 
Quercetin 37
a
 ± 2.1 0.415 0.18-0.97 0.96 
Kaempferol 29
b
 ± 4.4 0.512 0.19-1.40 0.94 
Rutin 21
c
 ± 3.7 0.472 0.14-1.55 0.85 
Flavones Apigenin 13
d
 ± 3.3 0.667*  0.88 
Flavanols Epicatechin 19
c
 ± 2.8 1.381*  0.82 
Dihydrochalcones Phloretin 8
d 
± 3.4 1.110 0.71- 1.70 0.98 
Stilbenes Stilbenes 
Resveratrol 15 ± 1.3 0.970 0.70- 1.33 0.99 
trans-Stilbene no activity no activity   
1 
The values are expressed as means ± SD based on three biological replicates. Means with different 
superscripts are significantly different at P value <0.05 using one-way ANOVA.  
2 
Activity to inhibit ACE is expressed as the concentration of phenolic compound (mM) to inhibit 50% of 
ACE enzyme activity; the IC50 value is calculated from the sigmoid curve in Prism and is given together 
with the 95% confidence interval; the goodness of curve fitting is given with the R
2
 value. * this indicates 
that the IC50 values were extrapolated.  
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2.4.4 Quantitative structure activity relationship for phenolic acids 
 
The best multiple linear regression (MLR) analysis equation obtained for the logIC50 
values of the phenolic acids (Compounds 2-7 and 9-12) is as follows (figure 2.3):  
logIC50 = 4.618 (± 0.54) - 4.042 (± 0.54) AlogP + 0.07 (± 0.01) vol - 1.63 (± 0.21) HBA 
with n=10, F=18.83, p=0.002, R
2
=0.904 
 
Figure 2.3: Linear regression correlation between the observed and the predicted IC50 
value for 10 different phenolic acids (Compounds 2-7 and 9-12).  
 
where AlogP is a measure of hydrophobicity based on the octanol-water partition 
coefficient, vol is the calculated 3D volume of each molecule, and HBA is the numbers 
of hydrogen bond acceptors. A high correlation (R
2
=0.9) between observed and predicted 
IC50 values (from MLR analysis equation) of the phenolic acids was obtained. It should 
be noticed that tannic acid and ellagic acid were not included in the analysis since they 
have a different and more polymerized structure compared to the other phenolic acids. 
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2.4.5 Molecular docking experiments 
 
Here tACE was used since it is the only available structure and it is highly identical to the 
C terminal half of the somatic ACE that has been shown to be sufficient for blood 
pressure regulation (357). In addition, the ligand-protein interaction was evaluated on the 
basis of the Chemgauss4 score. The docking results from lisinopril were shown in figure 
2.4.  
 
 
 
 
 
 
 
Figure 2.4: Docking of lisinopril in the binding cavity of ACE, showing interactions with 
zinc and amino acids in the active site. Lisinopril in the cavity is shown in yellow and the 
zinc ion is shown in blue. Green dashed lines are used to show hydrogen bonds, while the 
dashed orange ones represent charge-charge interaction. Orange stacks were used to show 
the pi stacking. 
 
2.4.5.1 Phenolic acids, catechol and pyrogallol 
 
Table 2.3 represents the intermolecular interactions between ACE binding site residues 
and predicted poses for most of the tested phenolic compounds (Compounds 2-7, 9-15, 
17, 19 and 21-22).  
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Table 2.3: Intermolecular Interactions between ACE Inhibitors and the ACE Binding Site 
Ligands 
The active site 
 S1 S2' Other 
Zinc Tyr523 Ala354 Glu384 His353 Lys511 Gln281 His513 Asp453 Tyr520 Glu411 Asp415 Lys454 
2 C H   Pi, C         
3 C    Pi, C C H       
4 C    Pi, C C H   H    
5 C H   C C     C   
6 C H   H, C C H   H C   
7 C    Pi, C      C   
9 C    Pi      C   
10 C    Pi  H    C   
11 C    Pi  H    C   
12 C  H  Pi      C   
13  H  H H   H      
14  H  H Pi   H      
15 C    Pi, C, H C H    C   
17 
 
 H H  Pi, H   H      
19 C    C, Pi      C H, H H 
21     H H H     H H 
22     Pi         
Lisinopril  C  H  H, C H, C H    C C  
C, charge-charge interactions; H, hydrogen bonding; Pi, pi (stacking) interaction. 
 
It can be seen that all phenolic acids formed charge-charge interactions with the zinc ion 
in the active site of ACE. Additionally, different types of molecular interactions with the 
amino acids in the active site were found for all phenolic compounds tested. Figures 
2.5A-D show the docking results from the predicted poses for gallic, protochatechuic, 
caffeic and syringic acids at the ACE binding site. From these results it could be clearly 
observed that gallic, protochatechuic and caffeic acids are able to make interaction with 
the zinc ion in the active site via their carboxylate group. On the other hand, syringic acid 
interacts with the zinc ion via its hydroxyl group. Caffeic acid interacts with its acrylic 
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acid group with amino acid residues at both the S2’ and S1 binding site, while for 
protocathechuic acid the carboxylate group only interacts with the S2’ binding site. It 
should also be noticed that tannic acid could not fit into the active site of ACE. 
Concerning pyrogallol and catechol, neither of these compounds interacted with 
the zinc in the active site. However, these compounds formed interactions with amino 
acids in the active site of ACE (Table 2.3).  
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Figure 2.5: Docking of A. gallic acid; B. protocatechuic acid; C. caffeic acid; D. syringic 
acid; E. quercetin; F. epicatechin; G. resveratrol and H. trans-stilbene in the binding 
cavity of ACE, showing interactions with zinc and amino acids in the active site. The 
ligands in the cavity are shown in yellow and the zinc ion in blue. Green dashed lines are 
used to show hydrogen bonds, while the full green ones represent charge-charge 
interaction. Orange stacks were used to show the pi stacking. Chemical structures were 
drawn not to scale. 
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2.4.5.2 Flavonoids and stilbenes 
 
As shown in Table 2.3, quercetin, rutin and epicatechin formed molecular interactions 
with the ACE binding site residues. The quercetin molecule docks into ACE, interacting 
with the zinc via the 3-hydroxyl group in the C-ring (Figure 2.5E). Epicatechin is able to 
form an interaction with the zinc ion via the A-ring hydroxyl on position 7 (Figure 2.5F). 
On the other hand, rutin did not show any interaction with the zinc in the active centre of 
ACE. 
With regard to stilbenes, resveratrol did not show interaction with the zinc metal 
but it establishes some interactions via its hydroxyl groups with amino acids in the active 
site of ACE (Figure 2.5G). In contrast, with the exception of pi-stacking, no interactions 
were observed between trans-stilbene and both zinc and amino acids in the active site of 
ACE (Figure 2.5H). 
2.5 Discussion 
 
The data from in vivo studies about the potential role of phenolic compounds in reducing 
BP formed a strong basis for our study with phenolic compounds. Also, the available data 
raised the interest to investigate the structural differences of phenolic compounds in terms 
of ACE inhibition and thereby blood pressure-reducing potency. We therefore gave 
attention in this paper to pure phenolic compounds with regards to their potency to inhibit 
ACE activity. The ACE inhibitory properties of 22 pure phenolic compounds 
representing different classes and subclasses were evaluated. Together with the obtained 
results, structure-activity relationship analysis and molecular docking were used for a 
better understanding how these phenolic compounds interact with the ACE enzyme. To 
discuss and analyze the results obtained, the phenolic compounds as included in this 
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study were categorized into three groups. 
The first group includes tannic acid that was proposed to inhibit ACE. 
Considering all the results reported in this study, tannic acid exhibited the highest ACE 
inhibitory activity. Tannic acid is available in high quantities and is well-known to bind 
and/or precipitate proteins (358-362). Indeed, some studies showed that the high ACE 
inhibitory activity found for gallotannin (363) and procyanidin hexamer (364) was 
reduced by 86% and 65% after addition of BSA and albumin, respectively. To a similar 
extent, our earlier unpublished data confirmed that tannic acid can cause 88 ± 2% 
precipitation of BSA protein at a concentration of 3.5 mM which is >10 times higher than 
the calculated IC50 value (0.23 mM) for inhibition of ACE. Also, it should be mentioned 
that the precipitation of BSA by tannic acid was only seen at very high concentrations 
and that precipitation with the ACE protein has never been confirmed in our own 
experiments testing ACE inhibition. Additionally, our docking experiments demonstrated 
that tannic acid did not fit into the active site of ACE due to its too large polymer size. 
However, it has been reported for phlorotannin, belonging together with tannic acid to the 
group of tannins, that the hexameric phenol, dieckol, also inhibited the activity of ACE 
and this by binding on the outside of the ACE molecule (365) As such, although we 
cannot explain the exact mechanism(s) of ACE inhibition by tannic acid, this compound 
showed a high activity, which is in line with the blood pressure lowering activity found 
for tannic acid in spontaneously hypertensive rats (154). 
The second group includes phenolic acids and flavonoids like quercetin that are 
expected to inhibit ACE activity via interaction with the zinc ion in the active site. All the 
tested phenolic acids exhibited ACE inhibition with IC50 values ranging between 2 and 
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9.3 mM. Our structure-activity relationship analysis helped to understand the key 
structural elements influencing ACE inhibitory activity of the phenolic acids. It was 
observed that the hydroxybenzoic acids, differing only in the numbers of hydroxyl groups 
on the benzene ring, showed a significant increase in ACE inhibitory activity with 
increasing numbers of hydroxyl groups. A similar observation was seen with the 
hydroxycinnamic acids. Indeed, previous studies reported the significance of hydroxyl 
groups on phenolic compounds for zinc metalloproteinase inhibition (366, 367). In 
addition, the 2-fold lower IC50 value of caffeic acid compared to protocatechuic acid and 
the similar observation seen when comparing ferulic acid with vanillic acid confirm the 
importance of the acrylic group for ACE inhibition (368). Another functional group that 
seems to influence the ACE inhibitory activity of phenolic acids is a methoxy group. 
Methylation of 3 and 5-hydroxyl groups of gallic acid to generate syringic acid caused a 
3-fold decrease in ACE inhibitory activity. A similar reduction in ACE inhibitory activity 
was observed when comparing caffeic acid and ferulic acid. The reduced ACE inhibitory 
activity seen in the presence of a methoxy group might be explained by the steric 
hindrance caused by this structure, which might hamper the binding to the active site of 
ACE.  
To determine the molecular properties that influence the ACE inhibitory activity 
of the phenolic acids under consideration, MLR analysis was done using molecular 
descriptors. It was clear that the presence of certain functional groups such as hydroxyl, 
carboxyl and acrylic acid groups, which can act as hydrogen bond acceptors or donors, 
seems to increase the potency to inhibit ACE. On the other hand, the presence of 
methoxy groups negatively influences its ACE inhibitory activity. For instance, syringic 
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acid, that is the least active phenolic acid, contains two methoxy groups, which makes the 
number of hydrogen bond acceptors is low. In contrast, gallic acid possessing five 
hydrogen bond acceptor groups, showed a higher activity. This suggests that the overall 
contribution, rather than the presence or absence of certain functional groups (hydroxyl, 
carboxyl, etc), influences the potential of phenolic acids to inhibit ACE activity. 
Furthermore, our docking studies revealed that most of the phenolic acids included in this 
study formed charge-charge interactions with the zinc ion in the active site of ACE via 
the oxygen atom in the carboxylate moiety. Additionally, these compounds made 
different molecular interactions with the amino acids at the active site of ACE which 
gives rise to a stable complex between the phenolic acid molecule and ACE. This 
interaction with the zinc ion, stabilized by other interactions with amino acids in the 
active site, may have caused the ACE inhibitory activity seen by phenolic acids. It is well 
known that the synthetic inhibitor lisinopril complexes the zinc via its carboxylic moiety 
and subsequently different interactions with key amino acids in the active centre are 
established to stabilize this complex (357). Therefore, it can be suggested that the 
phenolic acids inhibit ACE activity in a manner similar to lisinopril. Additionally, to 
confirm the competition with the substrate on the active site, the ACE inhibition pattern 
of phenolic compounds on ACE can be investigated by Lineweaver–Burk plot in which 
the enzyme activity can be measured in the presence of different concentrations of the 
substrate (HHL). Then, from the kinetic study obtained, it can be distinguish between 
competitive, non-competitive and inhibitor. 
With regard to the flavonoids included in this study, these compounds all 
inhibited ACE but with different potencies. It is known that flavonoids have a wide range 
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of structures differing in substitution patterns to the A-, B- and C-ring (369) which might 
influence their bioactivity. However, it was not possible to test a wider range of 
flavonoids for ACE inhibitory activity due to the poor water solubility of flavonoids. As a 
consequence, a larger structure-activity relationship analysis could not be established in 
this project. Recently, a study reported on the importance of the catechol group on the B-
ring in flavonoids for ACE inhibition (98) In agreement, we believe that this might 
explain the higher activity seen with quercetin compared to kaempferol and apigenin in 
which the catechol group is lacking. With respect to the flavonol quercetin, the flavanol 
epicatechin exerted a significantly lower activity at 0.075 mM and a 3-fold increase in 
IC50 value. Epicatechin lacks the keto group in C4 and the C2-C3 double bond, causing 
the flavonoid skeleton to lose its planar structure and subsequently changing the 
molecular electronic distribution. Previous studies reported that the planar structure of 
flavonoids (370) and cyanidins (97) is an important factor for ACE inhibition. Docking 
results of both quercetin and epicatechin showed that the absence of the keto group and 
the C2-C3 double bond shifts the zinc binding site to the 7-OH moiety. Tsutsumi et 
al.(371) reported on the importance of the hydroxyl group on position 7 in the structure of 
flavonoids for inhibiting ACE enzyme activity. However, according to studies pertaining 
to metal chelation of phenolic compounds in solution, zinc and other metal ions have a 
stronger binding affinity to the 3-hydroxy-keto group, which is absent in epicatechin 
(372, 373) This may justify the higher activity seen for quercetin than for epicatechin.  
The third group includes other flavonoids (rutin), stilbenes (resveratrol) and the 
other phenolic compounds (catechol and pyrogallol) that may inhibit ACE activity via 
only interactions with amino acids in the active site. ACE is a zinc metallopeptidase, in 
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which the zinc ion at the active site is essential for ACE catalysis. Thus, the interaction 
with zinc in the active site of ACE is considered an important mechanism in ACE 
inhibition. However, based on a quantum mechanical and molecular mechanical study, 
the interaction with the zinc ion does not seem to be the only mechanism, since it has 
been shown that ACE may cleave a substrate without interaction between the substrate 
and zinc (374). The third group of our phenolic compounds did inhibit ACE activity but 
did not show any interaction with the zinc in the active site. Therefore, we believe that 
the ACE inhibitory activity seen by this group may be due to the interactions established 
via hydrogen bonds between the hydroxyl groups and amino acids in the active site that 
block the catalytic activity of ACE enzyme.  
Finally, the results in this study need to be placed in a larger perspective. To exert 
an ACE inhibitory effect in vivo, phenolic compounds have to be transported through the 
intestinal wall to reach the blood stream. The IC50 values for phenolic compounds in this 
study are higher than the concentrations reported in blood plasma (375). Nevertheless, in 
previous studies several phenolic compounds were shown to have antihypertensive 
effects in vivo (154). To explain these ACE inhibitory activities in vivo, we agree with the 
statement of Actis-Goretta et al (253) that a local enrichment of phenolic compounds near 
the membrane surface in the vascular endothelial cells is possible since ACE is a 
membrane-bound enzyme. As such, repeated exposure to phenolic compounds coming 
from plant-based diets (39) might result in an accumulation near the endothelial lining 
with concentrations higher than those circulating in the blood hereby enhancing the 
interaction with ACE. Additionally, the existence of ACE activity in the intestinal 
mucosa was demonstrated in some studies (376, 377). This might suggest that in case of 
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high concentrations of phenolic compounds present in the gastrointestinal tract, enzyme 
inhibition at the intestinal level may occur.  
In conclusion, the present data indicate that phenolic compounds inhibit ACE 
activity in vitro and that the activity against ACE and the mode of action depend on the 
class (subclass) and the structure of the phenolic compound. We believe that these 
structure-function relationships can be useful to design new ACE inhibitors based on 
phenolic compounds. Further strategies like encapsulation and chemical modification to 
increase the solubility and bioavailability, and subsequently formulate biologically active 
phenolic compounds that reach the target site need to be evaluated. 
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Chapter 3 Analysis of interaction of phenolic compounds with the 
cholecystokinin signaling pathway to explain effects on reducing 
food intak 
 
3.1 Abstract 
 
CCK regulates food intake by inducing both satiation and satiety which are mediated by 
CCK1R activation. In this study, we investigated the possible interactions of 7 phenolic 
compounds of different classes (tannic acid, gallic acid, benzoic acid, hydroxybenzoic 
acid, protocatechuic acid, and quercetin) with the CCK1R signaling pathway.  
As major results, the tested phenolic compounds could not activate the CCK1R in 
a specific cell-based bioassay. In contrast, we observed an anti-CCK1R activity. This 
antagonistic action might be explained by blocking of the functioning of the CCK1R 
receptor, although the exact mechanism of interaction remains unknown. For tannic acid, 
we also measured a sequestration activity of the CCK hormone in vitro.  
In conclusion, the reported activity of phenolic compounds against food intake 
and weight is not based on an activation of the CCK1R. Taking into account the complex 
regulation of food intake, further work is necessary to unravel other essential mechanisms 
involved to explain the reported effects of phenolic compounds against food intake.  
3.2 Introduction 
 
Because of the high cost of the drugs used in the treatment of obesity and the potential 
associated side-effects like gastrointestinal and kidney problems (378), the search for 
alternatives based on natural products is needed.  
Phenolic compounds are one class of important natural compounds, already 
extensively studied in terms of their potential use in the prevention and treatment of 
different diseases, of which obesity is receiving an increasing attention. The potential role 
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of phenolic compounds in obesity mangement and body weight reduction was suggested 
by animal (282-284, 290-292) and human (298-302) studies. In vitro studies provided 
evidence on the beneficial effect of phenolic compounds in fighting obesity, mainly by 
inhibiting adipogenesis and inducing apoptosis of adipocytes (379, 380). In parallel, 
studies in animal models confirmed that some phenolic compounds suppress food intake 
(381-383). However, the mechanism(s) by which phenolic compounds might reduce food 
intake and weight is still under investigation.  
Food intake is a complex process partially regulated by gastrointestinal hormones 
that mediate sensing and signaling related to food intake in the central nervous system 
(384, 385). Cholecystokinin (CCK) is considered one of the most important gut hormones 
that induces both satiation and satiety and thereby food intake reduction mainly by 
activating CCK1R (125).   
 
Based on the reported in vivo data related to a possible reduction in food intake by 
phenolic compounds, we investigated the mechanistic effects by different classes of 
phenolic compounds on the CCK1R signaling pathway by measuring the increase in the 
calcium flux as an indication of the receptor activation. This analysis is done for the first 
time and we believe it is useful as the CCK pathway plays an essential role in the 
regulation of food intake. We used a cell-based bioassay with Chinese Hamster Ovary 
(CHO) cells overexpressing the rat CCK1R, and tested whether the different compounds 
could activate this G-protein coupled receptor (GPCR). In previous work, the natural 
ligand CCK activated this receptor at 1 nM (386). In addition, we analyzed whether 
phenolic compounds could antagonize the CCK signaling by a blockage of the CCK1R. 
We included also an experiment with thrombin receptor-activating peptide (Trap-7) being 
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the ligand of another GPCR, to investigate whether the effect of phenolic compounds is 
CCK specific or not. In other words, in case we see a decrease in response by Trap-7, this 
would indicate that the phenolic compounds interact and block the function of the GPCR 
in a non-specific manner. Of course in these experiments where we scored an 
antagonistic activity, we also investigated that the viability of the used CHO cells was not 
affected. In case this happens then this may lead to a false antagonistic effect against 
CCK1R due to cell mortality. Finally, we tested whether tannic acid and its monomeric 
metabolite gallic acid may sequester the CCK peptide and as such reduce the amount of 
freely available CCK hormone, because a protein precipitating activity has been reported 
before for tannic acid (387, 388). From this series of experiments at different levels of the 
CCK1R signaling pathway, it was aimed to unravel the mechanism behind the reported 
effects of phenolic compounds reducing food intake. Subsequently, this information is 
useful to better understand the role of the peptide CCK and its receptor in the complex 
regulation of food intake, and to document with mechanistic data a potential development 
of phenolic compounds as natural products in the prevention and treatment of obesity and 
metabolic syndrome diseases.  
3.3 Material and Methods 
3.3.1 Cell lines and products  
 
CHO cells overexpressing the rat CCK type 1 receptor (CHO-CCK1R) were prepared by 
Prof. Peter Willems [23], while the native non-CCK1R-expressing CHO-K1 cells were 
provided by Prof. Georges Leclercq (Ghent University Hospital, Department of Clinic 
Biology, Microbiology and Immunology, Ghent Belgium). Cells were cultured as 
described before (386). Ham’s F12 medium (1:1) (DMEM-F12), Advanced Dulbecco’s 
modified Eagle’s medium, fetal bovine serum (FBS), geneticin (G-418 antibiotic), 
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Penicillin-Streptomycin-L-Glutamine, Fluo-4AM, Pluronic F-127, Dulbecco's phosphate-
buffered saline (DPBS), Hank’s buffered salt solution (HBSS) and PrestoBlue™ were 
purchased from Invitrogen (Paisley, UK). Bovine serum albumin (BSA), HEPES, 
probenecid, lorglumide ((±)-4-[(3, 4-dichlorobenzoyl) amino]-5-(dipentylamino)-5-
oxopentanoic acid sodium salt; CR-1409), and phenolic compounds were purchased from 
Sigma-Aldrich (Bornem, Belgium; St. Louis, MO). Sulfated cholecystokinin octapeptide 
(CCK-8S) was purchased from Bachem (Weil am Rhein, Germany) and clear bottom 
black 96-well plates from Greiner (Frickenhausen, Germany).  
3.3.2 Cell-based bioassay to analyze activation of CCK1R  
 
As we already described in paragraph 1.3.3, CCK1R is a G-protein-coupled receptor, 
which upon activation, evokes an inositol trisphosphate (IP3)-induced calcium release 
from the endoplasmic reticulum. This intracellular calcium flux is a measure for the 
receptor activation and can be visualized with fluorescent sensor dyes. The change in the 
fluorescence signal was measured in a cell-based bioassay described previously (386). 
Briefly, CHO-CCK1R and native CHO-K1 cells (as a negative control) were seeded in 
96-well plates for 20-24 h before the assay. Then, medium was removed and cells were 
incubated in a fluorescence indicator dye (Fluo-4AM) for 1 h at 19 °C in the dark. Then, 
cells were washed with modified HBSS (HBSS supplemented with 20 mM HEPES, 2.5 
mM probenecid and 10 mg/ml BSA). When the receptor is activated by CCK-8S or other 
ligands, an increase in the fluorescence signal is observed. A microtitreplate reader 
Infinite pro 200 (Tecan, Männedorf, Switzerland) multimode plate reader with automated 
injection system was used to measure the fluorescence signal. Tecan was handled using i-
control™ software. Excitation and emission wavelengths were set to 480 nm and 520 nm 
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respectively, using Quad4 monochromators™ technology. Before sample addition, the 
basal fluorescence in a well was recorded for 6 s. Afterwards, CCK-8S or phenolic 
compound solutions (tannic acid, gallic acid, benzoic acid, hydroxybenzoic acid, 
protocatechuic acid, kaempferol, and quercetin) were injected automatically and the 
fluorescence measurements were taken continuously for an additional 36 s. All samples 
were prepared in modified HBSS. The phenolic acids were dosed at 20 and 200 µM, 
while quercetin and kaempferol were dosed at 10 and 100 µM. 
3.3.3 Cell-based bioassay to analyze antagonist action against 
CCK1R 
 
To investigate for antagonist activity, cells were pre-incubated for 30 min with different 
concentrations of the phenolic compounds given in section 3.3.2. Subsequently, cells 
were stimulated with 1 nM of CCK-8S and fluorescence measurements were done as 
described above in section 3.3.2. Concentrations of 20 and 200 µM were used for 
phenolic acids, while 10, 30, 60 and 100 µM were used for quercetin and kaempferol.  
3.3.4 Analysis of cell viability upon exposure to phenolic 
compounds  
Viability of phenolic compounds-treated cells was evaluated using PrestoBlue™. 
PrestoBlue™ reagent is a resazurin-based solution in which resazurin, blue in color and 
non-fluorescent, is converted to resorufin under the reducing power of viable cells. 
Resorufin has a red color and is highly fluorescent, thus can be used to determine cell 
viability and cytotoxicity. Briefly, after measuring the change in the calcium signal under 
the effect of pre-incubation with 20 and 200 µM of tannic acid and gallic acid and with 
10 and 100 µM of quercetin and kaempferol, cells were washed with buffer and re-
suspended in a fresh culture medium. Afterwards, PrestoBlue™ was added at a 
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concentration of 10% and cell viability was determined according to the manufacturer’s 
instructions.  
3.3.5 Analysis of the CCK-8S sequestering ability of tannic acid and 
gallic acid  
In this series, 20, 100 and 200 µM of tannic acid or gallic acid were incubated with 1 nM 
of CCK-8S for 30 min to allow for possible sequestration of CCK-8S peptide by the 
phenolic compound. Then, cells were challenged with the mixture of tannic acid+CCK-
8S or gallic acid+CCK-8S, and subsequently fluorescence was recorded as described 
above in section 3.3.2.  
3.3.6 Data analysis and statistics 
 
Response curves were generated using the following procedures described earlier (386). 
First, baseline fluorescence F0 was recorded during the first 6 s of the experiment before 
sample addition. Afterwards, samples were injected automatically and the fluorescence Fi 
was measured for an additional 36 s. Fi measurements were normalized to the basal 
fluorescence level F0 before sample addition. The kinetic response curves were generated 
by plotting the normalized fluorescence (Fi/F0) versus time (t). Net response was 
calculated as the normalized fluorescence values from CHO-CCK1R cells minus the 
normalized fluorescence values from CHO-K1 cells. Net responses were expressed as a 
percentage of the maximum net response as evoked by 1 nM of CCK-8S. The inhibiting 
effect of tannic acid and gallic acid was calculated as 100% minus the net response. 
Based on these results, sigmoid dose-response curves for the percentage of the maximum 
response/percentage of inhibition versus sample concentrations were derived with Prism 
v5 software (GraphPad Prism, La Jolla, CA) (354). Median 50%-response concentrations, 
i.e. effective EC50 (for CCK-8S) and inhibitory IC50 values (for tannic acid and gallic 
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acid), were calculated from the dose-response curves. The EC50 value represents the 
concentration of CCK-8S at which 50% of its maximum response is reached. The IC50 
value is the concentration of tannic acid or gallic acid at which 50% of the maximum 
response as evoked by 1 nM CCK-8S, is inhibited. Statistical analyses were performed 
using a one-way ANOVA analysis followed by Tukey post-hoc tests and differences 
were considered significant for p-values less than 0.05.  
 
3.4 Results  
3.4.1 Phenolic compounds do not activate CCK1R 
 
The 7 phenolic compounds were tested for their potency to activate the CCK1R with the 
CHO-CCK1R cells in comparison with non-transformed CHO-K1 cells. As a positive 
control, the cells were exposed to 1 nM of CCK-8S. It was clear that there was no 
fluorescence increase in both cell types with any of the phenolic compounds, while there 
was a clear stimulation with 1 nM CCK-8S alone (figure 3.1). 
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Figure 3.1: No activation of the CCK1R upon incubation of CHO-CCK1R and CHO-K1 
cells with 8 phenolic compounds: tannic acid (A) and gallic acid (B) benzoic acid (C), 
hydroxybenzoic acid (D), protocatechuic acid (E), quercetin (F), and kaempferol (G). The 
phenolic acids were dosed at 20 or 200 µM, and quercetin, and kaempferol at 10 or 100 
µM. The response to 1 nM of CCK-8S in CHO-CCK1R cells was used as a positive 
control representing full activation of the CCK1R; the response of CHO-K1 cells to 1 nM 
of CCK-8S as a negative control. The data are expressed as normalized fluorescence 
kinetics (Fi/F0) based on 5 measurements per treatment.  
 
3.4.2 Phenolic compounds pose antagonistic action against CCK1R 
 
When CHO-CCK1R cells were pre-incubated with 20 or 200 µM of tannic acid and 
gallic acid and then challenged with CCK-8S, a significantly lower response (p-values < 
0.05) was measured as compared with the response to CCK-8S alone (Fig 3.2A, B). In 
contrast, incubation of CHO-CCK1R cells with benzoic acid, p-hydroxybenzoic acid and 
protocatechuic acid did not show any change in the fluorescence signal (Figure 3.2C-E). 
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When CHO-CCK1R cells were pre-incubated with quercetin, and kaempferol, this 
resulted in some inhibition but less than 50 % effect even at the highest concentration of 
100 µM tested (Fig 3.2F-G).  
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Figure 3.2: The antagonistic effect of 7 phenolic compounds on the CCK-8S-evoked 
response in CHO-CCK1R cells. Cells were pre-incubated during 30 min with tannic acid 
(A), gallic acid (B), benzoic acid (C), hydroxybenzoic acid (D) and protocatechuic acid 
(E) at 20 and 200 µM, and during 30 min with quercetin (F) and kaempferol (G) at 
10,30,60  and 100 µM, and then exposed to 1 nM of CCK-8S. The kinetic response was 
measured as described in M&M. The response to 1 nM of CCK-8S in CHO-CCK1R cells 
without pre-incubation with phenolic compound was used as a positive control; the 
response of CHO-K1 cells to 1 nM of CCK-8S as a negative control. The data are based 
on a minimum of 5 measurements per treatment. 
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Based on dose-response curves (Figure 3.3A, B) with increasing concentrations of 
either tannic acid or gallic acid, the respective IC50 value was 35 and 397 µM (Table 3.1). 
Due to a low water solubility of quercetin, and kaempferol, higher concentrations than 
100 µM could not be tested, and therefore, IC50 values for these 3 compounds could not 
be calculated. 
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Figure 3.3: Dose-response curve for the antagonistic effect by pre-incubation for 30 min 
of CHO-CCK1R cells with different concentrations of tannic acid (A) and gallic acid (B). 
Data are presented as percentages of inhibition of the maximum response as evoked by 1 
nM of CCK-8S, and the curves were drawn in Prism v5. Each curve is based on 3 
independent experiments in which 5 measurements were performed per treatment. 
 
 
Table 3.1: Inhibitory effect of tannic acid and gallic acid on the CCK-8S-evoked 
response, expressed as IC50 value. 
Treatment IC50 (95%CI; R
2
) (µM) 
Tannic acid 35 (26-47; 0.959) 
Gallic acid 397 (309-511; 0.996) 
IC50 values, as calculated in Prism v5, represent that concentration of tannic acid and 
gallic acid at which 50% of the maximum response, as evoked by 1 nM of CCK-8S, is 
inhibited. Data are based on 3 independent experiments in which 5 measurements were 
performed per treatment. 
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3.4.3 Phenolic compounds also pose antagonistic action against 
TRAP receptor 
 
In addition to the antagonistic activity by phenolic compounds against the response of 
CCK1R as evoked by CCK-8S, we also tested the effect of tannic acid and gallic acid 
against the response as evoked by thrombin receptor-activating peptide (Trap-7). Upon 
pre-incubation with the phenolic acids, it was clear that the response by 250 µM of Trap-
7 was inhibited and this was the case in the two cell lines CHO-CCK1R and CHO-K1 
cells (Figure 3.4A, B). 
 
Figure 3.4: The antagonistic effect of two phenolic compounds on the thrombin receptor-
stimulating peptide (Trap-7)-evoked response in CHO-CCK1R and CHO-K1 cells. Cells 
were pre-incubated during 30 min with tannic acid (A) and gallic acid (B) at 200 µM, and 
then exposed to 250 µM of Trap-7. The kinetic response was measured as described in 
M&M. The response to 250 µM of Trap-7 in CHO-CCK1R and CHO-K1 cells without 
pre-incubation with phenolic compound was used as a respective negative control. The 
data are based on 5 measurements per treatment.  
 
3.4.4 Phenolic compounds do not affect viability of CHO-CCK1R 
cells  
 
In this set of experiments we evaluated whether the incubation with phenolic compounds 
had a negative effect on the viability of the CHO-CCK1R cells. In case the cells would be 
affected, this may lead to a false antagonistic effect against CCK1R. As shown in Table 
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3.2, treatment with tannic acid, gallic acid, kaempferol, and quercetin did not cause a 
reduction in cell viability compared to non-treated cells, at the concentrations 
investigated.  
Table 3.2: Viability of CHO-CCK1R cells upon exposure to different concentrations of 
phenolic compounds. 
 Compound  Conc. (µM) Cell viability (%) 
Tannic acid 20 102 ± 3 
 
200 102 ± 4 
Gallic acid 20 104 ± 4 
 
200 100 ± 4 
Kaempferol 10 98 ± 3 
 
100 100 ± 2 
Quercetin 10 99 ± 2 
 
100 99 ± 3 
 
 
 
 
 
  
Data are given as percentages of the control (non-treated) cells. Each value is expressed 
as mean ± SEM based on 3 independent experiments.  
 
3.4.5 Tannic acid can sequester CCK-8S  
 
CCK-8S is a peptide and tannic acid is well known to sequester proteins/peptides. 
Therefore, it was hypothesized that tannic acid might bind CCK-8S and so reduce the 
amount of CCK-8S hormone freely available for CCK1R activation. In case this happens 
it may explain, or partially, the antagonistic activity against CCK1R as observed for 
tannic acid. To test this hypothesis, tannic acid and its monomer gallic acid were 
incubated with CCK-8S for 30 min without cells, and then CHO-CCK1R cells were 
exposed to the mixture of tannic acid+CCK-8S or gallic acid+CCK-8S. Figure 3.5A and 
3.5B shows that the mixture with 200 µM tannic acid caused a small, but significant, 
decrease compared to the response with CCK-8S alone. The other mixtures did not show 
significant differences. Indeed, when different concentrations of CCK-8S (0.01-1 nM) 
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were combined with tannic acid at 20, 100 and 200 µM, then the 50%-effective 
concentration of CCK-8S was significantly increased with increasing concentrations of 
tannic acid (Table 3.3). The 95% confidence intervals of the EC50 value were overlapping 
for CCK-8S alone and in mixture with 20 µM tannic acid. With tannic acid at 100 µM 
there was a small shift, and with 200 µM the estimated EC50 value was increased 17 
times. These data confirm that the effect by tannic acid is concentration dependent, and 
that there was no effect by the monomer gallic acid. 
Figure 3.5: The effect of pre-incubation of 1 nM CCK-8S with tannic acid (A) and gallic 
acid (B) on CCK-evoked kinetics in CHO-CCK1R cells. Cells were stimulated with 1 nM 
of CCK-8S alone as well as with the mixture of 1 nM of CCK-8S with 20, 100 and 200 
µM phenolic compound. The data are based on 5 measurements per treatment. 
 
 
Table 3.3: Inhibitory effect of different concentrations of tannic acid on the median 50%-
effect concentration (EC50) of the natural ligand CCK-8S.  
Treatment EC50 (95%CI; R
2
) (nM) 
CCK-8S alone  0.024 (0.017-0.035; 0.985) 
CCK-8S + 20 µM tannic acid 0.051 (0.029-0.090; 0.971) 
CCK-8S + 100 µM tannic acid 0.169 (0.138-0.206; 0.995) 
CCK-8S + 200 µM tannic acid 0.427 (0.315-0.580; 0.990) 
EC50 values represent that concentration of CCK-8S at which 50% activity of the maximum response, as 
evoked by 1 nM CCK-8S alone, is realized. The dose-response curves were drawn in Prism v5, and each 
curve is estimated with at least 5 concentrations of CCK-8S with each point based on 5 measurements per 
treatment.  
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3.5 Discussion  
 
Recently, there are indications from a few studies on the possible role phenolic 
compounds and food rich in phenolic compounds in reducing food intake by mediating 
the satiety signals like CCK (279, 348). 
In this study, we provide for the first time mechanistic data to understand the 
effects of phenolic compounds that were reported to reduce food intake in animal models. 
Specifically, we investigated whether phenolic compounds can activate the CCK1R 
signaling pathway which might contribute to their effect on food intake suppression. The 
effect of different phenolic compounds on the CCK response at the level of the CCK1R 
by measuring the change in the calcium flux and on the amounts of CCK-8S available 
was tested. However, all tested phenolic compounds did not show any activation of the 
CCK1R. Thus, it can be concluded that the reported food intake reduction by phenolic 
compounds is not mediated via an activation of the CCK1R signaling pathway.  
Although not expected, in contrast to an activation of CCK1R, we observed an 
antagonistic activity against CCK signaling. We investigated whether this can be 
provoked due to a blockage of the CCK1R by the phenolic compound and/or a 
sequestration of CCK peptide hormone. The first hypothesis for an antagonistic activity 
can be supported by the fact that, when CHO cells were incubated with tannic acid and its 
monomer gallic acid, there was an antagonistic activity against the response evoked by 
thrombin receptor-activating peptide (Trap-7), which is binding on another membrane 
GPCR. In agreement, a previous study demonstrated that quercetin, apigenin and 
genistein were able to inhibit the thrombin receptor-mediated response (389). However, it 
should be remarked here that although phenolic compounds might potentially block 
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different membrane GPCRs in vitro and so inhibiting peptide-evoked responses, further 
research is needed to unravel the exact interaction of the phenolic compound with the 
membrane GPCR. Secondly, based on the literature, phenolic compounds can bind 
proteins and peptides (387, 390, 391). Thus, binding of CCK-8S and thereby 
sequestration of the peptide leading to a reduced amount of freely available CCK 
hormone, may be the reason for the inhibition of the CCK-evoked response. Indeed pre-
incubation of CCK-8S with tannic acid did reduce the CCK-evoked response and the 
effect was dose-dependent. On the other hand, pre-incubation of CCK-8S with gallic 
acid, the monomeric metabolite of tannic acid, did not affect the CCK-8S-evoked 
response. This is in agreement with Kawamoto et al [12] who reported that the numbers 
of the galloyl groups, which are responsible for the formation of hydrophobic 
associations and hydrogen bonds, determine the power to bind and precipitate protein. 
Taking all together, we can postulate that tannic acid and gallic acid may provoke a non-
specific blockage of the CCK1R and thus hinder or even prevent further activation by 
CCK-8S, and for tannic acid we expect also sequestration of CCK peptide thus reducing 
the amount of freely available hormone. This agrees with a recent study where quercetin 
was reported as a non-specific inhibitor of GPCRs by the effect of colloidal formulation 
with the agonist hormone and with the receptor (392). However, it should be remarked 
that this inhibition of CCK1R signaling by both tannic acid and gallic acid was seen in 
vitro at high concentrations which are expected to be irrelevant to the physiological 
concentrations in vivo post consumption. Therefore, such effects are not likely to be 
achieved in vivo.  
To conclude, this is the first work that investigated the effect of different phenolic 
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compounds on the CCK1R signaling pathway. We could demonstrate that phenolic 
compounds do not activate the CCK1R. Thus, their reported effect in literature with a 
reduction in food intake and weight could involve CCK secretion or other 
mechanisms/signaling pathways like CCK2R pathway or influencing other satiety 
hormones pathway like glucagon-like peptide-1 pathway, peptide YY and ghrelin. On the 
other hand, tannic acid and its monomer gallic acid antagonized the CCK signaling in 
vitro as they inhibited the CCK-8S-evoked response; however, this was at high 
concentrations which are biologically not reached. Given the importance of the 
physiological and biological role of CCK hormone and its receptor CCK1R but also the 
complex regulation of food intake, we believe that further work is necessary to unravel 
other essential mechanisms involved to explain the reported effects of phenolic 
compounds against food intake.  
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Chapter 4 Favonoids stimulate cholecystokinin secretion from the 
enteroendocrine STC-1 cells 
4.1 Abstract 
Animal experiments showed that flavonoids might have the potential for an anti-obesity 
effect by reducing weight and food intake. However, the exact mechanisms that could be 
involved in these proposed effects are still under investigation. In this study, we 
investigated the possible effects of flavonoids (quercetin, kaempferol, apigenin, rutin and 
baicalein) on stimulation of the CCK release in vitro using enteroendocrine STC-1 cells. 
In comparison with the control, quercetin, kaempferol and apigenin resulted in a 
significant increase in CCK secretion with quercetin showing the highest activity. On the 
other hand, no significant effect was seen by rutin and baicalein. 
Based on the cell-based results in this work, it can be suggested that the reported 
activity of flavonoids against food intake and weight could be mediated by stimulation of 
the CCK signal which in turn is responsible for inducing satiety and food intake 
reduction. Nonetheless, future animal and human studies are needed to confirm this 
conclusion at organism level.  
4.2 Introduction  
 
Cholecystokinin (CCK) as key hormone in food intake regulation is released from the 
endocrine cells (I cell) in response to the ingestion of nutrients into the small intestine. 
The STC-1 cell line was derived from murine intestinal neuroendocrine tumor cells and 
has already been proven to act as a suitable model to study CCK secretion and production 
(393).  
 In the previous chapter, we showed that phenolic compounds did not stimulate 
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CCK1R activation. Thus, in this study we go further to investigate the possible effect of 
some selected flavonoids (figure 4.1A) on stimulation of CCK secretion in vitro using 
enteroendocrine STC-1 cells. The data should help in a better understanding of the 
mechanism(s) behind the reported activities of flavonoids and foods rich in flavonoids to 
lower food intake. Forskolin was used as a positive control (figure 4.1B). 
A)                                                                         B) 
                       
Figure 4.1: A represents the structure of flavonoids used in the study. Quercetin, R1 = 
R3 = R4 = OH, R2 = H; Kaempferol, R1 = R4 = OH, R2 = R3 = H; Rutin, R1 = 
Glycoside, R2 = H, R3 = R4 = OH; Apigenin, R1 = R2 = R3 = H, R4 = OH; Baicalein, 
R1 = R3 = R4 = H, R2 = OH. B is the strucrure of forskolin which was used as a positive 
control. 
 
 
4. 3. Materials and methods 
 
4.3.1 Materials 
 
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), Penicillin-
Streptomycin, Dulbecco's phosphate-buffered saline (DPBS), Hank’s buffered salt 
solution (HBSS), Pierce™ IP Lysis Buffer, Halt™ Protease and Phosphatase Inhibitor 
Cocktail (100X), PrestoBlue™, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide were purchased from Invitrogen (Paisley, UK). HEPES, forskolin, quercetin, 
kaempferol, rutin, apigenin, baicalein were purchased from Sigma-Aldrich (Bornem, 
Belgium; St. Louis, MO). For the RIA (radioimmunoassay), EURIA CCK kit for CCK 
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determination was purchased from Euro-Diagnostica, Malmo, Sweden. 
4.3.2 Cell culture  
 
The intestinal neuroendocrine tumor STC-1 cells were purchased from ATCC (USA) and 
cultured according to instructions from ATCC. Cells were grown in Dulbecco's modified 
Eagle's Medium (DMEM, 4.5 g/L glucose) supplemented with 10% FBS, 1% penicillin 
and streptomycin. Then, incubation was done at 37°C in the presence of 10% CO2.  
4. 3.3 Stimulation of CCK secretion 
 
Forskolin was used as a positive control as it is already reported to stimulate CCK 
secretion from STC-1 cells (394). Cells were seeded in T25 flasks for 2 days. On the third 
day, when confluency reached almost 70%, the medium was removed and cells were 
washed twice with Hanks' Balanced Salt Solution buffer (HBSS) supplemented with 20 
mM HEPES, pH 7.4. Samples (with forskolin, quercetin, kaempferol, apigenin, rutin and 
baicalein) were prepared in the same buffer used for washing in the presence of 0.1% 
DMSO. Cells were incubated with flavonoid samples for 2h at 37°C, under 10% CO2 
atmosphere. As a final concentration, 100 µM of forskolin and 20 µM of flavonoids were 
used. The concentration of forskolin was selected based on reported literature, while the 
flavonoid concentration was based on their solubility and the limitation to avoid possible 
complexation for CCK as already reported in previous work (395). Control flasks 
contained only buffer. Supernatants were collected and kept at -80°C until CCK 
determination. 
 After collecting supernatants, cells were washed once with ice cold phosphate-
buffered saline (PBS). Afterwards, 1 ml of cell lysis buffer supplemented with 1% 
protease and phosphatase inhibitor was added and flasks were incubated on ice for 5 min 
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with periodic mixing. Next, cell lysate was collected with a scraper and transferred to 
eppendorf tubes and centrifuged at 13,000 g for 10 min. Supernatants were transferred to 
other tubes and kept in -80°C for determination of CCK concentration. 
 CCK measurement was done by RIA using a rabbit antiserum raised against CCK-8 
sulphate conjugated to bovine serum albumin. The cross-reactivities of this antiserum 
were really low for the non sulfated member of the gastrin/CCK family that share the 
same C-terminal penta-peptide (Cholecystokinin 26-33 non-sulfated <0.01%, 
Cholecystokinin 30-33 <0.01%, Gastrin-17 sulphate 0.5 %, and Gastrin-17 non-sulfated 
<0.01%) but it should bind all biological active forms with equimolar potency 
(Cholecystokinin 26-33 sulphate 100.0%, Cholecystokinin-33 sulphate 134.0%). The 
sensitivity of the assay has been optimized at 0.3 pmol/L.  
4.3.4 Western Blot 
 
Extracted protein from STC-1 cells was combined with loading buffer, vortexed, heated 
at 95 °C for 5 min and then electrophoresed in 4-20% polyacrylamide gel, with each lane 
receiving equivalent amounts of protein (10 µg). Gels were then transferred to 
polyvinylidene fluoride membranes (Immun-Blot™ PVDF) (BioRad, Nazareth Eke, 
Belgium) for antibody probing. Membranes were incubated with blocking buffer (50 mL 
of 1x phosphate buffered saline containing 0.2% (v/v) Tween-20 and 5% (w/v) bovine 
serum albumin) for 60 min at room temperature. Further, the membrane was incubated 
with rabbit polyclonal anti-CCK primary antibody (ab83180, immunogen: synthetic 
peptide designed within residues 
IQQARKAPSGRMSIVKNLQNLDPSHRISDRDYMGWMDFGRRSAEEYEYPS, 
corresponding to internal sequence amino acids 66-115 of human CCK) at the 
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recommended dilution 1:1000 over night and at 4 °C. Horseradish peroxidase conjugated 
goat anti-rabbit IgG (Gentaur, Kampenhout, Belgium) was used as secondary antibody at 
dilution of 1:2500. Next, the membranes were then treated with enhanced 
chemiluminescence (ECL) reagent (GE Healthcare, UK) and subsequently the signal was 
detected by means of a ChemiDoc MP Imaging System (BioRad, Nazareth Eke, 
Belgium).  
4.3.5 Analysis of cell viability upon exposure to phenolic 
compounds 
 
Viability of STC-1 cells treated with forskolin and flavonoids was evaluated by the 
PrestoBlue™ and MTT assay. PrestoBlue™ reagent is a resazurin-based solution in 
which resazurin, blue in color and non-fluorescent, is converted to resorufin under the 
reducing power of viable cells. Resorufin has a red color and is highly fluorescent, thus 
can be used to determine cell viability and cytotoxicity. The MTT assay is a colorimetric 
assay for assessing mitochondrial activity of viable cells. Briefly for both assays, Cells 
were seeded for 2 days at 40,000 cells per well in 96 well plates. Afterwards, medium 
was removed and cells were treated with 100 µM forskolin, 20 µM quercetin, 
kaempferol, apigenin, rutin and baicalein. After incubation for 2h, cells were washed with 
buffer and re-suspended in fresh culture medium. Both assays were carried out as 
reported before (395, 396). Each treatment was done in 3 technical replicates and 3 
biological replicates  
4.4 Results  
 
4.4.1 Flavonoids do not affect cell viability  
In this set of experiments, the effect of incubation of cells with forskolin and flavonoids 
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at the concentrations planned to be used for the secretion experiment was evaluated. The 
results from the two cell viability assays with Presto blue and MTT confirmed that 
neither forskolin nor flavonoids resulted in a reduction in the viability of the exposed 
STC-1 cells compared to the controls (Figure 4.2). 
 
Figure 4.2: Viability of STC-1 cells upon exposure to 100 µM of forskolin and 20 µM of 
flavonoids. Two assays were used, Presto blue and MTT. Each value is based on three 
biological replicates and expressed as the mean ± SEM. Values are presented as a 
percentage of the control (non treated cells). 
 
4.4.2 CCK detection  
4.4.2.1 CCK production in STC-1 cells  
 
First, the production of the prepropeptide of CCK by STC-1 cells was confirmed by 
western blot (Figure 4.3A). All samples (extracts from control cells and cells treated with 
forskolin and the different flavonoids) gave an intense band that was seen at around 12 
kDa. On the other hand, in all samples from the culture medium including the control, 2 
faint bands were seen: one was around 37 kDa in addition to a very faint one at around 10 
kDa (Figure 4.3B). However, when an equal volume of sample (extract) was loaded on 
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the gel (and not equal amount of protein), the bands were clearer. Thus, the low 
concentration of the protein in the culture medium (supernatants) could be the reason 
behind seeing very faint bands when loading based on equal amount of protein. 
 
      A 
 
 B                                                           C 
         
Figure 4.3: The prepropeptide of CCK in STC-1 cells. A represents the prepropeptide of 
CCK in the extracts of STC-1 cells. B and C represent the prepropeptide of CCK in the 
culture medium of treated cells compared to control (non treated). In B, equal amount of 
protein was loaded on the gel for all samples. In C, an equal volume of sample (extract) 
was loaded for all samples. 
 
 
4.3.2.2 Flavonoids stimulate CCK secretion  
 
Further, CCK release from STC-1 cells was studies and quantified by RIA assay as it is 
already known as the most sensitive method for quantification of the active form of CCK. 
As it is shown from figure 4.4, forskolin which was used as a positive control resulted in 
a significant increase in CCK secretion as a percentage of the total CCK content 
(secreted+ intracellular) compared to control (no-treated) cells. Interestingly, all 
flavonoids caused an increase in the CCK secretion at the concentration used. Quercetin, 
kaempferol, apigenin and rutin resulted in a significantly higher CCK release compared 
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with the control. Rutin showed a lower activity compared to its aglycone quercetin. On 
the other hand, incubation the cells with the different flavonoids did not increase the 
cellular CCK content (Figure 4.5).  
 
Figure 4.4: The effect of forskolin and flavonoids on stimulation of CCK secretion from 
STC-1 cells. Data are the mean of three biological replicates ± SEM. Secreted CCK was 
expressed as a percentage of the total CCK content (secreted+intracellular). Different 
superscripts on the columns mean values were significantly different at P value <0.05 
using one-way ANOVA.  
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Figure 4.5: The effect of forskolin and flavonoids on the cellular CCK content of STC-1 
cells. Data are the mean of three biological replicates ± SEM. Data are expressed as a 
percentage of the cellular CCK content of the control. Different superscripts on the 
columns mean values were significantly different at P value <0.05 using one-way 
ANOVA.  
 
4.5 Discussion 
 
In this study, we aimed to investigate the stimulation of CCK release by different 
flavonoids. First, the production of the prepropeptide of CCK in STC-1 cells was 
confirmed by western blot though the incubation time used was only 2h which is 
probably not enough to check the effect of different treatments on CCK gene expression 
level. Next, we showed that the different flavonoids were able to induce the release of 
CCK by STC-1 cells in vitro with some difference in the activity. Quercetin showed a 
significant and higher CCK releasing potential compared to its glycoside named rutin. 
This is in agreement with a previous study which showed that hesperetin, but not its 
glycoside hesperidin, was able to stimulate CCK secretion (348). Indeed, it is known that 
the beneficial effects of flavonoids on human health, including antioxidant, anti-
inflammatory and anti-obesity effects, depend on both the position and number of 
hydroxyl groups (397). O-glycosylation of flavonoid aglycones was reported to reduce 
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different bioactivities such as antioxidant and anti-inflammatory effects (398). Suh et al. 
(399) also demonstrated that both antioxidant and pancreatic-lipase-inhibitory activities 
of soybean were increased during fermentation due to the increase in the levels of 
aglycones and the level of the pancreatic lipase activity in vitro was highly correlated 
with anti-obesity effects in vivo. Therefore and from results obtained with the different 
flavonoids, it can be suggested that the OH groups in position 3 and 4 of the B ring and 
an OH group on position 3 in the C ring are important elements to stimulate CCK 
secretion. In addition, the aglycone has more activity than its glycosides.  
The CCK secretion may result from (a) activation of phospholipase C-β which is 
followed by the generation of IP3 and diacylglycerol (DAG) and subsequently increases 
in [Ca
2+
]i and activation of PKC, (b) activation of adenylyl cyclase with subsequent 
elevation in cAMP concentrations and activation of protein kinase A (PKA); and/or (c) 
other pathways that involve the activation of calcium channels that are important for 
sustained CCK secretion (400). Gaillard et al. (401) excluded the involvement of a seven-
transmembrane domain receptor in the peptone-evoked CCK release because the 
accumulation of phosphoinositides in peptone-treated cells was moderate, and PKA or 
PKC inhibition failed to modify the peptone-CCK secretion. However, the same study 
showed that stimulation of CCK release by peptones involved pertussis toxin-sensitive G 
protein(s) and was dependent on Ca
2+
 availability. Similarly, Kim et al. (402) showed that 
hesperetin evoked-CCK release is mediated by the extracellular Ca
2+
 influx and TRP 
channels, mainly TRPA1 (a member of the TRP family of ion channels). Another study 
suggested that the epigallocatechingallate can activate TRPA1 on the STC-1 cell surface 
and subsequently cause an increase in Ca
2+
 (403). Hence, further work to explore the 
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exact mechanisms behind the stimulation of CCK release by flavonoids is very crucial.  
To our knowledge, this is the first report on the effect of quercetin, kaempferol, rutin, 
apigenin and baicalein on CCK secretion from STC-1 cells. Results suggest that the 
reported effect of flavonoids towards food intake and weight could involve the 
stimulation of CCK release which in turns evokes a satiety signal responsible for food 
intake reduction. However, further work is still needed to explore the effect of the tested 
flavonoids on CCK release and appetite regulation in animal model which could attribute 
to their reported anti-obesity effects.  
 
 
 
 
 
  
 141 
 
 
 
 
 
 
 
  
 142 
 
Chapter 5 
 
General conclusion and future 
perspectives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 143 
 
  
 144 
 
Chapter 5 General conclusion and future perspectives 
 
 
5.1 Status and main outcomes obtained from this thesis: 
 
High blood pressure and obesity are both major health risk factors that threaten the life of 
humans worldwide. Although in most cases medication is needed, the search for 
alternatives from natural based products has been of great importance and research 
continues to investigate natural sources with the aim of finding new bioactive compounds 
that can help in the prevention and treatment of hypertension and obesity. Phenolic 
compounds, a group of compounds that are naturally found in fruits and vegetables, have 
been claimed for their health promoting effects. In vitro, in vivo and human studies 
indicated a positive role of phenolic compounds in the battle against hypertension and 
obesity. Many studies have already focused on investigating the possible mechanisms 
behind this activity. However, mechanisms involved in the control and regulation of 
blood pressure, body weight and food intake are many and complex. Therefore, more 
research in this field is needed to deduce firm conclusions. 
The aim of this work was to screen different phenolic compounds from different 
classes for their antihypertensive activity as determined by ACE inhibitory activity in 
vitro and to test their possible effects on the CCK pathway (CCK1R activation and CCK 
release/production) with use of different cell-based bioassays. Results obtained are 
discussed on the basis of their structures. 
Here below the main conclusions and achievements of this work are summarized in 
detail: 
 
 145 
 
In Chapter 1, a literature screening was done with the aim of collecting most recent 
information from human and animal studies on the potential role of phenolic compounds 
and food rich in phenolic compounds on hypertension and obesity. Based on this 
screening, we concluded that some phenolic compounds and their food rich sources 
showed promising effects as antihypertensive and antiobesity agents. Nonetheless, most 
results are based on complex food extracts or beverages and thus the effect of compounds 
other than phenolic compounds can often not be excluded (178, 183, 197, 198). In 
addition, different designs, different intervention times and different doses might result in 
different observations (194, 199, 200). Therefore and in addition to focus on phenolic 
compounds rich food sources, focus on specific compounds is very important. Studying 
phenolic rich food sources will provide information on possible synergistic/antagonistic 
effects of food matrix and its interference with possible effects of phenolic compounds. 
On the other hand, focusing on specific individual compounds is needed to confirm and 
approve the claimed health beneficial effects of these compounds and food sources in 
hypertension and obesity management.  
In chapter 1 also possible mechanisms involved in the antihypertensive and antiobesity 
effects reported by phenolic compounds has been discussed. With regard to blood 
pressure-reducing effects, a decrease in oxidative stress, improving the endothelial 
function and interference with RAAS, were suggested. However, the exact mechanism(s) 
of action by which phenolic compounds might decrease BP in humans still needs further 
investigation and confirmation. Concerning the plausible mechanisms involved in the 
antiobesity effects, inhibition of adipogenesis, interferences with lipid metabolism and 
energy expenditure were supported by most of the studies. In addition, possible effects on 
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food intake mediated by satiation and satiety inducing hormones should not be ignored 
although this is not well studied and investigated for the moment.  
In chapter 2, we studied the effect of phenolic compounds on ACE activity. 
Therefore, 22 phenolic compounds from different classes and sub(classes) (tannic acid, 
gallic acid, benzoic acid, p-hydroxybenzoic acid, syringic acid, vanillic acid, ellagic acid, 
protocatechuic acid, catechol, pyrogallol, caffeic acid, ferulic acid, p-coumaric acid, 
trans-cinnamic acid, quercetin, rutin, kaempferol, resveratrol, trans -stilbene, apigenin, 
epicatechin, and phloretin) were screened for in vitro ACE inhibitory activity. Tannic 
acid showed the highest activity (IC50=230 µM). All tested flavonoids showed ACE 
inhibitory activity with IC50 values ranging between 0.415 and 1.381 mM with quercetin 
being the most active compound. Phenolic acids showed ACE inhibition in a range from 
2 to 9.3 mM. QSAR analysis was performed for phenolic acids to investigate the key 
structural elements responsible for the difference in activity. It was elucidated that the 
number of hydroxyl groups on the benzene ring plays an important role for their activity. 
Substitution of hydroxyl groups by methoxy groups decreased their activity. Furthermore, 
docking studies were performed to investigate possible mechanisms involved in the ACE 
inhibitory activity. We concluded from this experiment that phenolic acids and flavonoids 
inhibit ACE via interaction with the zinc ion and this interaction is stabilized by other 
interactions with amino acids in the active site. On the other hand, other compounds such 
as resveratrol and pyrogallol may inhibit ACE via interactions with amino acids at the 
active site thereby blocking the catalytic activity of ACE. 
Food ingredients influencing food intake by the CCK pathway can stimulate indirectly 
or/and directly this pathway. They might stimulate CCK secretion which in its turns 
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stimulates satiety by activating CCK1R and/or they can directly stimulate CCK1R. The 
reported antiobesity effect of phenolic compounds could involve influencing satiety 
signals (279, 348). Therefore, in this part (Chapter 3) we investigated the effect of of a 
group of phenolic compounds (tannic acid, gallic acid, benzoic acid, hydroxybenzoic 
acid, protocatechuic acid, kaempferol and quercetin) on the CCK1R signaling pathway as 
an important pathway in food intake regulation. We used a cell-based bioassay with 
Chinese hamster ovary (CHO) cells overexpressing the rat CCK1R, and tested whether 
the different compounds could activate this CCK1R. From the results obtained in this 
piece of work, we could conclude that phenolic compounds do not activate the CCK1R. 
Thus, the proposed effect of phenolic compounds in literature on food intake and weight 
is not mediated by CCK1R activation. As such, phenolic compounds might stimulate 
CCK secretion which further acts on its receptor. In addition, we showed in this part that 
tannic acid and its monomer gallic acid antagonized the CCK signaling in vitro as they 
inhibited the CCK-8S-evoked response.  
In chapter 4, we selected some compounds out of the group of flavonoids 
(quercetin, kaempferol, apigenin, rutin and baicalein) to investigate possible stimulation 
of CCK release from the enteroendocrine STC-1 cells. First, we confirmed the production 
of CCK in STC-1 cells without treatment using western blot. No effect on CCK 
production by the tested flavonoids was found. A RIA assay was used to measure CCK 
production/release. Interestingly, a significant stimulation of CCK release from the cells 
was caused by quercetin, kaempferol and apigenin. At the same time, no toxic effects 
were seen on cell viability for all flavonoids studied.  
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5.2 Future perspectives 
 
5.2.1 In vitro screeing of ACE inhibitory activity and other 
mechanisms involved in blood pressure regulation 
 
Although we were able to build a structure-fucntion relationship with a group of phenolic 
compounds, enough information that can help to fully understand all key structural 
elements behind the potential ACE inhibitory activity of phenolic compounds are still not 
available. Therefore, more in vitro screening for phenolic compounds with different 
structures are still important. Data obtained from the in vitro screening about the 
structure-function relationships can help in developing new ACE inhibitors based on 
phenolic compounds.  
For the moment, not much information exists on all possible mechanisms that can 
mediate the effect of phenolic compounds on hypertension. New drug classes are now of 
importance, as well.  For instance inhibitors of vasopeptidases, aldosterone synthase and 
soluble epoxide hydrolase, agonists of natriuretic peptide A and vasoactive intestinal 
peptide receptor 2 are targeted to phase II/III of hypertension development. As well, 
inhibitors of aminopeptidase A, dopamine β-hydroxylase, and agonists of components of 
the angiotensin-converting enzyme 2/angiotensin(1–7)/Mas receptor axis are used in 
phase I or under preclinical development (267). Positive effects of phenolic compounds 
on some of these routes were already reported (257, 268, 269). Accordingly, it is 
important to open the door on these therapeutic targets and to investigate possible effects 
of phenolic compounds on these pathways. This could be done in vitro as an intial 
screening tool using pure phenolic compounds and phenolic compounds rich sources to 
investigate structure-function relationships. 
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5.2.2 More animal and human trials on phenolic compounds are 
still important to confirm the claimed antihypertensive effects  
 
Literature screening showed promising effects by phenolic compounds and phenolic 
compound-rich foods. Yet, more research on phenolic compounds rich foods and on pure 
compounds following well-designed and long-term studies is necessary in the processs of 
developing functional foods and/or functional food ingriedents or food supplements 
based on phenolic compounds. This is needed to confirm and approve the reported heath 
claims and to optimize doses in different food matrices and to establish a tolerable upper 
limit of intake.  
This first needs to be performed in animal models whereby special attention 
should be given to control possible side effects particularly in case of the use of pure 
compounds as supplementation before moving to human trials. Phenolic compounds can 
be both pro-oxidants and antioxidants and hence safety issues should be considered if 
high doses of phenolic compounds are consumed (404). Quercetin supplementation at a 
dose of 1000 mg/d for 1 month have been reported to cause adverse effects such as 
headache, nausea, and tingling of the extremities in humans (405). This addresses the 
importance of the in vivo evaluation for the safety potentail of a tolerable upper dose of a 
compound that can show health promoting effects and that is considerd as safe on the 
long term. SHR is the most frequently used model in animal studies (see literature 
review) as this is an accepted model for human essential or primary hypertension. Blood 
pressure of these rats can be measured with a direct (arterial) measurement or by using 
the indirect (tail-cuff) method. Direct measurement is more precise but the tail-cuff 
method is less complex and has a low impact on the animal (406). The choice between 
the two techniques should be based on the study objectives. A long-term study is the next 
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step to provide information on the effect of a compound on the long term and on the 
required dose to induce the required effect. In addition, this helps to evaluate mechanisms 
involved. This can be done within several weeks as we showed previously in the 
literature review. For instance, blood pressure could be recorded on a daily basis.  
For human studies, participants involved should be chosen from the target group. 
We already discussed results from several human intervention studies in the literature 
review. A double-blind, randomized, placebo-controlled design is the most appropriate 
for this type of research. Our literature review showed that very few pure compounds 
(mainly quercetin) were studied in humans. Therefore, it would be interesting that also 
other compounds that show activity in animals in parallel with food sources rich in 
phenolic compounds to be investigated in humans taking into account that data on the 
minimum and maximum dose that can be applied in humans should be obtained first from 
animal studies. Before going to the main human intervention trial, pilot study might be 
useful to confirm activity in humans, and to determine the dose requirements. This 
human pilot study can also provide the necessary information (magnitude of the effect, 
standard deviation) for the sample size calculation for the human intervention trial. 
 
In the EU, food claims have to be approved by the European Commission after 
evaluation by European Food Safety Authority (EFSA). To be approved by EFSA, food 
claims have to meet the following requirements: 1) characterization of the food 
constituent, 2) Relevance of the claimed effect to human health, 3) Scientific 
substantiation of the claimed effect. For example in case of developing phenolic 
compounds rich extract targeting ACE inhibition and blood pressure, the subject of the 
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health claim (particular compounds, class of phenolics) have to be sufficiently 
characterized in the extract. The health claim ‘maintenance of normal blood pressure’ is 
considered relevant to human health. To meet the third criterion and to establish a cause 
and effect relationship, evaluation of the effect in human in a representative study is 
essential. To be considered representative, many issues should be taken into account that 
will influence the results obtained from the clinical trial and further interpretation. First, 
the start from the target group which in the case of hypertension should be 
prehypertensive or stage I population. Charachteristics of participants at base line 
(smoking, weight, age, sex, medicated and non-medicated individual, etc…) need to be 
described. Perhaps specific epigenetic parameters could be evaluated before including 
these in the study. The dose applied and the way of administration needs attention. In 
case of functional foods, dosage and administration form (food matrix) should be the 
same as the product intended to be launched on the market. Diet restriction to avoid 
interference from additional intake of polyphenols from food items consumed daily 
should be avoided. The placebo group needs to be defined, as well as what they will 
receive. It s important to match for caloric content and appearance. For example in case 
the treatment group receives  polyphenols-rich extracts/ dark chocolate rich in flavonoids, 
the placebo product should be low or zero content in polyphenol (maybe white chocolate 
low in polyphenols could be an option). Another example: fruit juice rich in particular 
compound(s) versus placebo which could be only fruit juice. 
 
Interestingly, EFSA has already approved some health claims on phenolic 
compounds rich food sources: 
 152 
 
-  Cocoa flavanol:  EFSA concluded a cause and effect relationship has been 
established between the consumption of cocoa flavanols in the high flavanol 
cocoa extract (i.e. in capsules or tablets) and maintenance of normal endothelium-
dependent vasodilation. In order to obtain the claimed effect, 200 mg of cocoa 
flavanols should be consumed daily. This amount could be provided by less than 
one gram of high flavanols cocoa extract in capsules or tablets, and can be 
consumed in the context of a balanced diet. The target population is the general 
population. 
 
- Polyphenols in olive: EFSA concluded that a cause and effect relationship has 
been established between the consumption of olive oil polyphenols (standardised 
by the content of hydroxytyrosol and its derivatives) and protection of LDL 
particles from oxidative damage. The Panel considers that in order to bear the 
claim, 5 mg of hydroxytyrosol and its derivatives (e.g. oleuropein complex and 
tyrosol) in olive oil should be consumed daily. These amounts, if provided by 
moderate amounts of olive oil, can be easily consumed in the context of a 
balanced diet. The concentrations in some olive oils may be too low to allow the 
consumption of this amount of polyphenols in the context of a balanced diet. The 
target population is the general population 
 
- Water-soluble tomato concentrate developed in two variant forms named WSTC I 
(completely water-soluble syrup) and its low-sugar derivative, WSTC II, supplied 
in powder format: EFSA concluded that a cause and effect relationship has been 
established between the consumption of water-soluble tomato concentrate (i.e., 
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WSTC I and II) and the reduction in platelet aggregation in humans. In order to 
achieve the claimed effect, 3 g WSTC I or 150 mg WSTC II in up to 250 mL of 
either fruit juices, flavoured drinks or yogurt drinks (unless heavily pasteurised) 
should be consumed daily.  
5.2.3 In vivo experiments to investigate the effect of phenolic 
compounds on CCK-mediated food intake and body weight 
 
This can be done in short and long term studies. Afterwards, human interventions are 
important for confirmation. 
 5.2.3.1 Short term experiments  
 
The short term trials give information about the effect of the tested compounds on 
appetite within hours. Investigating the effect of the tested compounds on food intake is 
done within one day. This should include measuring meal frequency, meal duration and 
the total daily food intake (407). When a reduction in food intake is seen, further 
investigation for the role of CCK can be done by blood sample analysis. Therefore, the 
CCK concentration in the blood should be measured within 10 to 30 min after 
administration of the tested compound and compared with the values obtained from the 
control animals. Additionally, other gut hormones involved in food intake regulation like 
GLP-1 and PYY could be included to test whether the effect is specific to CCK only or to 
gut hormones in general. In case only a change is seen in the concentration of CCK in the 
blood of treated rats compared to the controls, it can be assumed that the CCK release is 
at least partially involved. In case of positive effects seen on the CCK concentration after 
treatment, dose-response experiments are needed to be established for a determination of 
the minimum concentration for which an effect can be seen. 
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 5.2.3.2 Long-term experiments  
 
As discussed in the literature review, evidence on the effect of some phenolic compounds 
on body weight reduction is already available (282-284, 290-292, 382, 383). However, 
negative results from some other studies (285-289) did not allow to reach a clear 
conclusion. Further research is thus necessary. The aim of the long-term experiments is to 
see a decrease in weight or weight gain in the test animals compared to the control 
animals. Rodents with environmentally driven changes in weight are used in research that 
investigates the tendency for weight gain and weight loss. These models are often 
developed by giving the animals access to high fat diets, usually over a period of 3-4 
months (408). This results in generating animals with a high body weight gain and 
predominantly in the form of fat, insulin resistance, glucose intolerance and elevated 
cholesterol and triglyceride level. The C57BL/6 mouse is a well-known model prone to 
study effects on weight gain (409). In addition, many commonly used Sprague-Dawley 
rats have been proposed as a rodent model for polygenetic obesity because they readily 
become obese following a standard diet (410). Administration of the test compounds can 
be done in 2 ways. First, it can be by adding the compound at the same time when 
introducing the obesity-induced diet. The aim of this design is to check the effect of these 
compounds on the prevention of body weight gain. Also, application of test compounds 
could be after inducing obesity. In both designs, animals should receive during a certain 
amount of time, every day a certain dose of the tested compound and subsequently in 
addition to food intake measurement, their body weight should be monitored on a day-to-
day or week-to-week basis (411). It is important in long term experiments to monitor 
adverse effects by daily inspection for signs of toxicity by e.g. measuring body 
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temperature or abnormal behavior of the treated animal compared to control animals.  
In short- and long-term studies, it would not be appropriate to mix pure phenolic 
compounds with animal food or water, which might cause positive false effects on food 
intake because of taste aversion or individual preferences for flavors. In addition, since 
phenolic compounds have a low bioavailability (50), we suggest that the use of a gavage 
which brings the treatment to the stomach could be a preferred choice for administration. 
In this way the administered compound still needs to pass the gastro-intestinal tract to be 
absorbed into the blood stream, and so the effect of gastro-intestinal digestion and absorption 
is not excluded as in the case of intravenous injection. This also ensures an accurate and 
precise dosing in the animals. 
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Summary 
 
In this PhD project, a detailed overview is given from all animal and human studies 
published on the effects of phenolic compounds and their suggested role in fighting 
hypertension and obesity. The ACE and CCK pathways play an important role in blood 
pressure and food intake as well as body weight maintenance. In the cell-free experiments 
on ACE, we could demonstrate that phenolic compounds from different classes showed 
ACE inhibitory activity. However, it should be remarked here that for some compounds 
the inhibitory activity was only at a high concentration that might most likely not be 
reached in vivo. Nonetheless, our data on modeling and SAR analysis helped to 
understand the key groups of the phenolic molecule that could influence the activity, and 
this in turn should help to design new ACE inhibitors based on phenolic compounds. 
Regarding the CCK pathway, none of the tested compounds could stimulate the CCK1R 
in vitro. Interestingly, cell-based assays with the enteroendocrine STC-1 cells 
demonstrated for the first time that some phenolic compounds showed a significant 
stimulation of the release of the satiety peptide CCK. Thus, mediation of the CCK 
pathway could be, at least partially, involved in the antiobesity effects of phenolic 
compounds. 
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Samenvatting 
In dit doctoraatsproject wordt een gedetailleerd overzicht gegeven van alle dierlijke en 
menselijke studies gepubliceerd omtrent de effecten van fenolische verbindingen en hun 
voorgestelde rol in de strijd tegen hoge bloeddruk en obesitas. De twee pathways van 
ACE en CCK spelen een belangrijke rol in de regulatie van de bloeddruk en 
voedselinname en het onderhoud van het lichaamsgewicht. In de celvrije-experimenten 
omtrent ACE, kunnen we zien dat fenolische verbindingen uit verschillende klassen een 
remmende activiteit hebben op ACE. Er moet echter worden opgemerkt dat voor 
sommige verbindingen de remmende activiteit pas werd gezien bij een hoge concentratie 
die in vivo waarschijnlijk niet kan worden bereikt. Desalniettemin de verkregen data 
omtrent de modellering en structuur-activiteitsanalyse zullen helpen om de bijdrage in de 
ACE-inhibitorische activiteit van de belangrijkste groepen van de fenolische molecule te 
begrijpen, wat op zich zou moeten helpen om nieuwe ACE-remmers op basis van 
fenolverbindingen te ontwerpen. Wat betreft de CCK pathway, vertoonde geen enkele 
van de geteste verbindingen een stimulerende activiteit voor CCK1R in de in vitro 
proeven met CCK1R-CHO cellen. Daarnaast werd ook de activiteit van een aantal 
fenolische verbindinen op de vrijstelling/productie van CCK onderzocht met 
enteroendocrine STC-I cellen in vitro. Voor de eerste keer kon worden aangetoond dat 
fenolen de vrijstelling van het CCK verzadigingspeptide verhogen en dit zou kunnen 
bijdragen in de beschreven anti-obesitas effecten van polyfenolen.  
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